Secreted proteins

ABSTRACT

The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.

TECHNICAL FIELD

[0001] This invention relates to nucleic acid and amino acid sequences of secreted proteins and to the use of these sequences in the diagnosis, treatment, and prevention of liver, cell proliferative, autoimmune/inflammatory, cardiovascular, neurological, and deveopmental disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of secreted proteins.

BACKGROUND OF THE INVENTION

[0002] Protein transport and secretion are essential for cellular function. Protein transport is mediated by a signal peptide located at the amino terminus of the protein to be transported or secreted. The signal peptide is composed of about ten to twenty hydrophobic amino acids which target the nascent protein from the ribosome to a particular membrane bound compartment such as the endoplasmic reticulum (ER). Proteins targeted to the ER may either proceed through the secretory pathway or remain in any of the secretory organelles such as the ER, Golgi apparatus, or lysosomes. Proteins that transit through the secretory pathway are either secreted into the extracellular space or retained in the plasma membrane. Proteins that are retained in the plasma membrane contain one or more transmembrane domains, each comprised of about 20 hydrophobic amino acid residues. Secreted proteins are generally synthesized as inactive precursors that are activated by post-translational processing events during transit through the secretory pathway. Such events include glycosylation, proteolysis, and removal of the signal peptide by a signal peptidase. Other events that may occur during protein transport include chaperone-dependent unfolding and folding of the nascent protein and interaction of the protein with a receptor or pore complex. Examples of secreted proteins with amino terminal signal peptides are discussed below and include proteins with important roles in cell-to-cell signaling. Such proteins include transmembrane receptors and cell surface markers, extracellular matrix molecules, cytokines, hormones, growth and differentiation factors, enzymes, neuropeptides, and vasomediators. (Reviewed in Alberts, B. et al. (1994) Molecular Biology of The Cell, Garland Publishing, New York, N.Y., pp. 557-560, 582-592.)

[0003] Cell surface markers include cell surface antigens identified on leukocytic cells of the immune system. These antigens have been identified using systematic, monoclonal antibody (mAb)-based “shot gun” techniques. These techniques have resulted in the production of hundreds of mAbs directed against unknown cell surface leukocytic antigens. These antigens have been grouped into “clusters of differentiation” based on common immunocytochemical localization patterns in various differentiated and undifferentiated leukocytic cell types. Antigens in a given cluster are presumed to identify a single cell surface protein and are assigned a “cluster of differentiation” or “CD” designation. Some of the genes encoding proteins identified by CD antigens have been cloned and verified by standard molecular biology techniques. CD antigens have been characterized as both transmembrane proteins and cell surface proteins anchored to the plasma membrane via covalent attachment to fatty acid-containing glycolipids such as glycosylphosphatidylinositol (GPI). (Reviewed in Barclay, A. N. et al. (1995) The Leucocyte Antigen Facts Book, Academic Press, San Diego, Calif., pp. 17-20.)

[0004] Matrix proteins (MPs) are transmembrane and extracellular proteins which function in formation, growth, remodeling, and maintenance of tissues and as important mediators and regulators of the inflammatory response. The expression and balance of MPs may be perturbed by biochemical changes that result from congenital, epigenetic, or infectious diseases. In addition, MPs affect leukocyte migration, proliferation, differentiation, and activation in the immune response. MPs are frequently characterized by the presence of one or more domains which may include collagen-like domains, EGF-like domains, immunoglobulin-like domains, and fibronectin-like domains. In addition, MPs may be heavily glycosylated and may contain an Arginine-Glycine-Aspartate (RGD) tripeptide motif which may play a role in adhesive interactions. MPs include extracellular proteins such as fibronectin, collagen, galectin, vitronectin and its proteolytic derivative somatomedin B; and cell adhesion receptors such as cell adhesion molecules (CAMs), cadherins, and integrins. (Reviewed in Ayad, S. et al. (1994) The Extracellular Matrix Facts Book Academic Press, San Diego, Calif., pp.2-16; Ruoslahti, E. (1997) Kidney Int. 51:1413-1417; Sjaastad, M. D. and Nelson, W. J. (1997) BioEssays 19:47-55.)

[0005] Mucins are highly glycosylated glycoproteins that are the major structural component of the mucus gel. The physiological functions of mucins are cytoprotection, mechanical protection, maintenance of viscosity in secretions, and cellular recognition. MUC6 is a human gastric mucin that is also found in gall bladder, pancreas, seminal vesicles, and female reproductive tract (Toribara, N. W. et al. (1997) J. Biol. Chem. 272:16398-16403). The MUC6 gene has been mapped to human chromosome 11 (Toribara, N. W. et al. (1993) J. Biol. Chem 268:5879-5885). Hemomucin is a novel Drosophila surface mucin that may be involved in the induction of antibacterial effector molecules (Theopold, U. et al. (1996) J. Biol. Chem. 217:12708-12715).

[0006] Tuftelins are one of four different enamel matrix proteins that have been identified so far. The other three known enamel matrix proteins are the amelogenins, enamelin and ameloblastin. Assembly of the enamel extracellular matrix from these component proteins is believed to be critical in producing a matrix competent to undergo mineral replacement. (Paine C. T. et al. (1998) Connect Tissue Res.38:257-267). Tuftelin mRNA has been found to be expressed in human ameloblastoma tumor, a non-mineralized odontogenic tumor (Deutsch D. et al. (1998) Connect Tissue Res. 39:177-184)

[0007] Olfactomedin-related proteins are extracellular matrix, secreted glycoproteins with conserved C-terminal motifs. They are expressed in a wide variety of tissues and in broad range of species, from Caenorhabditis elegans to Homo sapiens. Olfactomedin-related proteins comprise a gene family with at least 5 family members in humans. One of the five, TIGR/myocilin protein, is expressed in the eye and is associated with the pathogenesis of glaucoma (Kulkarni, N. H. et al., (2000) Genet. Res. 76:41-50). Research by Yokoyama et al. (1996) found a 135-amino acid protein, termed AMY, having 96% sequence identity with rat neuronal olfactomedin-releated ER localized protein in a neuroblastoma cell line cDNA library, suggesting an essential role for AMY in nerve tissue (Yokoyama, M. et al., (1996) DNA Res.3:311-320). Neuron-specific olfactomedin-related glycoproteins isolated from rat brain cDNA libraries show strong sequence similarity with olfactomedin. This similarity is suggestive of a matrix-related function of these glycoproteins in neurons and neurosecretory cells (Danielson, P. E. et al., (1994) J. Neurosci. Res. 38:468-478).

[0008] Mac-2 binding protein is a 90-kD serum protein (90K) and another secreted glycoprotein, isolated from both the human breast carcinoma cell line SK-BR-3, and human breast milk. It specifically binds to a human macrophage-associated lectin, Mac-2. Structurally, the mature protein is 567 amino acids in length and is preceded by an 18-amino acid leader. There are 16 cysteines and seven potential N-linked glycosylation sites. The first 106 amino acids represent a domain very similar to an ancient protein superfamily defined by a macrophage scavenger receptor cysteine-rich domain (Koths, K. et al., (1993) J. Biol. Chem. 268:14245-14249). 90K is elevated in the serum of subpopulations of AIDS patients and is expressed at varying levels in primary tumor samples and tumor cell lines. Ullrich et al. (1994) have demonstrated that 90K stimulates host defense systems and can induce interleukin-2 secretion. This immune stimulation is proposed to be a result of oncogenic transformation, viral infection or pathogenic invasion (Ulrich; A., et al. (1994) J. Biol. Chem. 269:18401-18407).

[0009] Semaphorins are a large group of axonal guidance molecules consisting of at least 30 different members and are found in vertebrates, invertebrates, and even certain viruses. All semaphorins contain the sema domain which is approximately 500 amino acids in length. Neuropilin, a semaphorin receptor has been shown to promote neurite outgrowth in vitro. The extracellular region of neuropilins consists of three different domains: CUB, discoidin, and MAM domains. The CUB and the MAM motifs of neuropilin have been suggested as having roles in protein-protein interactions and are suggested to be involved in the binding of semaphorins through the sema and the C-terminal domains (reviewed in Raper, J. A. (2000) Curr. Opin. Neurobiol. 10:88-94). Plexins are neuronal cell surface molecules that mediate cell adhesion via a homophilic binding mechanism in the presence of calcium ions. Plexins have been shown to be expressed in the receptors and neurons of particular sensory systems (Ohta, K et al. (1995) Cell 14:1189-1199). There is evidence that suggests that some plexins function to control motor and CNS axon guidance in the developing nervous system Plexins, which themselves contain complete semaphorin domains, may be both the ancestors of classical semaphorins and binding partners for semaphorins (Winberg, M. L. et al (1998) Cell 95:903-916).

[0010] Human pregnancy-specific beta 1-glycoprotein (PSG) is a family of closely related glycoproteins of molecular weights of 72 KDa, 64 KDa, 62 KDa, and 54 KDa. Together with the carcinoembryonic antigen, they comprise a subfamily within the immunoglobulin superfamily (Plouzek C. A. and Chou J. Y. Endocrinology 129:950-958) Different subpopulations of PSG have been found to be produced by the trophoblasts of the human placenta, and the amnionic, and chorionic membranes (Plouzek C. A et al. (1993) Placenta 14:277-285).

[0011] Autocrine motility factor (AMF) is one of the motility cytokines regulating tumor cell migration, therefore identification of the signaling pathway coupled with it has critical importance. Autocrine motility factor receptor (AMFR) expression has been found to be associated with tumor progression in thymoma (Ohta Y. et al. (2000) Int J Oncol. 17:259-264). AMFR is a cell surface glycoprotein of molecular weight 78 KDa.

[0012] Hormones are secreted molecules that travel through the circulation and bind to specific receptors on the surface of, or within, target cells. Although they have diverse biochemical compositions and mechanisms of action, hormones can be grouped into two categories. One category includes small lipophilic hormones that diffuse through the plasma membrane of target cells, bind to cytosolic or nuclear receptors, and form a complex that alters gene expression. Examples of these molecules include retinoic acid, thyroxine, and the cholesterol-derived steroid hormones such as progesterone, estrogen, testosterone, cortisol, and aldosterone. The second category includes hydrophilic hormones that function by binding to cell surface receptors that transduce signals across the plasma membrane. Examples of such hormones include amino acid derivatives such as catecholamines (epinephrine, norepinephrine) and histamine, and peptide hormones such as glucagon, insulin, gastrin, secretin, cholecystokinin, adrenocorticotropic hormone, follicle stimulating hormone, luteinizing hormone, thyroid stimulating hormone, and vasopressin. (See, for example, Lodish et al. (1995) Molecular Cell Biology, Scientific American Books Inc., New York, N.Y., pp. 856-864.)

[0013] Pro-opiomelanocortin (POMC) is the precursor peptide of corticotropin (ACTH) a hormone synthesized by the anterior pituitary gland, which functions in the stimulation of the adrenal cortex. POMC is also the precursor peptide of the hormone, beta-lipotropin (beta-LPH),. Each hormone includes smaller peptides with distinct biological activities: alpha-melanotropin (alpha-MSH) and corticotropin-like intermediate lobe peptide (CLIP) are formed from ACTH; gamma-lipotropin (gamma-LPH) and beta-endorphin are peptide components of beta-LPH, while beta-MSH is contained within gamma-LPH. Adrenal insufficiency due to ACTH deficiency, resulting from a genetic mutation in exons 2 and 3 of POMC has defined a endocrine disorder characterized by early-onset obesity, adrenal insufficiency, and red hair pigmentation (Chretien, M. et al., (1979) Canad. J. Biochem. 57:1111-1121, Krude, H. et al., (1998) Nature Genet. 19:155-157, Online Mendelian Inheritance in Man, OMIM. Johns Hopkins University, Baltimore, Md. MIM Number: 176830: Aug. 1, 2000. World Wide Web URL: www.ncbi.nlm.nih.gov/omim/).

[0014] Growth and differentiation factors are secreted proteins which function in intercellular communication. Some factors require oligomerization or association with membrane proteins for activity. Complex interactions among these factors and their receptors trigger intracellular signal transduction pathways that stimulate or inhibit cell division, cell differentiation, cell signaling, and cell motility. Most growth and differentiation factors act on cells in their local environment (paracrine signaling). There are three broad classes of growth and differentiation factors. The first class includes the large polypeptide growth factors such as epidermal growth factor, fibroblast growth factor, transforming growth factor, insulin-like growth factor, and platelet-derived growth factor. The second class includes the hematopoietic growth factors such as the colony stimulating factors (CSFs). Hematopoietic growth factors stimulate the proliferation and differentiation of blood cells such as B-lymphocytes, T-lymphocytes, erythrocytes, platelets, eosinophils, basophils, neutrophils, macrophages, and their stem cell precursors. The third class includes small peptide factors such as bombesin, vasopressin, oxytocin, endothelin, transferrin, angiotensin II, vasoactive intestinal peptide, and bradykinin which function as hormones to regulate cellular functions other than proliferation.

[0015] Growth and differentiation factors play critical roles in neoplastic transformation of cells in vitro and in tumor progression in vivo. Inappropriate expression of growth factors by tumor cells may contribute to vascularization and metastasis of tumors. During hematopoiesis,,growth factor misregulation can result in anemias, leukemias, and lymphomas. Certain growth factors such as interferon are cytotoxic to tumor cells both in vivo and in vitro. Moreover, some growth factors and growth factor receptors are related both structurally and functionally to oncoproteins. In addition, growth factors affect transcriptional regulation of both proto-oncogenes and oncosuppressor genes. (Reviewed in Pimentel, E. (1994) Handbook of Growth Factors, CRC Press, Ann Arbor, Mich., pp. 1-9.)

[0016] The Slit protein, first identified in Drosophila, is critical in central nervous system midline formation and potentially in nervous tissue histogenesis and axonal pathfinding. Itoh et al. have identified mammalian homologues of the slit gene (human Slit-1, Slit-2, Slit-3 and rat Slit-1). The encoded proteins are putative secreted proteins containing EFG-like motifs and leucine-rich repeats, both are conserved protein-protein interaction domains. Slit-1, -2, and -3 mRNAs are expressed in the brain, spinal cord, and thyroid, respectively (Itoh, A. et al., (1998) Brain Res. Mol. Brain Res. 62:175-186). The Slit family of proteins are indicated to be functional ligands of glypican-i in nervous tissue and suggests that their interactions may be critical in certain stages during central nervous system histogenesis (Liang, Y. et al., (1999) J. Biol. Chem 274:17885-17892).

[0017] Neuropeptides and vasomediators (NP/VM) comprise a large family of endogenous signaling molecules. Included in this family are neuropeptides and neuropeptide hormones such as bombesin, neuropeptide Y, neurotensin, neuromedin N, melanocortins, opioids, galanin, somatostatin, tachykinins, urotensin II and related peptides involved in smooth muscle stimulation, vasopressin, vasoactive intestinal peptide, and circulatory system-borne signaling molecules such as angiotensin, complement, calcitonin, endothelins, formyl-methionyl peptides, glucagon, cholecystokinin and gastrin. NP/VMs can transduce signals directly, modulate the activity or release of other neurotransmitters and hormones, and act as catalytic enzymes in cascades. The effects of NP/VMs range from extremely brief to long-lasting. (Reviewed in Martin, C. R. et al. (1985) Endocrine Physiology, Oxford University Press, New York, N.Y., pp.57-62.)

[0018] NP/VMs are involved in numerous neurological and cardiovascular disorders. For example, neuropeptide Y is involved in hypertension, congestive heart failure, affective disorders, and appetite regulation. Somatostatin inhibits secretion of growth hormone and prolactin in the anterior pituitary, as well as inhibiting secretion in intestine, pancreatic acinar cells, and pancreaticbeta-cells. A reduction in somatostatin levels has been reported in Alzheimer's disease and Parkinson's disease. Vasopressin acts in the kidney to increase water and sodium absorption, and in higher concentrations stimulates contraction of vascular smooth muscle, platelet activation, and glycogen breakdown in the liver. Vasopressin and its analogues are used clinically to treat diabetes insipidus. Endothelin and angiotensin are involved in hypertension, and drugs, such as captopril, which reduce plasma levels of angiotensin, are used to reduce blood pressure (Watson, S. and S. Arkinstall (1994) The G-protein Linked Receptor Facts Book, Academic Press, San Diego Calif., pp. 194; 252; 284; 55; 111).

[0019] Neuropeptides have also been shown to have roles in nociception (pain). Vasoactive intestinal peptide appears to play an important role in chronic neuropathic pain. Nociceptin, an endogenous ligand for for the opioid receptor-like 1 receptor, is thought to have a predominantly anti-nociceptive effect, and has been shown to have analgesic properties in different animal models of tonic or chronic pain (Dickinson, T. and Fleetwood-Walker, S. M. (1998) Trends Pharmacol. Sci. 19:346-348).

[0020] Other proteins that contain signal peptides include secreted proteins with enzymatic activity. Such activity includes, for example, oxidoreductase/dehydrogenase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, or ligase activity. For example, matrix metalloproteinases are secreted hydrolytic enzymes that degrade the extracellular matrix and thus play an important role in tumor metastasis, tissue morphogenesis, and arthritis (Reponen, P. et al. (1995) Dev. Dyn. 202:388-396; Firestein, G. S. (1992) Curr. Opin. Rheumatol. 4:348-354; Ray, J. M. and Stetler-Stevenson, W. G. (1994) Eur. Respir. J. 7:2062-2072; and Mignatti, P. and Rifkin, D. B. (1993) Physiol. Rev. 73:161-195). Additional examples are the acetyl-CoA synthetases which activate acetate for use in lipid synthesis or energy generation (Luong, A. et al. (2000) J. Biol. Chem. 275:26458-264566). The result of acetyl-CoA synthetase activity is the formation of acetyl-CoA from acetate and CoA. Acetyl-CoA sythetases share a region of sequence similarity identified as the AMP-binding domain signature. Acetyl-CoA synthetase has been shown to be associated with hypertension (H. Toh, (1991) Protein Seq. Data Anal. 4:111-117, and Iwai, N. et. al., (1994) Hypertension 23:375-380).

[0021] A number of isomerases catalyze steps in protein folding, phototransduction, and various anabolic and catabolic pathways. One class of isomerases is known as peptidyl-prolyl cis-trans isomerases (PPIases). PPIases catalyze the cis to trans isomerization of certain proline imidic bonds in proteins. Two families of PPIases are the FK506 binding proteins (FKBPs), and cyclophilins (CyPs). FKBPs bind the potent immunosuppressants FK506 and rapamycin, thereby inhibiting signaling pathways in T-cells. Specifically, the PPIase activity of FKBPs is inhibited by binding of FK506 or rapamycin. There are five members of the FKBP family which are named according to their calculated molecular masses (FKBP12, FKBP13, FKBP25, FKBP52, and FKBP65), and localized to different regions of the cell where they associate with different protein complexes (Coss, M. et al. (1995) J. Biol. Chem. 270:29336-29341; Schreiber, S. L. (1991) Science 251:283-287).

[0022] The peptidyl-prolyl isomerase activity of CyP may be part of the signaling pathway that leads to T-cell activation. CyP isomerase activity is associated with protein folding and protein trafficking, and may also be involved in assembly/disassembly of protein complexes and regulation of protein activity. For example, in Drosophila, the CyP NinaA is required for correct localization of rhodopsins, while a mammalian CyP (Cyp40) is part of the Hsp90/Hsc70 complex that binds steroid receptors. The mammalian CypA has been shown to bind the gag protein from human immunodeficiency virus 1 (HIV-1), an interaction that can be inhibited by cyclosporin. Since cyclosporin has potent anti-HIV-1 activity, CypA may play an essential function in HIV-1 replication. Finally, Cyp40 has been shown to bind and inactivate the transcription factor c-Myb, an effect that is reversed by cyclosporin. This effect implicates CyPs in the regulation of transcription, transformation, and differentiation (Bergsma, D. J. et al (1991) J. Biol. Chem. 266:23204-23214; Hunter, T. (1998) Cell 92: 141-143; and Leverson, J. D. and Ness, S. A. (1998) Mol. Cell. 1:203-211).

[0023] Gamma-carboxyglutamic acid (Gla) proteins rich in proline (PRGPs) are members of a family of vitamin K-dependent single-pass integral membrane proteins. These proteins are characterized by an extracellular amino terminal domain of approximately 45 amino acids rich in Gla. The intracellular carboxyl terminal region contains one or two copies of the sequence PPXY, a motif present in a variety of proteins involved in such diverse cellular functions as signal transduction, cell cycle progression, and protein turnover (Kulman, J. D. et al., (2001) Proc. Natl. Acad. Sci. U.S.A. 98:1370-1375). The process of post-translational modification of glutamic residues to form Gla is Vitamin K-dependent carboxylation. Proteins which contain Gla include plasma proteins involved in blood coagulation. These proteins are prothrombin, proteins C, S, and Z, and coagulation factors VII, IX, and X. Osteocalcin (bone-Gla protein, BGP) and matrix Gla-protein (MGP) also contain Gla Friedman, P. A., and C. T. Przysiecki (1987) Int. J. Biochem. 19:1-7; C. Vermeer (1990) Biochem. J. 266:625-636).

[0024] The Drosophila sp. gene crossveinless 2 is characterized as having a putative signal or transmembrane sequence, and a partial Von Willebrand Factor D domain similar to those domains known to regulate the formation of intramolecular and intermolecular bonds and five cysteine-rich domains, known to bind BMP-like (bone morphogenetic proteins) ligands. These features suggest that crossveinless 2 may act extracelluarly or in the secretory pathway to directly potentiate ligand signaling and hence, involvement in the BMP-like signaling pathway known to play a role in vein specification (Conley, C. A. et al., (2000) Development 127:3947-3959). The dorsal-ventral pattering in both vertebrate and Drosophila embryos requires a conserved system of extracellular proteins to generate a positional information gradient.

[0025] The presence of signal peptides has also been seen in proteins associated with prostate cancer. The development of androgen-independent cells in prostate tumors is useful as a method of determining disease progression. As with most tumors, prostate cancer develops through a multistage progression ultimately resulting in an aggressive tumor phenotype. The initial step in tumor progression involves the hyperproliferation of normal luminal and/or basal epithelial cells. Androgen responsive cells become hyperplastic and evolve into early-stage tumors. Although early-stage tumors are often androgen-sensitive and respond to androgen ablation, a population of androgen-independent cells evolve from the hyperplastic population. These cells represent a more advanced form of prostate tumor that may become invasive and potentially become metastatic to the bone, brain, or lung.

[0026] Expression Profiling

[0027] Array technology can provide a simple way to explore the expression of a single polymorphic gene or the expression profile of a large number of related or unrelated genes. When the expression of a single gene is examined, arrays are employed to detect the expression of a specific gene or its variants. When an expression profile is examined, arrays provide a platform for identifying genes that are tissue specific, are affected by a substance being tested in a toxicology assay, are part of a signaling cascade, carry out housekeeping functions, or are specifically related to a particular genetic predisposition, condition, disease, or disorder.

[0028] Foam Cell Formation and Secreted Proteins

[0029] Atherosclerosis and the associated coronary artery disease and cerebral stroke represent the most common cause of death in industrialized nations. Although certain key risk factors have been identified, a full molecular characterization that elucidates the causes and provides care for this complex disease has not been achieved. Molecular characterization of growth and regression of atherosclerotic vascular lesions requires identification of the genes that contribute to features of the lesion including growth, stability, dissolution, rupture and, most lethally, induction of occlusive vessel thrombus.

[0030] An early step in the development of atherosclerosis is formation of the “fatty streak”. Lipoproteins, such as the cholesterol-rich low-density lipoprotein (LDL), accumulate in the extracellular space of the vascular intima, and undergo modification. Oxidation of LDL occurs most avidly in the sub-endothelial space where circulating antioxidant defenses are less effective. The degree of LDL oxidation affects its interaction with target cells. “Minimly oxidized” LDL (MM-LDL) is able to bind to LDL receptor but not to the oxidized LDL (Ox-LDL) or “scavenger” receptors that have been identified, including scavenger receptor types A and B, CD36, CD68/macrosialin and LOX-1 (Navab et al. (1994) Arterioscler Thromb Vasc Biol 16:831-842; Kodama et al. (1990) Nature 343:531-535; Acton et al. (1994) J Biol Chem 269:21003-21009; Eademann et al. (1993) J Biol Chem 268:11811-11816; Ramprasad et al. (1996) Proc Natl Acad Sci 92:14833-14838; Kataoka et al. (1999) Circulation 99:3110-3117). MM-LDL can increase the adherence and penetration of monocytes, stimulate the release of monocyte chemotactic protein 1 (MCP-1) by endothelial cells, and induce scavenger receptor A (SRA) and CD36 expression in macrophages (Cushing et al. (1990) Proc Natl Acad Sci 87:5134-5138; Yoshida et al. (1998) Arterioscler Thromb Vasc Biol 18:794-802; Steinberg (1997) J Biol Chem 272:20963-20966). SRA and the other scavenger receptors can bind Ox-LDL and enhance uptake of lipoprotein particles.

[0031] Mononuclear phagocytes enter the intima, differentiate into macrophages, and ingest modified lipids including Ox-LDL. In most cell types, cholesterol content is tightly controlled by feedback regulation of LDL receptors and biosynthetic enzymes (Brown and Goldstein (1986) Science 232:34-47). In macrophages, however, the additional scavenger receptors lead to unregulated uptake of cholesterol (Brown and Goldstein (1983) Annu Rev Biochem 52:223-261) and accumulation of multiple intracellular lipid droplets producing a “foam cell” phenotype. Cholesterol-engorged and dead macrophages contribute most of the mass of early “fatty streak” plaques and typical “advanced” lesions of diseased arteries. Numerous studies have described a variety of foam cell responses that contribute to growth and rupture of atherosclerotic vessel wall plaques. These responses include production of multiple growth factors and cytokines, which promote proliferation and adherence of neighboring cells; chemokines, which further attract circulating monocytes into the growing plaque; proteins, which cause remodeling of the extracellular matrix; and tissue factor, which can trigger thrombosis (Ross (1993) Nature 362:801-809; Quin et al. (1987) Proc Natl Acad Sci 84:2995-2998). Thus, cholesterol-loaded macrophages which occur in abundance in most stages of the atherosclerotic plaque formation contribute to inception of the atheroscerotic process and to eventual plaque rupture and occlusive thrombus.

[0032] During Ox-LDL uptake, macrophages produce cytokines and growth factors that elicit further cellular events that modulate atherogenesis such as smooth muscle cell proliferation and production of extracellular matrix. Additionally, these macrophages may activate genes involved in inflammation including inducible nitric oxide synthase. Thus, genes differentiatly expressed during foam cell formation may reasonably be expected to be markers of the atherosclerotic process.

[0033] Steroid Molecules and Secreted Proteins

[0034] The potential application of gene expression profiling is particularly relevant to measuring the toxic response to potential therapeutic compounds and of the metabolic response to therapeutic agents. Diseases treated with steroids and disorders caused by the metabolic response to treatment with steroids include adenomatosis, cholestasis, cirrhosis, hemangioma, Henoch-Schonlein purpura, hepatitis, hepatocellular and metastatic carcinomas, idiopathic thrombocytopenic purpura, porphyria, sarcoidosis, and Wilson disease. Response may be measured by comparing both the levels and sequences expressed in tissues from subjects exposed to or treated with steroid compounds such as mifepristone, progesterone, beclomethasone, medroxyprogesterone, budesonide, prednisone, dexamethasone, betamethasone, or danazol with the levels and sequences expressed in normal untreated tissue. Steroids are a class of lipid-soluble molecules, including cholesterol, bile acids, vitamin D, and hormones, that share a common four-ring structure based on cyclopentanoperhydrophenantbrene and that carrry out a wide variety of functions. Cholesterol, for example, is a component of cell membranes that controls membrane fluidity. It is also a precursor for bile acids which solubilize lipids and facilitate absorption in the small intestine during digestion. Vitamin D regulates the absorption of calcium in the small intestine and controls the concentration of calcium in plasma. Steroid hormones, produced by the adrenal cortex, ovaries, and testes, include glucocorticoids, mineralocorticoids, androgens, and estrogens. They control various biological processes by binding to intracellular receptors that regulate transcription of specific genes in the nucleus. Glucocorticoids, for example, increase blood glucose concentrations by regulation of gluconeogenesis in the liver, increase blood concentrations of fatty acids by promoting lipolysis in adipose tissues, modulate sensitivity to catcholamines in the central nervous system, and reduce inflammation. The principal mineralocorticoid, aldosterone, is produced by the adrenal cortex and acts on cells of the distal tubules of the kidney to enhance sodium ion reabsorption. Androgens, produced by the interstitial cells of Leydig in the testis, include the male sex hormone testosterone, which triggers changes at puberty, the production of sperm and maintenance of secondary sexual characteristics. Female sex hormones, estrogen and progesterone, are produced by the ovaries and also by the placenta and adrenal cortex of the fetus during pregnancy. Estrogen regulates female reproductive processes and secondary sexual characteristics. Progesterone regulates changes in the endometrium during the menstrual cycle and pregnancy.

[0035] Steroid hormones are widely used for fertility control and in anti-inflammatory treatments for physical injuries and diseases such as arthritis, asthma, and auto-immune disorders. Progesterone, a naturally occurring progestin is primarily used to treat amenorrhea, abnormal uterine bleeding, or as a contraceptive. Endogenous progesterone is responsible for inducing secretory activity in the endometrium of the estrogen-primed uterus in preparation for the implantation of a fertilized egg and for the maintenance of pregnancy. It is secreted from the corpus luteum in response to luteinizing hormone (LH). The primary contraceptive effect of exogenous progestins involves the suppression of the midcycle surge of LH. At the cellular level, progestins diffuse freely into target cells and bind to the progesterone receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone from the hypothalamus and blunt the pre-ovulatory LH surge, thereby preventing foilicular maturation and ovulation. Progesterone has minimal estrogenic and androgenic activity. Progesterone is metabolized hepatically to pregnanediol and conjugated with glucuronic acid.

[0036] Medroxyprogesterone (MAM), also known as 6α-methyl-17-hydroxyprogesterone, is a synthetic progestin with a pharmacological activity about 15 times greater than progesterone. MAH is used for the treatment of renal and endometrial carcinomas, amenorrhea, abnormal uterine bleeding, and endometriosis associated with hormonal imbalance. MAH has a stimulatory effect on respiratory centers and has been used in cases of low blood oxygenation caused by sleep apnea, chronic obstructive pulmonary disease, or hypercapnia.

[0037] Mifepristone, also known as RU-486, is an antiprogesterone drug that blocks receptors of progesterone. It counteracts the effects of progesterone, which is needed to sustain pregnancy. Mifepristone induces spontaneous abortion when administered in early pregnancy followed by treatment with the prostaglandin, misoprostol. Further, studies show that mifepristone at a substantially lower dose can be highly effective as a postcoital contraceptive when administered within five days after unprotected intercourse, thus providing women with a “morning-after pill” in case of contraceptive failure or sexual assault. Mifepristone also has potential uses in the treatment of breast and ovarian cancers in cases in which tumors are progesterone-dependent. It interferes with steroid-dependent growth of brain meningiomas, and may be useful in treatment of endometriosis where it blocks the estrogen-dependent growth of endometrial tissues. It may also be useful in treatment of uterine fibroid tumors and Cushing's Syndrome. Mifepristone binds to glucocorticoid receptors and interferes with cortisol binding. Mifepristone also may act as an anti-glucocorticoid and be effective for treating conditions where cortisol levels are elevated such as AIDS, anorexia nervosa, ulcers, diabetes, Parkinson's disease, multiple sclerosis, and Alzheimer's disease.

[0038] Danazol is a synthetic steroid derived from ethinyl testosterone. Danazol indirectly reduces estrogen production by lowering pituitary synthesis of follicle-stimulating hormone and LH. Danazol also binds to sex hormone receptors in target tissues, thereby exhibiting anabolic, antiestrognic, and weakly androgenic activity. Danazol does not possess any progestogenic activity, and does not suppress normal pituitary release of corticotropin or release of cortisol by the adrenal glands. Danazol is used in the treatment of endometriosis to relieve pain and inhibit endometrial cell growth. It is also used to treat fibrocystic breast disease and hereditary angioedema.

[0039] Corticosteroids are used to relieve inflammation and to suppress the immune response. They inhibit eosinophil, basophil, and airway epithelial cell function by regulation of cytokines that mediate the inflammatory response. They inhibit leukocyte infiltration at the site of inflammation, interfere in the function of mediators of the inflammatory response, and suppress the humoral immune response. Corticosteroids are used to treat allergies, asthma, arthritis, and skin conditions. Beclomethasone is a synthetic glucocorticoid that is used to treat steroid-dependent asthma, to relieve symptoms associated with allergic or nonallergic (vasomotor) rhinitis, or to prevent recurrent nasal polyps following surgical removal. The anti-inflammatory and vasoconstrictive effects of intranasal beclomethasone are 5000 times greater than those produced by hydrocortisone. Budesonide is a corticosteroid used to control symptoms associated with allergic rhinitis or asthma. Budesonide has high topical anti-inflammatory activity but low systemic activity. Dexamethasone is a synthetic glucocorticoid used in anti-inflammatory or immunosuppressive compositions. It is also used in inhalants to prevent symptoms of asthma. Due to its greater ability to reach the central nervous system, dexamethasone is usually the treatment of choice to control cerebral edema. Dexamethasone is approximately 20-30 times more potent than hydrocortisone and 5-7 times more potent than prednisone. Prednisone is metabolized in the liver to its active form, prednisolone, a glucocorticoid with anti-inflammatory properties. Prednisone is approximately 4 times more potent than hydrocortisone and the duration of action of prednisone is intermediate between hydrocortisone and dexamethasone. Prednisone is used to treat allograft rejection, asthma, systemic lupus erythematosus, arthritis, ulcerative colitis, and other inflammatory conditions. Betamethasone is a synthetic glucocorticoid with antiinflammatory and immunosuppressive activity and is used to treat psoriasis and fungal infections, such as athlete's foot and ringworm.

[0040] The anti-inflammatory actions of corticosteroids are thought to involve phospholipase A₂ inhibitory proteins, collectively called lipocortins. Lipocortins, in turn, control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of the precursor molecule arachidonic acid. Proposed mechanisms of action include decreased IgE synthesis, increased number of β-adrenergic receptors on leukocytes, and decreased arachidonic acid metabolism. During an immediate allergic reaction, such as in chronic bronchial asthma, allergens bridge the IgE antibodies on the surface of mast cells, which triggers these cells to release chemotactic substances. Mast cell influx and activation, therefore, is partially responsible for the inflammation and hyperirritability of the oral mucosa in asthmatic patients. This inflammation can be retarded by administration of corticosteroids.

[0041] The effects upon liver metabolism and hormone clearance mechanisms are important to understand the pharmacodynamics of a drug. The human C3A cell line is a clonal derivative of HepG2/C3 (hepatoma cell line, isolated from a 15-year-old male with liver tumor), which was selected for strong contact inhibition of growth. The use of a clonal population enhances the reproducibility of the cells. C3A cells have many characteristics of primary human hepatocytes in culture: i) expression of insulin receptor and insulin-like growth factor II receptor; ii) secretion of a high ratio of serum albumin compared with α-fetoprotein iii) conversion of ammonia to urea and glutamine; iv) metabolize aromatic amino acids; and v) proliferate in glucose-free and insulin-free medium The C3A cell line is now well established as an in vitro model of the mature human liver (Mickelson et al. (1995) Hepatology 22:866-875; Nagendra et al. (1997) Am J Physiol 272:G408-G416).

[0042] The discovery of new secreted proteins, and the polynucleotides encoding them, satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of liver, cell proliferative, autoimmune/inflammatory, cardiovascular, neurological, and developmental disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of secreted proteins.

SUMMARY OF THE INVENTION

[0043] The invention features purified polypeptides, secreted proteins, referred to collectively as “SECP” and individually as “SECP-1,” “SECP-2,” “SECP-3,” “SECP-4,” “SECP-5,” “SECP-6,” “SECP-7,” “SECP-8,” “SECP-9,” “SECP-10,” “SECP-11,” “SECP-12,” “SECP-13,” “SECP-14,” “SECP-15,” “SECP-16,” “SECP-17,” “SECP-18,” “SECP-19,” “SECP-20,” “SECP-21,” “SECP-22,” “SECP-23,” “SECP-24,” “SECP-25,” “SECP-26,” “SECP-27,” “SECP-28,” “SECP-29,” and “SECP-30.” In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-30.

[0044] The invention farther provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-30. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:31-60.

[0045] Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

[0046] The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

[0047] Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30.

[0048] The invention further provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:31-60, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:31-60, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

[0049] Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:31-60, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:31-60, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

[0050] The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:31-60, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:31-60, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

[0051] The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-30. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional SECP, comprising administering to a patient in need of such treatment the composition.

[0052] The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional SECP, comprising administering to a patient in need of such treatment the composition.

[0053] Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-30,b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional SECP, comprising administering to a patient in need of such treatment the composition.

[0054] The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

[0055] The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

[0056] The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO:31-60, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

[0057] The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:31-60, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:31-60, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ D NO:31-60, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:31-60, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

[0058] Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

[0059] Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog, and the PROTEOME database identification numbers and annotations of PROTEOME database homologs, for polypeptides of the invention The probability scores for the matches between each polypeptide and its homolog(s) are also shown.

[0060] Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

[0061] Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.

[0062] Table 5 shows the representative cDNA library for polynucleotides of the invention.

[0063] Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

[0064] Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

[0065] Table 8 shows single nucleotide polymorphisms found in polynucleotide sequences of the invention, along with allele frequencies in different human populations.

DESCRIPTION OF THE INVENTION

[0066] Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

[0067] It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to “a host cell” includes a plurality of such host cells, and a reference to “an antibody” is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

[0068] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

[0069] Definitions

[0070] “SECP” refers to the amino acid sequences of substantially purified SECP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

[0071] The term “agonist” refers to a molecule which intensifies or mimics the biological activity of SECP. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of SECP either by directly interacting with SECP or by acting on components of the biological pathway in which SECP participates.

[0072] An “allelic variant” is an alternative form of the gene encoding SECP. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

[0073] “Altered” nucleic acid sequences encoding SECP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as SECP or a polypeptide with at least one functional characteristic of SECP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding SECP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding SECP. The encoded protein may also be “altered,” and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent SECP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of SECP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

[0074] The terms “amino acid” and “amino acid sequence” refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where “amino acid sequence” is recited to refer to a sequence of a naturally occurring protein molecule, “amino acid sequence” and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

[0075] “Amplification” relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

[0076] The term “antagonist” refers to a molecule which inhibits or attenuates the biological activity of SECP. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of SECP either by directly interacting with SECP or by acting on components of the biological pathway in which SECP participates.

[0077] The term “antibody” refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab′)₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind SECP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

[0078] The tern “antigenic determinant” refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (articular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

[0079] The term “aptamer” refers to a nucleic acid or oligonucleotide molecule that binds to a specific molecular target. Aptamers are derived from an in vitro evolutionary process (e.g., SELEX (Systematic Evolution of Ligands by EXponential Enrichment), described in U.S. Pat. No. 5,270,163), which selects for target-specific aptamer sequences from large combinatorial libraries. Aptamer compositions may be double-stranded or single-stranded, and may include deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules. The nucleotide components of an aptamer may have modified sugar groups (e.g., the 2′-OH group of a ribonucleotide may be replaced by 2′-F or 2′-NH₂), which may improve a desired property, e.g., resistance to nucleases or longer lifetime in blood. Aptamers may be conjugated to other molecules, e.g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system. Aptamers may be specifically cross-linked to their cognate ligands, e.g., by photo-activation of a cross-linker. (See, e.g., Brody, E. N. and L. Gold (2000) J. Biotechnol. 74:5-13.)

[0080] The term “intramer” refers to an aptamer which is expressed in vivo. For example, a vaccinia virus-based RNA expression system has been used to express specific RNA aptamers at high levels in the cytoplasm of leukocytes (Blind, M. et al. (1999) Proc. Natl Acad. Sci. USA 96:3606-3610).

[0081] The term “spiegelmer” refers to an aptamer which includes L-DNA, L-RNA, or other left-handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on substrates containing right-handed nucleotides.

[0082] The term “antisense” refers to any composition capable of base-pairing with the “sense” (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2′-methoxyethyl sugars or 2′-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2′-deoxyuracil, or 7-deaza-2′-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation “negative” or “minus” can refer to the antisense strand, and the designation “positive” or “plus” can refer to the sense strand of a reference DNA molecule.

[0083] The term “biologically active” refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, “immunologically active” or “immunogenic” refers to the capability of the natural, recombinant, or synthetic SECP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

[0084] “Complementary” describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5′-AGT-3′ pairs with its complement, 3′-TCA-5′.

[0085] A “composition comprising a given polynucleotide sequence” and a “composition comprising a given amino acid sequence” refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding SECP or fragments of SECP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilzing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

[0086] “Consensus sequence” refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City Calif.) in the 5′ and/or the 3′ direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison Wis.) or Phrap (University of Washington, Seattle Wash.). Some sequences have been both extended and assembled to produce the consensus sequence.

[0087] “Conservative amino acid substitutions” are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions. Original Residue Conservative Substitution Ala Gly, Ser Arg His, Lys Asn Asp, Gln, His Asp Asn, Glu Cys Ala, Ser Gln Asn, Glu, His Glu Asp, Gln, His Gly Ala His Asn, Arg, Gln, Glu Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu, Ile Phe His, Met, Leu, Trp, Tyr Ser Cys, Thr Thr Ser, Val Trp Phe, Tyr Tyr His, Phe, Trp Val Ile, Leu, Thr

[0088] Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

[0089] A “deletion” refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

[0090] The term “derivative” refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

[0091] A “detectable label” refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalendy or noncovalently joined to a polynucleotide or polypeptide.

[0092] “Differential expression” refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.

[0093] “Exon shuffling” refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.

[0094] A “fragment” is a unique portion of SECP or the polynucleotide encoding SECP which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

[0095] A fragment of SEQ ID NO:31-60 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:31-60, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:31-60 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:31-60 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:31-60 and the region of SEQ ID NO:31-60 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

[0096] A fragment of SEQ ID NO:1-30 is encoded by a fragment of SEQ ID NO:31-60. A fragment of SEQ ID NO:1-30 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-30. For example, a fragment of SEQ ID NO:1-30 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-30. The precise length of a fragment of SEQ ID NO:1-30 and the region of SEQ ID NO:1-30 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

[0097] A “full length” polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A “full length” polynucleotide sequence encodes a “full length” polypeptide sequence.

[0098] “Homology” refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

[0099] The terms “percent identity” and “% identity,” as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithim Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

[0100] Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison Wis.). CLUSTAL V is described in Higgins, D. G. and P. M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D. G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and “diagonals saved”=4. The “weighted” residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polynucleotide sequences.

[0101] Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S. F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, Md., and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including “blastn,” that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called “BLAST 2 Sequences” that is used for direct pairwise comparison of two nucleotide sequences. “BLAST 2 Sequences” can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gov/bl2.html. The “BLAST 2 Sequences” tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the “BLAST 2 Sequences” tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

[0102] Matrix: BLOSUM62

[0103] Reward for match: 1

[0104] Penalty for mismatch: 2

[0105] Open Gap: 5 and Extension Gap: 2 penalties

[0106] Gap x drop-off: 50

[0107] Expect: 10

[0108] Word Size: 11

[0109] Filter: on

[0110] Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ D number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

[0111] Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

[0112] The phrases “percent identity” and “% identity,” as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

[0113] Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and “diagonals saved”=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polypeptide sequence pairs.

[0114] Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the “BLAST 2 Sequences” tool Version 2.0.12 (Apr.-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

[0115] Matrix:.BLOSUM62

[0116] Open Gap: 11 and Extension Gap: 1 penalties

[0117] Gap x drop-off: 50

[0118] Expect: 10

[0119] Word Size: 3

[0120] Filter: on

[0121] Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

[0122] “Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

[0123] The term “humanized antibody” refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

[0124] “Hybridization” refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the “washing” step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68° C. in the presence of about 6×SSC, about 1% (w/v) SDS, and about 100 μg/ml sheared, denatured salmon sperm DNA.

[0125] Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5° C. to 20° C. lower than the thermal melting point (T_(m)) for the specific sequence at a defined ionic strength and pH. The T_(m) is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_(m) and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2^(nd) ed., vol. 1-3, Cold Spring Harbor Press, Plainview N.Y.; specifically see volume 2, chapter 9.

[0126] High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68 ° C. in the presence of about 0.2×SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65° C., 60° C., 55° C., or 42° C. may be used. SSC concentration may be varied from about 0.1 to 2×SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 μg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

[0127] The term “hybridization complex” refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C₀t or R₀t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

[0128] The words “insertion” and “addition” refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

[0129] “Immune response” can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

[0130] An “immunogenic fragment” is a polypeptide or oligopeptide fragment of SECP which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term “immunogenic fragment” also includes any polypeptide or oligopeptide fragment of SECP which is useful in any of the antibody production methods disclosed herein or known in the art.

[0131] The term “microarray” refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

[0132] The terms “element” and “array element” refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

[0133] The term “modulate” refers to a change in the activity of SECP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of SECP.

[0134] The phrases “nucleic acid” and “nucleic acid sequence” refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

[0135] “Operably linked” refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

[0136] “Peptide nucleic acid” (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

[0137] “Post-translational modification” of an SECP may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of SECP.

[0138] “Probe” refers to nucleic acid sequences encoding SECP, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. “Primers” are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

[0139] Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

[0140] Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2^(nd) ed., vol. 1-3, Cold Spring Harbor Press, Plainview N.Y.; Ausubel, F. M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York N.Y.; Innis, M. et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego Calif. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge Mass.).

[0141] Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas Tex.) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge Mass.) allows the user to input a “mispriming library,” in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify filly or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

[0142] A “recombinant nucleic acid” is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

[0143] Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

[0144] A “regulatory element” refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5′ and 3′ untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

[0145] “Reporter molecules” are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

[0146] An “RNA equivalent,” in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

[0147] The term “sample” is used in its broadest sense. A sample suspected of containing SECP, nucleic acids encoding SECP, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

[0148] The terms “specific binding” and “specifically binding” refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope “A,” the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

[0149] The term “substantially purified” refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

[0150] A “substitution” refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

[0151] “Substrate” refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

[0152] A “transcript image” or “expression profile” refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

[0153] “Transformation” describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term “transformed cells” includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

[0154] A “transgenic organism,” as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. In one alternative, the nucleic acid can be introduced by infection with a recombinant viral vector, such as a lentiviral vector (Lois, C. et al. (2002) Science 295:868-872). The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

[0155] A “variant” of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the “BLAST 2 Sequences” tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 55%; at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an “allelic” (as defined above), “splice,” “species,” or “polymorphic” variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional fiuctional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass “single nucleotide polymorphisms” (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

[0156] A “variant” of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the “BLAST 2 Sequences” tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.

THE INVENTION

[0157] The invention is based on the discovery of new human secreted proteins (SECP), the polynucleotides encoding SECP, and the use of these compositions for the diagnosis, treatment, or prevention of liver, cell proliferative, autoimmune/inflammatory, cardiovascular, neurological, and developmental disorders.

[0158] Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown. Column 6 shows the Incyte ID numbers of physical, full length clones corresponding to the polypeptide and polynucleotide sequences of the invention. The full length clones encode polypeptides which have at least 95% sequence identity to the polypeptide sequences shown in column 3.

[0159] Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database and the PROTEOME database. Columns 1 and 2 show the polypeptidese identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (GenBank ID NO:) of the nearest GenBank homolog and the PROTEOME database identification numbers (PROTEOME ID NO:) of the nearest PROTEOME database homologs. Column 4 shows the probability scores for the matches between each polypeptide and its homolog(s). Column 5 shows the annotation of the GenBank and PROTEOME database homolog(s) along with relevant citations where applicable, all of which are expressly incorporated by reference herein.

[0160] Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison Wis.). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs including the locations of signal peptides (as indicated by “Signal Peptide” and/or “signal_cleavage”). Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

[0161] Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are secreted proteins.

[0162] For example, SEQ ID NO:1 is 99% identical, from residue G18 to residue T289, to human IgG Fc receptor I (GenBank ID g180279) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 5.4e-146, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:1 also contains immunoglobulin domains as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS analyses provide further corroborative evidence that SEQ ID NO:1 is a secreted protein (note that “immunoglobulin domains” are characteristic of matrix proteins).

[0163] As another example, SEQ ID NO:11 is 150 residues in length and is 100% identical, from residue M1 to residue S105, to human transmembrane gamma-carboxyglutamic acid protein 4 (TGM4) (GenBank ID g12656635) as determined by the Basic Local Alignment Search Tool (BIAST). (See Table 2.) The BLAST probability score is 8.4e-54, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:11 also contains a Vitamin K-dependent carboxylation/gamma-carboxyglutamic (GLA) domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:11 is a member of a family of vitamin K-dependent single-pass integral membrane proteins.

[0164] As another example, SEQ ID NO:16 is 519 amino acids in length and is 100% identical, from residue M274 to residue E519 to human AD021 protein (GenBank ID g7578787) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 8.3e-134, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance.

[0165] As another example, SEQ ID NO:22 is 81% identical, from residue M1 to residue Q138,to murine putative protein sequence (GenBank ID g12845943) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 9.1e-57, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:22 also contains signal cleavage sites as determined by searching for statistically significant matches in the SPScan weight matrix analysis program (See Table 3.)

[0166] As another example, SEQ ID NO:23 is 28% identical, fromresidue S42 to residue P345, to human Mac-2 binding protein (GenBank ID g307153) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 9.3e-27, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:23 also contains a BTB/POZ domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.)

[0167] SEQ ID NO:2-10, SEQ ID NO:12-15, SEQ ID NO:17-21, and SEQ ID NO:24-30 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ ID NO:1-30 are described in Table 7.

[0168] As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Column 1 lists the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:), the corresponding Incyte polynucleotide consensus sequence number (Incyte ID) for each polynucleotide of the invention, and the length of each polynucleotide sequence in basepairs. Column 2 shows the nucleotide start (5′) and stop (3′) positions of the cDNA and/or genomic sequences used to assemble the full length polynucleotide sequences of the invention, and of fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:31-60 or that distinguish between SEQ ID NO:31-60 and related polynucleotide sequences.

[0169] The polynucleotide fragments described in Column 2 of Table 4 may refer specifically, for example, to Incyte cDNAs derived from tissue-specific cDNA libraries or from pooled cDNA libraries. Alternatively, the polynucleotide fragments described in column 2 may refer to GenBank cDNAs or ESTs which contributed to the assembly of the full length polynucleotide sequences. In addition, the polynucleotide fragments described in column 2 may identify sequences derived from the ENSEMBL (The Sanger Centre, Cambridge, UK) database (i.e., those sequences including the designation “ENST”). Alternatively, the polynucleotide fragments described in column 2 may be derived from the NCBI RefSeq Nucleotide Sequence Records Database (i.e., those sequences including the designation “NM” or “NT”) or the NCBI RefSeq Protein Sequence Records (i.e., those sequences including the designation “NP”). Alternatively, the polynucleotide fragments described in column 2 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an “exon stitching” algorithm For example, a polynucleotide sequence identified as FL_XXXXXXX_N₁₋N₂₋YYYYY_N₃₋N₄ represents a “stitched” sequence in which XXXXXX is the identification number of the cluster of sequences to which the algorithm was applied, and YYYYY is the number of the prediction generated by the algorithm, and N_(1,2,3, . . . ,) if present, represent specific exons that may have been manually edited during analysis (See Example V). Alternatively, the polynucleotide fragments in column 2 may refer to assemblages of exons brought together by an “exon-stretching” algorithm For example, a polynucleotide sequence identified as FLXXXXXX_gAAAAA_gBBBBB_(—)1_N is a “stretched” sequence, with XXXXXX being the Incyte project identification number, gAAAAA being the GenBank identification number of the human genomic sequence to which the “exon-stretching” algorithm was applied, GBBBBB being the GenBank identification number or NCBI RefSeq identification number of the nearest GenBank protein homolog, and N referring to specific exons (See Example V). In instances where a RefSeq sequence was used as a protein homolog for the “exon-stretching” algorithm, a RefSeq identifier (denoted by “NM,” “NP,” or “NT”) may be used in place of the GenBank identifier (i.e., gBBBBB).

[0170] Alternatively, a prefix identifies component sequences that were hand-edited, predicted from genomic DNA sequences, or derived from a combination of sequence analysis methods. The following Table lists examples of component sequence prefixes and corresponding sequence analysis methods associated with the prefixes (see Example IV and Example V). Prefix Type of analysis and/or examples of programs GNN, Exon prediction from genomic sequences using, for GFG, example, GENSCAN (Stanford University, CA, USA) ENST or FGENES (Computer Genomics Group, The Sanger Centre, Cambridge, UK). GBI Hand-edited analysis of genomic sequences. FL Stitched or stretched genomic sequences (see Example V). INCY Full length transcript and exon prediction from mapping of EST sequences to the genome. Genomic location and EST composition data are combined to predict the exons and resulting transcript.

[0171] In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in Table 4 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

[0172] Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

[0173] Table 8 shows single nucleotide polymorphisms (SNPs) found in polynucleotide sequences of the invention, along with allele frequencies in different human populations. Columns 1 and 2 show the polynucleotide sequence identification number (SEQ ID NO:) and the corresponding Incyte project identification number (PID) for polynucleotides of the invention. Column 3 shows the Incyte identification number for the EST in which the SNP was detected (EST ID), and column 4 shows the identification number for the SNP (SNP ID). Column 5 shows the position within the EST sequence at which the SNP is located (EST SNP), and column 6 shows the position of the SNP within the full-length polynucleotide sequence (CB1 SNP). Column 7 shows the allele found in the EST sequence. Columns 8 and 9 show the two alleles found at the SNP site. Column 10 shows the amino acid encoded by the codon including the SNP site, based upon the allele found in the EST. Columns 11-14 show the frequency of allele 1 in four different human populations. An entry of n/d (not detected) indicates that the frequency of allele 1 in the population was too low to be detected, while n/a (not available) indicates that the allele frequency was not determined for the population.

[0174] The invention also encompasses SECP variants. A preferred SECP variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the SECP amino acid sequence, and which contains at least one functional or structural characteristic of SECP.

[0175] The invention also encompasses polynucleotides which encode SECP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:31-60, which encodes SECP. The polynucleotide sequences of SEQ ID NO:31-60, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxynbose.

[0176] The invention also encompasses a variant of a polynucleotide sequence encoding SECP. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding SECP. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:31-60 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:31-60. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of SECP.

[0177] In addition, or in the alternative, a polynucleotide variant of the invention is a splice variant of a polynucleotide sequence encoding SECP. A splice variant may have portions which have significant sequence identity to the polynucleotide sequence encoding SECP, but will generally have a greater or lesser number of polynucleotides due to additions or deletions of blocks of sequence arising from alternate splicing of exons during mRNA processing. A splice variant may have less than about 70%, or alternatively less than about 60%, or alternatively less than about 50% polynucleotide sequence identity to the polynucleotide sequence encoding SECP over its entire length; however, portions of the splice variant will have at least about 70%, or alternatively at least about 85%, or alternatively at least about 95%, or alternatively 100% polynucleotide sequence identity to portions of the polynucleotide sequence encoding SECP. Any one of the splice variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of SECP.

[0178] It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding SECP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, maybe produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring SECP, and all such variations are to be considered as being specifically disclosed.

[0179] Although nucleotide sequences which encode SECP and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring SECP under appropriately selected conditions of stringency, it maybe advantageous to produce nucleotide sequences encoding SECP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding SECP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

[0180] The invention also encompasses production of DNA sequences which encode SECP and SECP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding SECP or any fragment thereof.

[0181] Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:31-60 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G. M. and S. L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A. R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in “Definitions.”

[0182] Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the KIenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland Ohio), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway N.J.), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg Md.). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno Nev.), PTC200 thermal cycler (MJ Research, Watertown Mass.) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Applied Biosystems), the NEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale Calif.), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F. M. (1997) Short Protocols in Molecular Biologs, John Wiley & Sons, New York N.Y., unit 7.7; Meyers, R. A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York N.Y., pp. 856-853.)

[0183] The nucleic acid sequences encoding SECP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomiclocus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences inhuman and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J. D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto Calif.) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For an PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth Minn.) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68° C. to 72° C.

[0184] When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5′ regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5′ non-transcribed regulatory regions.

[0185] Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

[0186] In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode SECP may be cloned in recombinant DNA molecules that direct expression of SECP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express SECP.

[0187] The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter SECP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

[0188] The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara Calif.; described in U.S. Pat. No. 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F. C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of SECP, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through “artificial” breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

[0189] In another embodiment, sequences encoding SECP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M. H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, SECP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York N.Y., pp. 55-60; and Roberge, J. Y. et al. (1995) Science 269:202-204.) Automated synthesis maybe achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of SECP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

[0190] The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R. M. and, F. Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

[0191] In order to express a biologically active SECP, the nucleotide sequences encoding SECP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5′ and 3′ untranslated regions in the vector and in polynucleotide sequences encoding SECP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding SECP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding SECP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

[0192] Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding SECP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview N.Y., ch. 4, 8, and 16-17; Ausubel, F. M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

[0193] A variety of expression vector/host systems may be utilized to contain and express sequences encoding SECP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S. M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York N.Y., pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R. M. et al. (1985) Nature 317(6040):813-815; McGregor, D. P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I. M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

[0194] In bacterial systems, a number of cloning and expression vectors maybe selected depending upon the use intended for polynucleotide sequences encoding SECP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding SECP can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla Calif.) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding SECP into the vector's multiple cloning site disrupts the lacZ gene, allowing a calorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletionsin the cloned sequence. (See, e.g., Van Heeke, G. and S. M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of SECP are needed, e.g. for the production of antibodies, vectors which direct high level expression of SECP may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

[0195] Yeast expression systems may be used for production of SECP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, G. A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C. A. et al. (1994) Bio/Technology 12:181-184.)

[0196] Plant systems may also be used for expression of SECP. Transcription of sequences encoding SECP may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York N.Y., pp. 191-196.)

[0197] In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding SECP may be ligated into an adenovinus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses SECP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

[0198] Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J. J. et al. (1997) Nat. Genet 15:345-355.)

[0199] For long term production of recombinant proteins in mammalian systems, stable expression of SECP in cell lines is preferred. For example, sequences encoding SECP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

[0200] Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in tk⁻ and apr⁻ cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, dhfr confers resistance to methotrexate; neo confers resistance to the aminoglycosides neomycin and G-418; and als and pat confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., trpB and hisD, which alter cellular requirements for metabolites. (See, e.g., Hartn, S. C. and R. C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β-glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C. A. (1995) Methods Mol. Biol. 55:121-131.)

[0201] Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding SECP is inserted within a marker gene sequence, transformed cells containing sequences encoding SECP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding SECP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

[0202] In general, host cells that contain the nucleic acid sequence encoding SECP and that express SECP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

[0203] Immunological methods for detecting and measuring the expression of SECP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on SECP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul Minn., Sect IV; Coligan, J. E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York N.Y.; and Pound, J. D. (1998) Immunochemical Protocols, Humana Press, Totowa N.J.)

[0204] A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding SECP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding SECP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison Wis.), and US Biochemical. Suitable reporter molecules or labels which maybe used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

[0205] Host cells transformed with nucleotide sequences encoding SECP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode SECP may be designed to contain signal sequences which direct secretion of SECP through a prokaryotic or eukaryotic cell membrane.

[0206] In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a “prepro” or “pro” form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI3 8) are available from the American Type Culture Collection (ATCC, Manassas Va.) and may be chosen to ensure the correct modification and processing of the foreign protein.

[0207] In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding SECP may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric SECP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of SECP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, c-myc, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodlin, and metal-chelate resins, respectively. FLAG, c-nyc, and hemagglutinin (HA) enable immunoaffimity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the SECP encoding sequence and the heterologous protein sequence, so that SECP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

[0208] In a further embodiment of the invention, synthesis of radiolabeled SECP may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ³⁵S-methionine.

[0209] SECP of the present invention or fragments thereof may be used to screen for compounds that specifically bind to SECP. At least one and up to a plurality of test compounds may be screened for specific binding to SECP. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

[0210] In one embodiment, the compound thus identified is closely related to the natural ligand of SECP, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J. E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which SECP binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express SECP, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing SECP or cell membrane fractions which contain SECP are then contacted with a test compound and binding, stimulation, or inhibition of activity of either SECP or the compound is analyzed.

[0211] An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with SECP, either in solution or affixed to a solid support, and detecting the binding of SECP to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

[0212] SECP of the present invention or fragments thereof maybe used to screen for compounds that modulate the activity of SECP. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for SECP activity, wherein SECP is combined with at least one test compound, and the activity of SECP in the presence of a test compound is compared with the activity of SECP in the absence of the test compound. A change in the activity of SECP in the presence of the test compound is indicative of a compound that modulates the activity of SECP. Alternatively, a test compound is combined with an in vitro or cell-free system comprising SECP under conditions suitable for SECP activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of SECP may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

[0213] In another embodiment, polynucleotides encoding SECP or their mammalian homologs may be “knocked out” in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Pat. No. 5,175,383 and U.S. Pat. No. 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capeccbi, M. R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J. D. (1996) Clin. Invest. 97:1999-2002; Wagner, K. U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

[0214] Polynucleotides encoding SECP may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J. A. et al. (1998) Science 282:1145-1147).

[0215] Polynucleotides encoding SECP can also be used to create “knockin” humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding SECP is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress SECP, e.g., by secreting SECP in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

[0216] Therapeutics

[0217] Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of SECP and secreted proteins. In addition, the expression of SECP is closely associated with diseased breast, brain, brain tumor, diseased brain, nervous, developmental, and diseased endometrial tissues, bone cancer, adrenal and brain tissues, and with neighboring tissues associated with tumors of the lung and ovary, dendritic cells, and kidney cortex tissue associated with a renal cancinoma, nasal, cribriform and ovarian tumor tissues. In addition, examples of tissues expressing SECP can be found in Table 6. Therefore, SECP appears to play a role in liver, cell proliferative, autoimmune/inflammatory, cardiovascular, neurological, and developmental disorders. In the treatment of disorders associated with increased SECP expression or activity, it is desirable to decrease the expression or activity of SECP. In the treatment of disorders associated with decreased SECP expression or activity, it is desirable to increase the expression or activity of SECP.

[0218] Therefore, in one embodiment, SECP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of SECP. Examples of such disorders include, but are not limited to, a liver disorder such as adenomatosis, cholestasis, cirrhosis, hemangioma, Henoch-Schonlein purpura, hepatitis, hepatocellular and metastatic carcinomas, idiopathic thrombocytopenic purpura, porphyria, sarcoidosis, and Wilson disease and for diagnosis of liver disorders and detecting metabolic and toxicological responses to treatment with steroids; a cell proliferative disorder such as actinickeratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, a cancer of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erylbroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenicpurpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a cardiovascular disorder such as congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, complications of cardiac transplantation, arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, and complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system including Down syndrome, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; and a developmental disorder such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss.

[0219] In another embodiment, a vector capable of expressing SECP or a fragment or derivative thereof may be administered to a subject, to treat or prevent a disorder associated with decreased expression or activity of SECP including, but not limited to, those described above.

[0220] In a further embodiment, a composition comprising a substantially purified SECP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of SECP including, but not limited to, those provided above.

[0221] In still another embodiment, an agonist which modulates the activity of SECP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of SECP including, but not limited to, those listed above.

[0222] In a further embodiment, an antagonist of SECP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of SECP. Examples of such disorders include, but are not limited to, those liver, cell proliferative, autoimmune/inflammatory, cardiovascular, neurological, and developmental disorders described above. In one aspect, an antibody which specifically binds SECP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express SECP.

[0223] In an additional embodiment, a vector expressing the complement of the polynucleotide encoding SECP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of SECP including, but not limited to, those described above.

[0224] In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects. An antagonist of SECP may be produced using methods which are generally known in the art. In particular, purified SECP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind SECP. Antibodies to SECP may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polygonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use. Single chain antibodies (e.g., from camels or llamas) may be potent enzyme inhibitors and may have advantages in the design of peptide mimetics, and in the development of immuno-adsorbents and biosensors (Muyldermans, S. (2001) J. Biotechnol. 74:277-302).

[0225] For the production of antibodies, various hosts including goats, rabbits, rats, mice, camels, dromedaries, llamas, humans, and others may be immunized by injection with SECP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

[0226] It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to SECP have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of SECP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

[0227] Monoclonal antibodies to SECP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R. J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S. P. et al. (1984) Mol. Cell Biol. 62:109-120.)

[0228] In addition, techniques developed for the production of “chimeric antibodies,” such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S. L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M. S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce SECP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D. R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

[0229] Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

[0230] Antibody fragments which contain specific binding sites for SECP may also be generated. For example, such fragments include, but are not limited to, F(ab′)₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab′)₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W. D. et al. (1989) Science 246:1275-1281.)

[0231] Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between SECP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering SECP epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

[0232] Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for SECP. Affinity is expressed as an association constant, K_(a), which is defined as the molar concentration of SECP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_(a) determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple SECP epitopes, represents the average affinity, or avidity, of the antibodies for SECP. The K_(a) determined for a preparation of monoclonal antibodies, which are monospecific for a particular SECP epitope, represents a true measure of affinity. High-affinity antibody preparations with K_(a) ranging from about 10⁹ to 10¹² L/mole are preferred for use in immunoassays in which the SECP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_(a) ranging from about 10⁶ to 10⁷ L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of SECP, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J. E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York N.Y.).

[0233] The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of SECP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

[0234] In another embodiment of the invention, the polynucleotides encoding SECP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding SECP. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding SECP. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa N.J.)

[0235] In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J. E. et al. (1998) J. Allergy Clin. Immunol. 102(3):469-475; and Scanlon, K. J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A. D. (1990) Blood 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J. J. (1995) Br. Med. Bull. 51(1):217-225; Boado, R. J. et al. (1998) J. Pharm. Sci. 87(11):1308-1315; and Morris, M. C. et al. (1997) Nucleic Acids Res. 25(14):2730-2736.)

[0236] In another embodiment of the invention, polynucleotides encoding SECP may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R. M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R. G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R. G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassamias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R. G. (1995) Science 270:404-410; Verma, I. M. and N. Somia (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in SECP expression or regulation causes disease, the expression of SECP from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

[0237] In a further embodiment of the invention, diseases or disorders caused by deficiencies in SECP are treated by constructing mammalian expression vectors encoding SECP and introducing these vectors by mechanical means into SECP-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R. A. and W. F. Anderson (1993) Annu. Rev. Biochem 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H Récipon (1998) Curr. Opin. Biotechnol. 9:445-450).

[0238] Expression vectors that may be effective for the expression of SECP include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX, PCR2-TOPOTA vectors (Invitrogen, Carlsbad Calif.), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla Calif.), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto Calif.). SECP may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F. M. V. and H. M. Blau (1998) Curr. Opin Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F. M. V. and H. M. Blau, supra)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding SECP from a normal individual.

[0239] Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F. L. and A. J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

[0240] In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to SECP expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding SECP under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus cis-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M. A. et al. (1987) J. Virol. 61:1639-1646; Adam, M. A. and A. D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Pat. No. 5,910,434 to Rigg (“Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant”) discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M. L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

[0241] In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding SECP to cells which have one or more genetic abnormalities with respect to the expression of SECP. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M. E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Pat. No. 5,707,618 to Armentano (“Adenovirus vectors for gene therapy”), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P. A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verna, I. M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

[0242] In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding SECP to target cells which have one or more genetic abnormalities with respect to the expression of SECP. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing SECP to cells of the central nervous system, for which HSV has a tropism The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type l-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X et al. (1999) Exp. Eye Res. 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Pat. No. 5,804,413 to DeLuca (“Herpes simplex virus strains for gene transfer”), which is hereby incorporated by reference. U.S. Pat. No. 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W. F. et al. (1999) J. Virol. 73:519-532 and Xu, H. et al. (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

[0243] In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding SECP to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K-J. Li (1998) Curr. Opin. Biotechnol. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for SECP into the alphavirus genome in place of the capsid-coding region results in the production of a large number of SECP-coding RNAs and the synthesis of high levels of SECP in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S. A. et al. (1997) Virology 228:74-83). The wide host range of alpha viruses will allow the introduction of SECP into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

[0244] Oligonucleotides derived from the transcription initiation site, e.g., between about positions −10 and +10 from the start site, may also be employed to inhibit gene expression Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J. E. et al. (1994) in Huber, B. E. and B. I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco N.Y., pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

[0245] Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding SECP.

[0246] Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

[0247] Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis:. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding SECP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

[0248] RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5′ and/or 3′ ends of the molecule, or the use of phosphorothioate or 2′ O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

[0249] An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding SECP. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased SECP expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding SECP may be therapeutically useful, and in the treatment of disorders associated with decreased SECP expression or activity, a compound which specifically promotes expression of the polynucleotide encoding SECP may be therapeutically useful.

[0250] At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding SECP is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system Alterations in the expression of a polynucleotide encoding SECP are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding SECP. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Pat. No. 5,932,435; Arndt, G. M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M. L. et al. (2000) Biochem Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T. W. et al (1997) U.S. Pat. No. 5,686,242; Bruice, T. W. et al. (2000) U.S. Pat. No. 6,022,691).

[0251] Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C. K. et al. (1997) Nat Biotechnol. 15:462-466.)

[0252] Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

[0253] An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remingon's Pharmaceutical Sciences (Maack Publishing, Easton Pa.). Such compositions may consist of SECP, antibodies to SECP, and mimetics, agonists, antagonists, or inhibitors of SECP.

[0254] The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

[0255] Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J. S. et al., U.S. Pat. No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

[0256] Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

[0257] Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising SECP or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, SECP or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S. R. et al. (1999) Science 285:1569-1572).

[0258] For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

[0259] A therapeutically effective dose refers to that amount of active ingredient, for example SECP or fragments thereof, antibodies of SECP, and agonists, antagonists or inhibitors of SECP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED₅₀ (the dose therapeutically effective in 50% of the population) or LD₅₀ (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD₅₀/ED₅₀ ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED₅₀ with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

[0260] The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

[0261] Normal dosage amounts may vary from about 0.1 μg to 100,000 μg, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

[0262] Diagnostics

[0263] In another embodiment, antibodies which specifically bind SECP may be used for the diagnosis of disorders characterized by expression of SECP, or in assays to monitor patients being treated with SECP or agonists, antagonists, or inhibitors of SECP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for SECP include methods which utilize the antibody and a label to detect SECP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

[0264] A variety of protocols for measuring SECP, including ELISAs, RIAS, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of SECP expression. Normal or standard values for SECP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to SECP under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of SECP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

[0265] In another embodiment of the invention, the polynucleotides encoding SECP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of SECP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of SECP, and to monitor regulation of SECP levels during therapeutic intervention.

[0266] In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding SECP or closely related molecules may be used to identify nucleic acid sequences which encode SECP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5′ regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding SECP, allelic variants, or related sequences.

[0267] Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the SECP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:31-60 or from genomic sequences including promoters, enhancers, and introns of the SECP gene.

[0268] Means for producing specific hybridization probes for DNAs encoding SECP include the cloning of polynucleotide sequences encoding SECP or SECP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and maybe used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ³²P or ³⁵S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

[0269] Polynucleotide sequences encoding SECP may be used for the diagnosis of disorders associated with expression of SECP. Examples of such disorders include, but are not limited to, a liver disorder such as adenomatosis, cholestasis, cirrhosis, hemangioma, Henoch-Schonlein purpura, hepatitis, hepatocellular and metastatic carcinomas, idiopathic thrombocytopenic purpura, porphyria, sarcoidosis, and Wilson disease and for diagnosis of liver disorders and detecting metabolic and toxicological responses to treatment with steroids; a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, a cancer of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid artritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a cardiovascular disorder such as congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, complications of cardiac transplantation, arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothromnbosis, vascular tumors, and complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system including Down syndrome, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; and a developmental disorder such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss. The polynucleotide sequences encoding SECP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered SECP expression. Such qualitative or quantitative methods are well known in the art.

[0270] In a particular aspect, the nucleotide sequences encoding SECP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding SECP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding SECP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

[0271] In order to provide a basis for the diagnosis of a disorder associated with expression of SECP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding SECP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this maimer may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

[0272] Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

[0273] With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

[0274] Additional diagnostic uses for oligonucleotides designed from the sequences encoding SECP may involve the use of PCR These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding SECP, or a fragment of a polynucleotide complementary to the polynucleotide encoding SECP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

[0275] In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding SECP may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding SECP are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the ampliers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego Calif.).

[0276] SNPs may be used to study the genetic basis of human disease. For example, at least 16 common SNPs have been associated with non-insulin-dependent diabetes mellitus. SNPs are also useful for examining differences in disease outcomes in monogenic disorders, such as cystic fibrosis, sickle cell anemia, or chronic granulomatous disease. For example, variants in the mannose-binding lectin, MBL2, have been shown to be correlated with deleterious pulmonary outcomes in cystic fibrosis. SNPs also have utility in pharmacogenomics, the identification of genetic variants that influence a patient's response to a drug, such as life-threatening toxicity. For example, a variation in N-acetyl transferase is associated with a high incidence of peripheral neuropathy in response to the anti-tuberculosis drug isoniazid, while a variation in the core promoter of the ALOX5 gene results in diminished clinical response to treatment with an anti-asthma drug that targets the 5-lipoxygenase pathway. Analysis of the distribution of SNPs in different populations is useful for investigating genetic drift, mutation, recombination, and selection, as well as for tracing the origins of populations and their migrations. (Taylor, J. G. et al. (2001) Trends Mol. Med. 7:507-512; Kwok, P.-Y. and Z. Gu (1999) Mol. Med. Today 5:538-543; Nowotny, P. et al. (2001) Curr. Opin. Neurobiol. 11:637-641.)

[0277] Methods which may also be used to quantify the expression of SECP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P. C. et al. (1993)J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and aspectrophotometric or colorimetric response gives rapid quantitation.

[0278] In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

[0279] In another embodiment, SECP, fragments of SECP, or antibodies specific for SECP may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

[0280] A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilkamer et al., “Comparative Gene Transcript Analysis,” U.S. Pat. No. 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

[0281] Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

[0282] Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E. F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N. L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at http://www.niehs.nih.gov/oc/news/toxchip.ht) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

[0283] In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

[0284] Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

[0285] A proteomic profile may also be generated using antibodies specific for SECP to quantify the levels of SECP expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem 270:103-111; Mendoze, L. G. et al. (1999) Biotechniques 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

[0286] Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N. L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

[0287] In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

[0288] In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

[0289] Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T. M. et al. (1995) U.S. Pat. No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R. A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M. J. et al. (1997) U.S. Pat. No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

[0290] In another embodiment of the invention, nucleic acid sequences encoding SECP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355; Price, C. M. (1993) Blood Rev. 7:127-134; and Trask, B. J. (199 1) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E. S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

[0291] Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding SECP on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

[0292] In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R. A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

[0293] In another embodiment of the invention, SECP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between SECP and the agent being tested may be measured.

[0294] Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with SECP, or fragments thereof, and washed. Bound SECP is then detected by methods well known in the art. Purified SECP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutraling antibodies can be used to capture the peptide and immobilize it on a solid support.

[0295] In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding SECP specifically compete with a test compound for binding SECP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with SECP.

[0296] In additional embodiments, the nucleotide sequences which encode SECP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

[0297] Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

[0298] The disclosures of all patents, applications, and publications mentioned above and below, including U.S. Ser. No. 60/285,207, U.S. Ser. No. 60/287,114, U.S. Ser. No. 60/288,640, U.S. Ser. No. 60/290,516, U.S. Ser. No. 60/292,184, U.S. Ser. No. 60/343,553, U.S. Ser. No. 60/358,279, U.S. Ser. No. 60/366,041, and U.S. Ser. No. 60/357,002, are hereby expressly incorporated by reference.

EXAMPLES

[0299] I. Construction of cDNA Libraries

[0300] Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto Calif.). Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

[0301] Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth Calif.), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin Tex.).

[0302] In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad Calif.), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA plasmid (Invitrogen), PCMV-ICIS plasmid (Stratagene), pIGEN (Incyte Genomics, Palo Alto Calif.), pRARE (Incyte Genomics), or pINCY (Incyte Genomics), or derivatives thereof Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5α, DH10B, or ElectroMAX DH10B from Life Technologies.

[0303] II. Isolation of cDNA Clones

[0304] Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg Md.); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4° C.

[0305] Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V. B. (1994) Anal. Biochem 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene Oreg.) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

[0306] III. Sequencing and Analysis

[0307] Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

[0308] The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM; PROTEOME databases with sequences from Homo sapiens, Rattus norvegicus, Mus musculus, Caenorhabditis elegans, Saccharomyces cerevisiae, Schizosaccharomyces pombe, and Candida albicans (Incyte Genomics, Palo Alto Calif.); hidden Markov model (HMM)-based protein family databases such as PFAM, INCY, and TIGRFAM (Haft, D. H. et al. (2001) Nucleic Acids Res. 29:41-43); and HMM-based protein domain databases such as SMART (Schultz et al. (1998) Proc. Natl. Acad. Sci. USA 95:5857-5864; Letunic, I. et al. (2002) Nucleic Acids Res. 30:242-244). (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S. R (1996) Curr. Opin. Struct. Biol. 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and PASTA. The full length polynucleotide sequences were translated to derive the corresponding fill length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, the PROTEOME databases, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, hidden Markov model (HMM)-based protein family databases such as PFAM, INCY, and TIGRPAM; and HMM-based protein domain databases such as SMART. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco Calif.) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

[0309] Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

[0310] The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:31-60. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 2.

[0311] IV. Identification and Editing of Coding Sequences from Genomic DNA

[0312] Putative secreted proteins were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode secreted proteins, the encoded polypeptides were analyzed by querying against PFAM models for secreted proteins. Potential secreted proteins were also identified by homology to Incyte cDNA sequences thathadbeen annotated as secreted proteins. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this informationwas used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

[0313] V. Assembly of Genomic Sequence Data with cDNA Sequence Data

[0314] “Stitched” Sequences

[0315] Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then “stitched” together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpri public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

[0316] “Stretched” Sequences

[0317] Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore “stretched” or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

[0318] VI. Chromosomal Mapping of SECP Encoding Polynucleotides

[0319] The sequences which were used to assemble SEQ ID NO:31-60 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm Sequences from these databases that matched SEQ ID NO:31-60 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Genethon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location

[0320] Map locations are represented by ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Genethon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI “GeneMap '99” World Wide Web site (http://www.ncbi.nlm.nih.gov/genemap/), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

[0321] VII. Analysis of Polynucleotide Expression

[0322] Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel (1995) supra, ch. 4 and 16.)

[0323] Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as: $\frac{{BLAST}\quad {Score} \times {Percent}\quad {Identity}}{5 \times {minimum}\quad \left\{ {{{length}\left( {{Seq}.\quad 1} \right)},{{length}\left( {{Seq}.\quad 2} \right)}} \right\}}$

[0324] The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and −4 for every mismatch Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced eitherby 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

[0325] Alternatively, polynucleotide sequences encoding SECP are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system;liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding SECP. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto Calif.).

[0326] VIII. Extension of SECP Encoding Polynucleotides

[0327] Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5′ extension of the known fragment, and the other primer was synthesized to initiate 3′ extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68° C. to about 72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

[0328] Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

[0329] High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg²⁺, (NH₄)₂SO₄, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 68° C., 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68 ° C., 5 min; Step 7: storage at 4° C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 57° C., 1 min; Step 4: 68° C., 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68 ° C., 5 min; Step 7: storage at 4° C.

[0330] The concentration of DNA in each well was determined by dispensing 100 μl PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene Oreg.) dissolved in 1× TE and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton Mass.), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by electrophoresis on a 1% agarose gel to determine which reactions were successful in extending the sequence.

[0331] The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison Wis.), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly Mass.) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37° C. in 384-well plates in LB/2× carb liquid media.

[0332] The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 72° C., 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72° C., 5 min; Step 7: storage at 4° C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

[0333] In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5′ regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

[0334] IX. Identification of Single Nucleotide Polymorphisms in SECP Encoding Polynucleotides

[0335] Common DNA sequence variants known as single nucleotide polymorphisms (SNPs) were identified in SEQ ID NO:31-60 using the LIFESEQ database (ncyte Genomics). Sequences from the same gene were clustered together and assembled as described in Example III, allowing the identification of all sequence variants in the gene. An algorithm consisting of a series of filters was used to distinguish SNPs from other sequence variants. Preliminary filters removed the majority of basecall errors by requiring a minimum Phred quality score of 15, and removed sequence alignment errors and errors resulting from improper trimming of vector sequences, chimeras, and splice variants. An automated procedure of advanced chromosome analysis analysed the original chromatogram files in the vicinity of the putative SNP. Clone error filters used statistically generated algorithms to identify errors introduced during laboratory processing, such as those caused by reverse transcriptase, polymerase, or somatic mutation. Clustering error filters used statistically generated algorithms to identify errors resulting from clustering of close homologs or pseudogenes, or due to contamination by non-human sequences. A final set of filters removed duplicates and SNPs found in immunoglobulins or T-cell receptors.

[0336] Certain SNPs were selected for further characterization by mass spectrometry using the high throughput MASSARRAY system (Sequenom, Inc.) to analyze allele frequencies at the SNP sites in four different human populations. The Caucasian population comprised 92 individuals (46 male, 46 female), including 83 from Utah, four French, three Venezualan, and two Amish individuals. The African population comprised 194 individuals (97 male, 97 female), all African Americans. The Hispanic population comprised 324 individuals (162 male, 162 female), all Mexican Hispanic. The Asian population comprised 126 individuals (64 male, 62 female) with a reported parental breakdown of 43% Chinese, 31%Japanese, 13% Korean,5% Vietnamese, and 8% other Asian. Allele frequencies were first analyzed in the Caucasian population; in some cases those SNPs which showed no allelic variance in this population were not further tested in the other three populations.

[0337] X. Labeling and Use of Individual Hybridization Probes

[0338] Hybridization probes derived from SEQ ID NO:31-60 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μCi of [γ-³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston Mass.). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

[0339] The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Scbleicher & Schuell, Durham N.H.). Hybridization is carried out for 16 hours at 40° C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1×saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

[0340] XI. Microarrays

[0341] The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra.), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

[0342] Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

[0343] Tissue or Cell Sample Preparation

[0344] Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/μl oligo-(dT) primer (21mer), 1× first strand buffer, 0.03 units/μl RNase inhibitor, 500 μM dATP, 500 μM dGTP, 500 μM dTTP, 40 μM dCTP, 40 μM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)⁺ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37° C. for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85° C. to the stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto Calif.) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook N.Y.) and resuspended in 14 μl 5×SSC/0.2% SDS.

[0345] Microarray Preparation

[0346] Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μg. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

[0347] Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester Pa.), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110° C. oven.

[0348] Array elements are applied to the coated glass substrate using a procedure described in U.S. Pat. No. 5,807,522, incorporated herein by reference. 1 μl of the array element DNA, at an average concentration of 100 ng/μl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

[0349] Microarrays are UV-crosslinked using a STRATALINER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford Mass.) for 30 minutes at 60° C. followed by washes in 0.2% SDS and distilled water as before.

[0350] Hybridization

[0351] Hybridization reactions contain 9 μl of sample mixture consisting of 0.2 μg each of Cy3 and Cy5 labeled cDNA synthesis products in 5×SSC, 0.2% SDS hybridizationbuffer. The sample mixture is heated to 65° C. for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μl of 5×SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60° C. The arrays are washed for 10 min at 45° C. in a first wash buffer (1×SSC, 0.1% SDS), three times for 10 minutes each at 45° C. in a second wash buffer (0.1×SSC), and dried.

[0352] Detection

[0353] Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara Calif.) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20× microscope objective (Nikon, Inc., Melville N.Y.). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm×1.8 cm array used in the present example is scanned with are solution of 20 micrometers.

[0354] In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater N.J.) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

[0355] The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

[0356] The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood Mass.) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum

[0357] A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal- analysis is the GEMTOOLS gene expression analysis program (Incyte).

[0358] Human THP-1 cells (American Type Culture Collection, Manassas Va.) were grown in RPMI1640 medium containing 10% fetal serum (v/v), 0.45% glucose (w/v), 10 mM Hepes, 1 mM sodium pyruvate, 1×10⁻⁵ M β-mercaptoethanol, penicillin (100 units/ml) and streptomycin (100 mg/ml). For oxidized-LDL loading experiments, cells were seeded at a density of 1×10⁶ cells/ml in medium containing 12-0-tetradecanoyl-phorbol-13-acetate (Research Biochemical International, Natick Mass.) at 1×10⁻⁷ M for 24 hr. The medium was then replaced by culture medium with or without 100 μg/ml of CuSO₄ “fully” oxidized LDL (Intracel, Rockville Md.) according to the method of Hammer et al. (1995; Arterio Thromb Vasc Biol 15:704-713). Medium was replaced every two days during the time of culture. Cells were treated with Ox-LDL over time points ranging from 30 minutes to 4 days. During this period, cells remained adherent and had a typical speckled Nile red staining pattern. RNA was prepared for expression profiling at 0, 0.5, 2.5, and 8 hours, and 1, 2, and 4 days of Ox-LDL exposure.

[0359] Steroid Treatment of Human Liver C3A Cells

[0360] Early confluent C3A cells were treated with mifepristone, progesterone, beclomethasone, medroxyprogesterone, budesonide, prednisone, dexamethasone, betamethasone, or danazol at concentrations of 1 μM, 10 μM, and 100 μM for 1, 3, and 6 hours. In all cases mRNA from untreated early confluent C3A cells were prepared in parallel.

[0361] In this way it was shown that for SEQ ID NO:31, SECP was downregulated at least 2-fold in three of six lung tumor tissues tested. In addition it was down-regulated at least 3-fold in a THP-1 model for foam cell formation. For SEQ ID NO:34, it was shown that SECP expression was up-regulated at least 2.5-fold in a C3A liver cell line when treated with the following steroid compounds: beclomethasone (Beclo), medroxyprogesterone (MAH), prednisone (Prdsne), dexamethasone (Dex), and with betamethas one (Betam).

[0362] XII. Complementary Polynucleotides

[0363] Sequences complementary to the SECP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring SECP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of SECP. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5′ sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the SECP-encoding transcript.

[0364] XIII. Expression of SECP

[0365] Expression and purification of SECP is achieved using bacterial or virus-based expression systems. For expression of SECP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the trp-lac (tac) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express SECP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of SECP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autoraphica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding SECP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic. modifications to baculovirus. (See Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

[0366] In most expression systems, SECP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutatlione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from SECP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified SECP obtained by these methods can be used directly in the assays shown in Examples XVII, XVIII, and XIX, where applicable.

[0367] XV. Functional Assays

[0368] SECP function is assessed by expressing the sequences encoding SECP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression Vectors of choice include PCMV SPORT Wife Technologies) and PCR3.1 (Invitrogen, Carlsbad Calif.), both of which contain the cytomegalovirus promoter. 5-10 μg of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μg of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York N.Y.

[0369] The influence of SECP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding SECP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success N.Y.). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding SECP and other genes of interest can be analyzed by northern analysis or microarray techniques.

[0370] XV. Production of SECP Specific Antibodies

[0371] SECP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M. G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize animals (e.g., rabbits, mice, etc.) and to produce antibodies using standard protocols.

[0372] Alternatively, the SECP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch 11.)

[0373] Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using FMOC chemistry and coupled to KLH (Sigma-Aldrich, St. Louis Mo.) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-SECP activity by, for example, binding the peptide or SECP to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

[0374] XVI. Purification of Naturally Occurring SECP Using Specific Antibodies

[0375] Naturally occurring or recombinant SECP is substantially purified by immunoaffinity chromatography using antibodies specific for SECP. An immunoaffinity column is constructed by covalently coupling anti-SECP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

[0376] Media containing SECP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of SECP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/SECP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and SECP is collected.

[0377] XVII. Identification of Molecules which Interact with SECP

[0378] SECP, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent (See, e.g., Bolton, A. E. and W. M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled SECP, washed, and any wells with labeled SECP complex are assayed. Data obtained using different concentrations of SECP are used to calculate values for the number, affinity, and association of SECP with the candidate molecules.

[0379] Alternatively, molecules interacting with SECP are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

[0380] SECP may also be used in the PATHCALLING process (CuraGen Corp., New Haven Conn.) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K et al. (2000) U.S. Pat. No. 6,057,101).

[0381] XVIII. Demonstration of SECP Activity

[0382] An assay for growth stimulating or inhibiting activity of SECP measures the amount of DNA synthesis in Swiss mouse 3T3 cells (McKay, I. and Leigh, I., eds. (1993) Growth Factors: A Practical Approach, Oxford University Press, New York, N.Y.). In this assay, varying amounts of SECP are added to quiescent 3T3 cultured cells in the presence of [³H]thymidine, a radioactive DNA precursor. SECP for this assay can be obtained by recombinant means or from biochemical preparations. Incorporation of [³H]thymidine into acid-precipitable DNA is measured over an appropriate time interval, and the amount incorporated is directly proportional to the amount of newly synthesized DNA. A linear dose-response curve over at least a hundred-fold SECP concentration range is indicative of growth modulating activity. One unit of activity per milliliter is defined as the concentration of SECP producing a 50% response level, where 100% represents maxima incorporation of [³H]thymidine into acid-precipitable DNA.

[0383] Alternatively, an assay for SECP activity measures the stimulation or inhibition of neurotransmission in cultured cells. Cultured CHO fibroblasts are exposed to SECP. Following endocytic uptake of SECP, the cells are washed with fresh culture medium and a whole cell voltage-clamped Xenopus myocyte is manipulated into contact with one of the fibroblasts in SECP-free medium. Membrane currents are recorded from the myocyte. Increased or decreased current relative to control values are indicative of neuromodulatory effects of SECP (Morimoto, T. et al. (1995) Neuron 15:689-696).

[0384] Alternatively, an assay for SECP activity measures the amount of SECP in secretory, membrane-bound organelles. Transfected cells as described above are harvested and lysed. The lysate is fractionated using methods known to those of skill in the art, for example, sucrose gradient ultracentrifigation. Such methods allow the isolation of subcellular components such as the Golgi apparatus, ER, small membrane-bound vesicles, and other secretory organelles. Immunoprecipitations from fractionated and total cell lysates are performed using SECP-specific antibodies, and immunoprecipitated samples are analyzed using SDS-PAGE and immunoblotting techniques. The concentration of SECP in secretory organelles relative to SECP in total cell lysate is proportional to the amount of SECP in transit through the secretory pathway.

[0385] Alternatively, AMP binding activity is measured by combining SECP with ³²P-labeled AMP. The reaction is incubated at 37° C. and terminated by addition of tridcloroacetic acid. The acid extract is neutralized and subjected to gel electrophoresis to remove unbound label. The radioactivity retained in the gel is proportional to SECP activity.

[0386] XIX. Demonstration of Immunoglobulin Activity

[0387] An assay for SECP activity measures the ability of SECP to recognize and precipitate antigens from serum. This activity can be measured by the quantitative precipitin reaction. (Golub, E. S. et al. (1987) Immunology: A Synthesis, Sinauer Associates, Sunderland, Mass., pages 113-115.) SECP is isotopically labeled using methods known in the art. Various serum concentrations are added to constant amounts of labeled SECP. SECP-antigen complexes precipitate out of solution and are collected by centrifugation. The amount of precipitable SECP-antigen complex is proportional to the amount of radioisotope detected in the precipitate. The amount of precipitable SECP-antigen complex is plotted against the serum concentration. For various serum concentrations, a characteristic precipitin curve is obtained, in which the amount of precipitable SECP-antigen complex initially increases proportionately with increasing serum concentration, peaks at the equivalence point, and then decreases proportionately with further increases in serum concentration. Thus, the amount of precipitable SECP-antigen complex is a measure of SECP activity which is characterized by sensitivity to both limiting and excess quantities of antigen.

[0388] Alternatively, an assay for SECP activity measures the expression of SECP on the cell surface. cDNA encoding SECP is transfected into a non-leukocytic cell line. Cell surface proteins are labeled with biotin (de 1a Puente, M. A. et al. (1997) Blood 90:2398-2405). Immunoprecipitations are performed using SECP-specific antibodies, and immunoprecipitated samples are analyzed using SDS-PAGE and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of SECP expressed on the cell surface.

[0389] Alternatively, an assay for SECP activity measures the amount of cell aggregation induced by overexpression of SECP. In this assay, cultured cells such as NIH3T3 are transfected with cDNA encoding SECP contained within a suitable mammalian expression vector under control of a strong promoter. Cotransfection with cDNA encoding a fluorescent marker protein, such as Green Huorescent Protein (CLONTECH), is useful for identifying stable transfectants. The amount of cell agglutination, or clumping, associated with transfected cells is compared with that associated with untransfected cells. The amount of cell agglutination is a direct measure of SECP activity.

[0390] Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims. TABLE 1 Incyte Polypeptide Incyte Polynucleotide Polynucleotide Incyte Full Length Incyte Project ID SEQ ID NO: Polypeptide ID SEQ ID NO: ID Clones 1895273 1 1895273CD1 31 1895273CB1 1895273CA2 70072222 2 70072222CD1 32 70072222CB1 813820CA2 3559223 3 3559223CD1 33 3559223CB1 3441255 4 3441255CD1 34 3441255CB1 1958917 5 1958917CD1 35 1958917CB1 90067353CA2 6219465 6 6219465CD1 36 6219465CB1 3576625 7 3576625CD1 37 3576625CB1 4765758 8 4765758CD1 38 4765758CB1 4765758CA2 7236661 9 7236661CD1 39 7236661CB1 6764860CA2, 6772618CA2, 7236661CA2 7714187 10 7714187CD1 40 7714187CB1 5136540 11 5136540CD1 41 5136540CB1 5136540CA2 3277403 12 3277403CD1 42 3277403CB1 90093289CA2, 90097965CA2 1517569 13 1517569CD1 43 1517569CB1 2415991 14 2415991CD1 44 2415991CB1 4031777CA2, 7383971CA2 2735742 15 2735742CD1 45 2735742CB1 1842245CA2, 1862749CA2, 2765810CA2, 3174585CA2, 6034213CA2, 6361652CA2, 7638315CA2, 7977239CA2, 8087951CA2, 8094152CA2, 8250338CA2, 8531020CA2, 8743705CA2 2768535 16 2768535CD1 46 2768535CB1 4239666CA2 6848851 17 6848851CD1 47 6848851CB1 7040722 18 7040722CD1 48 7040722CB1 56022479CA2 6430290 19 6430290CD1 49 6430290CB1 90076008CA2, 90076371CA2, 90076387CA2, 90076395CA2 2640251 20 2640251CD1 50 2640251CB1 6452666CA2, 8516219CA2 3839350 21 3839350CD1 51 3839350CB1 3839350CA2 6393813 22 6393813CD1 52 6393813CB1 1615668CA2, 2193894CA2, 6557563CA2, 6557564CA2, 7057161CA2 5685755 23 5685755CD1 53 5685755CB1 71728459 24 71728459CD1 54 71728459CB1 5405225CA2 1904303 25 1904303CD1 55 1904303CB1 2911343 26 2911343CD1 56 2911343CB1 90094777CA2, 90094885CA2 7500308 27 7500308CD1 57 7500308CB1 2343465CA2 7501098 28 7501098CD1 58 7501098CB1 4660380CA2 7503839 29 7503839CD1 59 7503839CB1 7503698 30 7503698CD1 60 7503698CB1

[0391] TABLE 2 GenBank ID NO: Polypeptide Incyte or PROTEOME Probability SEQ ID NO: Polypeptide ID ID NO: Score Annotation 1 1895273CD1 g180279 5.40E−146 [Homo sapiens] IgG Fc receptor I van de Winkel, J. G. J. et al., (1991) J. Biol. Chem. 266:13449-13455 6 6219465CD1 g6649221 2.40E−184 [Homo sapiens] selenoprotein N Lescure, A. et al.,(1999) J. Biol. Chem. 274:38147-38154 7 3576625CD1 g4406679 1.10E−54 [Homo sapiens] Human neuronal olfactomedin related ER localized protein Danielson, P. E. et al., (1994) J. Neurosci. Res. 38:468-78 10 7714187CD1 g3041877 1.30E−222 [Homo sapiens] IB3089A Nishiyama, H. et al. (1999) Genes Chromosomes Cancer 26:171-5 11 5136540CD1 g12656635 8.40E−54 [Homo sapiens] (AF326351) transmembrane gamma-carboxyglutamic acid protein 4 TMG4 Kulman, J. D. et al.,(2001) Proc. Natl. Acad. Sci. U.S.A. 98:1370-1375 12 3277403CD1 g9864185 8.10E−104 [Drosophila melanogaster] Crossveinless 2 Olson, D. J. et al., (2000) Development 127:3947-3959 16 2768535CD1 g7578787 8.30E−134 AD021 protein [Homo sapiens] 23 5685755CD1 g307153 9.30E−27 [Homo sapiens] Mac-2 binding protein Koths, K., Taylor, E., Halenbeck, R., Casipit, C. and Wang, A. (1993) Cloning and characterization of a human Mac-2 binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain J. Biol. Chem. 268:14245-14249 26 2911343CD1 g11225366 4.10E−13 [Homo sapiens] testis specific leucine rich repeat protein 28 7501098CD1 g12656635 2.6E−13 [Homo sapiens] transmembrane gamma-carboxyglutamic acid protein 4 TMG4 Kulman, J. D. et al. (2001) Identification of two novel transmembrane gamma- carboxyglutamic acid proteins expressed broadly in fetal and adult tissues. Proc. Natl. Acad. Sci. U.S.A. 98:1370-1375 685373|TMG4 2.2E−14 [Homo sapiens][Plasma membrane] Transmembrane gamma-carboxyglutamic acid protein 4, a putative transmembrane spanning protein which is a member of the Gla family, contains one cytoplasmic PPXY motif which may mediate interaction with WW domain-containing proteins Kulman, J. D. et al. (2001) Identification of two novel transmembrane gamma - carboxyglutamic acid proteins expressed broadly in fetal and adult tissues. Proc. Natl. Acad. Sci. U.S.A. 98:1370-1375.

[0392] TABLE 3 SEQ Incyte Amino ID Polypeptide Acid Signature Sequences, Analytical Methods NO: ID Residues Domains and Motifs and Databases 1 1895273CD1 289 Signal_cleavage: M1-G15 SPSCAN Signal Peptide: M1-G15 HMMER Immunoglobulin domain: G120-A177, G32-G85 HMMER_PFAM Transmembrane domain: L4-L20, TMAP P203-K230N-terminus is cytosolic RECEPTOR FC IMMUNOGLOBULIN PD01270: BLIMPS_PRODOM E33-F61, L131-R166, M1-S26 GAMMA FC RECEPTOR I HIGH AFFINITY BLAST_PRODOM IMMUNOGLOBULIN PRECURSOR FC GAMMA RI PD013195: W238-T289 RECEPTOR FC GAMMA AFFINITY IMMUNOGLOBULIN BLAST_PRODOM PRECURSOR PROTEIN TRANSMEMBRANE GLYCOPROTEIN SIGNAL PD002534: W19-W64, L4-G15 RECEPTOR FC GAMMA I HIGH AFFINITY BLAST_PRODOM IMMUNOGLOBULIN PRECURSOR PROTEIN TRANSMEMBRANE PD004578: S157-K237, N65-V108 GAMMA FC RECEPTOR I HIGH AFFINITY BLAST_PRODOM IMMUNOGLOBULIN PRECURSOR FC GAMMA RI PD013193: P107-T156 IG-LIKE C2-TYPE DOMAIN BLAST_DOMO DM03427P12314|189-331: F104-G247, P26151|198-339: F104-S246, I48471|199-336: E102-K235 MYELIN-ASSOCIATED GLYCOPROTEIN BLAST_DOMO DM00682|P12314|1-187: G18-L103 Potential Phosphorylation Sites: S25 S246 MOTIFS S255 T30 T99 T150 T156 T164 T227 Y173 Potential Glycosylation Sites: N67 MOTIFS N74 N78 N110 N155 2 70072222CD1 159 Signal_cleavage: M1-A26 SPSCAN Signal Peptide: M1-A26 HMMER Transmembrane domain: P55-C83 TMAP N-terminus is cytosolic Potential Phosphorylation Sites: MOTIFS S141 T90 T132 3 3559223CD1 559 Signal_cleavage: M1-S19 SPSCAN Potential Phosphorylation Sites: S17 S31 MOTIFS S66 S93 S187 S188 S242 S260 S267 S318 S331 S412 S442 S446 S525 S549 T141 T148 T160 T200 T245 T426 T467 T480 T488 Potential Glycosylation Sites: N248 N386 MOTIFS 4 3441255CD1 1222 Signal_cleavage: M1-F32 SPSCAN Signal Peptide: M11-S30 HMMER Signal Peptide: M11-E33 HMMER Signal Peptide: M11-S35 HMMER Transmembrane domain: P8-E34, P179-N196, TMAP R773-S793, W801-L821N-Terminus is non-cytosolic Potential Phosphorylation Sites: S30 MOTIFS S282 S444 S447 S465 S657 S701 S748 S806 S849 S873 S909 S976 S1007 S1033 S1060 T31 T54 T189 T249 T293 T416 T539 T672 T842 T844 T903 T1020 T1148 T1210 Potential Glycosylation Sites:N38 MOTIFS N676 N698 N719 N884 5 1958917CD1 696 Signal_cleavage: M1-A27 SPSCAN Signal Peptide: M3-A27 HMMER Signal Peptide: M3-A34 HMMER Transmembrane domain: S8-W36N-terminus TMAP is non-cytosolic do MUCIN; MUC5; TRACHEOBRONCHIAL; BLAST_DOMO DM05454|S55316|1-317: Q355-S581 Potential Phosphorylation Sites: S72 MOTIFS S99 S122 S184 S383 S473 S475 S499 S506 S511 S549 S612 S649 S662 T235 T248 T512 T542 T618 Potential Glycosylation Sites: N483 MOTIFS 6 6219465CD1 436 Signal_cleavage: M1-A43 SPSCAN Transmembrane domain: R25-A53, TMAP V231-I258 N-terminus is non-cytosolic EF-hand calcium-binding domain BLIMPS_PRINTS BL00018: D80-F92 Potential Phosphorylation Sites: MOTIFS S77 S88 S107 S319 S332 S359 S385 S404 T81 Y398 Potential Glycosylation Sites: N156 MOTIFS 7 3576625CD1 652 Signal_cleavage: M1-A27 SPSCAN Signal Peptide: M1-A27 HMMER Olfactomedin-like domain: G397-V652 HMMER_PFAM Transmembrane domain: A4-S21N-termincus TMAP is non-cytosolic PROTEIN PRECURSOR SIGNAL MYOCILIN BLAST_PRODOM TRABECULAR GLUCOCORTICOID GLYCOPROTEIN OLFACTOMEDIN MESH-WORK INDUCED RESPONSE PD006897: L440-T645 Potential Phosphorylation Sites: S21 MOTIFS S66 S82 S121 S155 S170 S242 S266 S314 S345 S382 S439 S519 S551 S574 T25 T151 T225 T275 T398 T565 T606 T624 Y75 Y236 Potential Glycosylation Sites: N159 N183 MOTIFS 8 4765758CD1 91 Signal_cleavage: M1-A42 SPSCAN Signal Peptide: M20-A42 HMMER Signal Peptide: M20-G44 HMMER Citrate synthase signature: E6-D67 PROFILESCAN Ribosomal protein S24e signature: K3-A57 PROFILESCAN Potential Phosphorylation Sites: MOTIFS S77 S82 T22 T70 T73 9 7236661CD1 155 Signal_cleavage: M1-G17 SPSCAN Signal Peptide: M1-G17 HMMER Signal Peptide: M1-A20 HMMER Potential Phosphorylation Sites: S38 MOTIFS S43 S91 S95 S135 T47 T90 T115 10 7714187CD1 765 Signal_cleavage: M1-A33 SPSCAN Signal Peptide: M15-A33 HMMER Signal Peptide: M15-A34 HMMER Signal Peptide: M15-D37 HMMER Signal Peptide: M15-Q38 HMMER Signal Peptide: M15-A40 HMMER Signal Peptide: M15-A33 HMMER Transmembrane domain: G8-A33 TMAP Membrane attack complex PROFILESCAN components/perforin signature: L103-K155 IB3089A PD147692: M1-C765 BLAST_PRODOM Potential Phosphorylation Sites: S42 MOTIFS S49 S72 S157 S218 S267 S315 S361 S380 S418 S523 S528 S539 S563 S579 S592 S735 T119 T191 T309 T442 T504 T536 T599 T620 T761 Potential Glycosylation Sites: N168 MOTIFS N337 N456 N562 N609 N641 11 5136540CD1 150 Signal_cleavage: M1-G17 SPSCAN Signal Peptide: M1-G17 HMMER Signal Peptide: M1-P19 HMMER Vitamin K-dependent carboxylation/gamma- HMMER_PFAM carboxyglutamic (GLA) domain: L57-A98 Vitamin K-dependent carboxylation PROFILESCAN domain: V35-S110 Coagulation factor GLA domain signature BLIMPS_PRINTS PR00001: V84-A98, D56-C69, N70-F83 GLA DOMAIN DM00454|P08709|22-100: K29-W93 BLAST_DOMO GLA DOMAIN DM00454|P00742|2-80: G32-W93 BLAST_DOMO GLA DOMAIN DM00454|P25155|2-80: C21-W93 BLAST_DOMO GLA DOMAIN DM00454|S49075|2-80: G32-W93 BLAST_DOMO Vitamin K-dependent carboxylation domain: D56-W93 MOTIFS Potential Phosphorylation Sites: S38 S97 MOTIFS S110 S120 T37 T102 12 3277403CD1 685 Signal_cleavage: M1-G33 SPSCAN Signal Peptide: R16-A39 HMMER Signal Peptide: L10-A39 HMMER Trypsin Inhibitor like cysteine rich HMMER_PFAM domain: C629-C682 von Willebrand factor type C domain: HMMER_PFAM C108-C163, C166-C224, C301-C357, C238-C289, C50-C105 von Willebrand factor type D domain: HMMER_PFAM C364-N514 C-terminal cystine knot BL01185: BLIMPS_BLOCKS C238-C286, K351-V389 SIGNAL PRECURSOR GLYCOPROTEIN BLAST_PRODOM VITELLOGENIN CELL REPEAT WILLEBRAND VON ALPHA TECTORIN PD001080: C331-C663 do MUCIN; VON; WILLEBRAND; HEMOCYTIN; BLAST_DOMO DM01378|P04275|512-692: A486-L669 do MUCIN; VON; WILLEBRAND; HEMOCYTIN; BLAST_DOMO DM01378|P04275|160-333: G495-P666 do MUCIN; VON; WILLEBRAND; HEMOCYTIN; BLAST_DOMO DM01378|P04275|986-1176: K492-H664 do MUCIN; VON; WILLEBRAND; HEMOCYTIN; BLAST_DOMO DM01378|P98092|370-549: K490-C663 Vitamin K-dependent carboxylation MOTIFS domain: K271-F308 VWFC domain signature: C67-C105, MOTIFS C186-C224, C319-C357 Potential Phosphorylation Sites: MOTIFS S118 S123 S273 S479 S525 S573 T78 T260 T358 T437 T466 T549 Potential Glycosylation Sites: N30 N116 MOTIFS N247 N255 N318 N441 13 1517569CD1 126 Signal_cleavage: M1-G33 SPSCAN Transmembrane Region: L58-S86 TMAP Potential Phosphorylation Sites: MOTIFS S56 T13 T27 T52 Y71 Potential Glycosylation Sites: N11 MOTIFS 14 2415991CD1 149 Signal Peptide: M1-G21 HMMER Potential Phosphorylation Sites: S122 MOTIFS Potential Glycosylation Sites: N33 MOTIFS 15 2735742CD1 114 Signal_cleavage: M1-A18 SPSCAN S63 S72 S105 MOTIFS 16 2768535CD1 519 Signal_cleavage: M1-L60 SPSCAN Transmembrane Region: L38-G56 TMAP N-terminus is cytosolic Potential Phosphorylation Sites: S28 S29 MOTIFS S80 S113 S199 S217 S239 S296 S327 T2 T34 T110 T124 Potential Glycosylation Sites: MOTIFS N98 N289 N322 17 6848851CD1 1164 Signal_cleavage: M1-A45 SPSCAN Transmembrane Region: S901-A923 TMAP N-terminus is cytosolic Potential Phosphorylation Sites: MOTIFS S18 S19 S65 S79 S107 S108 S110 S116 S128 S132 S216 S240 S241 S358 S379 S486 S506 S628 S665 S725 S956 S1027 T71 T78 T98 T112 T114 T162 T165 T209 T211 T225 T600 T604 T843 T1017 T1062 T1145 Y859 Potential Glycosylation Sites: MOTIFS N377 N413 N935 N1009 18 7040722CD1 112 Signal_cleavage: M1-E19 SPSCAN Signal Peptide: M2-G23 HMMER Potential Phosphorylation Sites: MOTIFS S102 T86 Potential Glycosylation Sites: N103 MOTIFS 19 6430290CD1 170 Signal_cleavage: M1-G54 SPSCAN Transmembrane Region: C23-S51 TMAP N-terminus is non-cytosolic Potential Phosphorylation Sites: MOTIFS S9 S51 S143 S144 T66 T121 20 2640251CD1 80 Signal_cleavage: M1-A42, M18-A42, M14-A42 SPSCAN Signal Peptide: M18-S44 HMMER Signal Peptide: M18-A42 HMMER Potential Phosphorylation Sites: S20 T4 T53 MOTIFS 21 3839350CD1 118 Signal_cleavage: M1-A18 SPSCAN Signal Peptide: M1-A18 HMMER Potential Phosphorylation Sites: S20 S50 T6 MOTIFS 22 6393813CD1 140 Signal_cleavage: M1-A42, M16-A42 SPSCAN Potential Phosphorylation Sites: MOTIFS S23 S33 S61 S72 S122 S124 23 5685755CD1 478 Signal_cleavage: M1-R31 SPSCAN Signal Peptide: M1-A32 HMMER BTB/POZ domain: Q47-L162 HMMER_PFAM Transmembrane domain: G10-T26N-terminus TMAP is non-cytosolic PROTEIN C ASSOCIATED MAMA CYCLOPHILIN BLAST_PRODOM PEPTIDYLPROLYL ISOMERASE PANCREAS CANCER ASSOCIATED MAC2 BINDING PD014408: L53-A323, S338-P362 SPERACT RECEPTOR AMINO-TERMINAL BLAST_DOMO DM05438|A47161|126-585: S42-P345 Potential Phosphorylation Sites: MOTIFS S346 S361 S368 S400 S434 S452 T179 T355 T476 Potential Glycosylation Sites:N44 MOTIFS N61 N100 N195 N307 24 71728459CD1 80 Signal_cleavage: M1-A15 SPSCAN Signal Peptide: M1-A15 HMMER Signal Peptide: M1-G28 HMMER Transmembrane domain: T4-W23 TMAP Potential Phosphorylation Sites: MOTIFS S26 S35 S54 S68 25 1904303CD1 505 Signal_cleavage: M1-A20 SPSCAN Signal Peptide: M1-A20 HMMER Signal Peptide: M1-G24 HMMER Transmembrane domain: V312-L340, TMAP P467-L494N-terminus is non-cytosolic Potential Phosphorylation Sites: MOTIFS S21 S174 S237 S364 S368 S413 S426 T46 T176 T203 T248 T288 T338 T411 Potential Glycosylation Sites: MOTIFS N220 N229 N278 N336 26 2911343CD1 321 Signal_cleavage: M39-A96 SPSCAN Leucine Rich Repeat: N67-P88, S89-P110, HMMER_PFAM C111-P131, S133-L162, E45-Q66 Potential Phosphorylation Sites: S36 S89 MOTIFS S175 S182 S183 S196 S304 S319 T23 T28 T42 T48 T58 T124 T145 T232 T260 T274 T311 T315 Potential Glycosylation Sites: N26 N138 MOTIFS 27 7500308CD1 60 Signal_cleavage: M1-P21 SPSCAN Signal Peptide: MI-125, M1-L26 HMMER Potential Phosphorylation Sites: S42 T33 MOTIFS 28 7501098CD1 45 Signal_cleavage: M1-G17 SPSCAN Signal Peptide: M1-G17 HMMER Signal Peptide: M1-G24 HMMER Signal Peptide: M1-P19 HMMER Histidine acid phosphatases PROFILESCAN signatures: M1-A44 29 7503839CD1 43 Signal_cleavage: M1-A13 SPSCAN Signal Peptide: M1-S18 HMMER Potential Phosphorylation Sites: MOTIFS S18 S19 T40 30 7503698CD1 456 Signal_cleavage: M1-A20 SPSCAN Signal Peptide: M1-A19, M1-S21, HMMER M1-A20, M1-G24 Potential Phosphorylation Sites: MOTIFS S21 S174 S315 S319 S364 S377 T46 T176 T203 T239 T289 T362 Potential Glycosylation Sites: MOTIFS N220 N229 N287

[0393] TABLE 4 Polynucleotide SEQ ID NO:/ Incyte ID/Sequence Length Sequence Fragments 31/1895273CB1/ 1-211, 1-320, 67-288, 67-335, 67-644, 69-216, 69-230, 69-286, 69-293, 69-331, 69-344, 69-358, 69-363, 69-481, 69- 1053 495, 69-591, 69-607, 69-617, 69-636, 112-506, 132-985, 150-394, 186-786, 188-967, 190-641, 190-726, 190-727, 241-713, 243-711, 258-1000, 264-950, 268-877, 276-991, 286-712, 287-995, 310-953, 326-614, 367-1027, 423-606, 428-1036, 429-679, 434-724, 455-709, 459-653, 459-676, 459-998, 471-1003, 483-697, 488-1032, 489-971, 503- 1050, 507-1023, 508-1053, 598-645, 743-1051 32/70072222CB1/ 1-550, 1-613, 4-295, 28-284, 360-627, 362-623, 372-623, 377-664, 406-930, 430-830, 451-607, 459-1027, 459- 1579 1048, 544-1022, 564-1027, 590-1146, 609-1134, 665-1320, 676-1263, 691-1053, 694-1146, 709-1320, 730-1209, 740-1263, 746-1061, 751-1015, 751-1223, 772-1205, 784-1270, 792-1332, 805-1234, 805-1246, 815-1322, 816- 1460, 843-1362, 860-1263, 876-1362, 904-1160, 925-1492, 943-1575, 976-1544, 1024-1307, 1033-1579, 1041- 1069, 1041-1339, 1041-1341, 1041-1342, 1041-1343, 1041-1346, 1041-1347, 1045-1172, 1046-1069, 1054-1579, 1057-1347, 1084-1544, 1104-1579, 1120-1579 33/3559223CB1/ 1-471, 51-284, 128-825, 129-705, 222-334, 253-785, 282-593, 283-699, 283-786, 357-400, 408-1003, 457-699, 457- 2440 826, 467-1050, 469-993, 520-1132, 534-752, 585-866, 585-1061, 635-1291, 703-966, 747-1291, 781-1350, 813- 1417, 820-1034, 906-1151, 925-1291, 942-1341, 1021-1294, 1064-1326, 1083-1591, 1110-1380, 1110-1673, 1132- 1482, 1164-1340, 1169-1705, 1237-1490, 1237-1553, 1237-1607, 1246-1793, 1253-1758, 1253-1843, 1270-1876, 1348-1997, 1418-1729, 1474-2026, 1486-1705, 1495-1683, 1495-1716, 1517-2020, 1551-2206, 1608-1890, 1611- 1754, 1653-2268, 1665-2002, 1671-1947, 1681-1942, 1691-1801, 1731-2269, 1741-2278, 1752-1821, 1759-2418, 1780-2270, 1793-2408, 1819-2366, 1827-2321, 1829-2018, 1829-2358, 1839-2404, 1846-2362, 1883-2345, 1889- 2337, 1901-2118, 1908-2061, 1908-2365, 1913-2171, 1913-2435, 1935-2420, 1936-2174, 1943-2314, 1957-2423, 1963-2440, 1968-2424, 1969-2423, 1970-2422, 1971-2411, 1975-2423, 1986-2423, 1997-2440, 2000-2266, 2009- 2420, 2018-2440, 2019-2277, 2020-2414, 2023-2440, 2036-2432, 2038-2440, 2043-2424, 2044-2434, 2053-2424, 2066-2420, 2070-2420, 2071-2420, 2095-2395, 2141-2440, 2146-2420, 2147-2420, 2157-2416, 2157-2430, 2158- 2334, 2158-2376, 2158-2390, 2201-2418, 2279-2420, 2311-2420 34/3441255CB1/ 1-349, 1-651, 243-430, 489-4133, 655-1312, 665-1263, 925-1207, 925-1545, 932-1543, 945-1617, 1040-1585, 1260- 4133 1709, 1293-1597, 1388-1675, 1388-2004, 1681-1927, 1700-1936, 1700-2164, 1725-2284, 1796-2295, 1809-2215, 2074-2304, 2074-2336, 2074-2465, 2127-2774, 2148-2409, 2205-2442, 2515-2735, 2515-2918, 2515-3045, 2517- 2784, 2640-2908, 2659-3187, 2725-3340, 2743-2990, 2776-3233, 2777-3023, 2790-3014, 2794-3321, 2832-3337, 2832-3649, 2841-3160, 2872-3447, 2948-3199, 2988-3368, 3027-3368, 3105-3321, 3237-3507, 3327-3983, 3327- 4004, 3381-4029, 3406-3904, 3427-4003, 3514-4077, 3594-4128, 3632-4077, 3653-3886, 3709-4018 35/1958917CB1/ 1-70, 1-623, 2-516, 185-463, 356-989, 464-660, 464-846, 609-803, 609-896, 609-1018, 609-1133, 609-1137, 617- 4689 1058, 617-1201, 660-1445, 676-1349, 677-904, 679-1420, 687-1445, 706-935, 709-1445, 725-1137, 726-1443, 779- 1137, 782-904, 852-1137, 936-1137, 977-1137, 1000-1137, 1029-1202, 1044-1137; 1089-1137, 1097-1137, 1113- 1137, 1138-1327, 1203-1327, 1203-1502, 1213-1744, 1328-1502, 1328-1616, 1375-1766, 1394-1654, 1394-1806, 1394-1827, 1489-2117, 1503-1744, 1617-1744, 1617-2054, 1655-2312, 1745-2054- 1777-2316, 1848-2366, 2001- 2435, 2047-2477, 2055-2275, 2092-2575, 2132-2409, 2180-2748, 2273-2762, 2283-2724, 2313-2555, 2355-2802, 2369-2917, 2467-3119, 2530-2979, 2547-3208, 2572-3124, 2576-2805, 2591-2896, 2603-2875, 2670-3140, 2671- 2971, 2683-3224, 2683-3269, 2695-3261, 2711-3335, 2821-3340, 2821-3354, 3048-3544, 3122-3694, 3160-3603, 3172-3376, 3217-3410, 3217-3752, 3245-3782, 3332-3875, 3349-3924, 3435-3924, 3503-4186, 3503-4244, 3504- 3748, 3551-3840, 3551-4036, 3611-4005, 3631-3845, 3714-3745, 3714-3750, 3714-3751, 3714-3753, 3714-3780, 3714-3781, 3714-3792, 3714-3797, 3714-3798, 3714-3801, 3714-3828, 3714-3829, 3714-3846, 3714-3848, 3714- 3876, 3714-3896, 3717-3755, 3718-3753, 3718-3800, 3719-4008, 3721-4145, 3735-3893, 3735-3896, 3761-3795, 3761-3801, 3761-3830, 3761-3887, 3761-3892, 3761-3923, 3761-3944, 3766-3944, 3768-3944, 3777-3850, 3782- 4032, 3782-4301, 3809-3843, 3809-3848, 3809-3877, 3809-3935, 3809-3940, 3809-3943, 3813-3847, 3813-3895, 3814-3943, 3816-3943, 3830-3944, 3856-3890, 3856-3896, 3856-3925, 3856-3944, 3856-3945, 3860-3894, 3860- 4689, 3861-3944, 3863-3944, 3877-3943, 3904-3938, 3904-3943, 3904-3949, 3904-4188, 3908-3942, 3909-3943, 3911-3943, 3930-4402, 3976-4498, 3979-4543, 3982-4587, 3993-4262, 3993-4480, 4083-4304, 4108-4359, 4136- 4328, 4136-4416, 4246-4537, 4360-4645, 4491-4547, 4628-4651 36/6219465CB1/ 1-1311, 168-355, 168-483, 168-548, 168-573, 168-588, 168-592, 168-601, 168-643, 168-646, 168-679, 168-682, 168- 3294 686, 168-689, 168-696, 168-715, 168-745, 168-765, 168-797, 168-819, 168-822, 168-835, 168-843, 169-745, 171- 551, 172-577, 172-587, 172-608, 172-745, 174-745, 175-771, 178-678, 178-733, 178-745, 187-642, 188-526, 189- 526, 202-498, 211-798, 216-745, 224-349, 224-532, 224-535, 224-745, 226-721, 229-745, 230-452, 230-525, 237- 415, 237-596, 238-526, 251-436, 263-772, 278-813, 306-951, 325-967, 326-800, 338-510, 341-510, 341-868, 347- 745, 382-790, 397-970, 513-745, 514-977, 561-1309, 567-800, 568-804, 570-772, 570-843, 593-1149, 641-1123, 641-1266, 663-1116, 698-1255, 703-1188, 727-1173, 740-1313, 755-1176, 763-1333, 765-1384, 772-1298, 785- 1417, 788-1148, 788-1366, 788-1381, 788-1389, 788-1467, 820-1413, 829-1319, 835-1313, 836-1437, 837-1511, 854-1422, 870-1516, 873-1212, 882-1101, 918-986, 936-986, 940-986, 951-986, 962-986, 1014-1226, 1014-1443, 1014-1456, 1014-1485, 1014-1544, 1014-1548, 1014-1685, 1015-1476, 1016-1105, 1031-1561, 1031-1588, 1046-1528, 1049-1458, 1049-1694, 1079-1590, 1086-1604, 1089-1469, 1096-1288, 1108-1730, 1109-1626, 1110- 1532, 1113-1384, 1113-1564, 1129-1341, 1136-1783, 1142-1640, 1144-1760, 1172-1692, 1177-1767, 1183-1790, 1186-1773, 1190-1524, 1194-1743, 1194-1790, 1200-1642, 1202-1790, 1207-1790, 1211-1783, 1215-1712, 1215- 1805, 1217-1747, 1223-1776, 1224-1790, 1236-1790, 1236-1864, 1237-1827, 1244-1682, 1244-1790, 1257-1905, 1259-1835, 1289-1790, 1292-1873, 1294-1648, 1295-1541, 1302-1790, 1335-1773, 1337-1790, 1344-1978, 1352- 1790, 1358-1663, 1370-2054, 1378-1888, 1411-1922, 1434-1596, 1434-1927, 1439-2074, 1445-1868, 1461-1868, 1477-1790, 1505-1958, 1506-1913, 1516-1807, 1529-1790, 1549-1793, 1587-1818, 1587-1889, 1587-1998, 1587- 2083, 1587-2139, 1587-2224, 1587-2254, 1589-2051, 1595-1840, 1640-2133, 1644-1960, 1646-2251, 1647-2275, 1648-2280, 1667-1970, 1670-1995, 1671-2250, 1672-2225, 1673-1939, 1677-2245, 1715-2331, 1720-1986, 1730- 2238, 1736-2233, 1753-1928, 1766-2356, 1770-2293, 1777-2448, 1792-2284, 1792:-2380, 1793-2244, 1797-2050, 1799-2441, 1804-2342, 1818-2225, 1822-2434, 1829-2135, 1846-2088, 1862-2540, 1885-2470, 1890-2483, 1892- 2145, 1909-2535, 1912-2526, 1933-2130, 1943-2516, 1954-2582, 1963-2492, 1971-2559, 1971-2614, 1980-2524, 1983-2503, 1989-2438, 1993-2464, 1999-2547, 1999-2733, 2008-2492, 2009-2420, 2009-2535, 2010-2614, 2017- 2464, 2051-2332, 2065-2669, 2071-2535, 2104-2689, 2109-2649, 2117-2669, 2118-2379, 2125-2748, 2131-2558, 2136-2639, 2146-2739, 2146-2802, 2155-2686, 2159-2821, 2161-2685, 2162-2748, 2170-2692, 2189-2702, 2200- 2740, 2222-2723, 2250-2764, 2264-2780, 2293-2720, 2296-2537, 2299-2748, 2328-2575, 2359-2608, 2359-2929, 2363-2599, 2381-2679, 2385-2729, 2393-2693, 2476-2690, 2493-3030, 2494-2712, 2494-2721, 2530-2776, 2608- 2872, 2618-2850, 2667-2925, 2667-2948, 2698-2949, 2700-2947, 2701-2920, 2706-2989, 2763-2964, 2763-2970, 2776-3020, 2781-2976, 2793-3038, 2859-3020, 2869-3140, 2967-3239, 3040-3186, 3040-3294 37/3576625CB1/ 1-90, 1-588, 62-157, 62-354, 62-464, 62-551, 62-564, 62-582, 62-686, 67-282, 67-571, 68-623, 71-657, 75-618, 78- 3635 571, 78-582, 80-493, 91-1959, 98-332, 98-354, 98-543, 98-549, 108-677, 125-756, 130-815, 175-814, 227-722, 245- 892, 258-622, 337-1004, 348-416, 355-433, 396-779, 423-661, 461-613, 677-1098, 792-1075, 798-1386, 810-1458, 818-1106, 866-1113, 876-1458, 935-1098, 1133-1568, 1141-1713, 1153-1445, 1167-1598, 1169-1383, 1355-1735, 1355-1739, 1355-1745, 1355-1794, 1355-1812, 1355-1836, 1355-1852, 1355-1856, 1355-1885, 1355-1887, 1355- 1891, 1355-1918, 1355-1926, 1355-1962, 1355-1976, 1356-1891, 1389-1695, 1389-1900, 1389-1965, 1389-2010, 1389-2017, 1414-1891, 1556-2122, 1556-2177, 1556-2185, 1556-2202, 1556-2216, 1567-1937, 1575-1988, 1578- 2212, 1579-2035, 1579-2081, 1579-2118, 1579-2215, 1579-2216, 1580-2190, 1581-2212, 1584-2216, 1588-1891, 1588-2216, 1641-2212, 1654-2216, 1658-1963, 1660-2216, 1674-2243, 1680-2212, 1714-2230, 1719-2295, 1726- 2121, 1734-1869, 1748-2305, 1752-2334, 1753-2203, 1760-2419, 1783-2305, 1806-2367, 1817-2393, 1866-2332, 1868-2527, 1877-2525, 1883-2554, 1884-2071, 1910-2141, 1919-2565, 1930-2345, 1934-2595, 1952-2422, 1996- 2712, 2040-2525, 2044-2726, 2053-2630, 2058-2754, 2092-2616, 2107-2707, 2114-2736, 2127-2713, 2128-2659, 2159-2740, 2168-2510, 2231-2749, 2240-2707, 2245-2491, 2246-2885, 2285-2961, 2320-2972, 2330-2895, 2350- 2806, 2380-2903, 2393-3096, 2495-2705, 2496-3107, 2511-3203, 2547-2927, 2553-3249, 2573-3263, 2602-3263, 2607-3232, 2623-3100, 2626-2882, 2643-3294, 2688-2943, 2689-3407, 2699-3154, 2699-3249, 2712-3274, 2719- 3350, 2734-3203, 2752-2993, 2759-3413, 2770-3455, 2773-3326, 2773-3437, 2779-3440, 2783-3146, 2796-2825, 2856-3402, 2863-3154, 2869-3322, 2887-3435, 2932-3635, 2947-3523, 2951-3473, 3002-3497, 3127-3635, 3129- 3522, 3131-3352, 3195-3431, 3200-3460, 3216-3483 38/4765758CB1/ 1-280, 1-611, 23-635 635 39/7236661CB1/ 1-56, 1-210, 1-379, 1-414, 1-503, 1-565, 1-793, 43-679, 63-679, 130-565, 202-793 793 40/7714187CB1/ 1-140, 15-532, 15-874, 158-262, 189-784, 379-662, 485-1033, 680-1171, 986-1068, 1062-1612, 1069-1599, 1292- 2741 1588, 1373-1629, 1374-1843, 1404-2741, 1585-1828, 1585-2271, 1587-1822, 1682-2250, 2065-2734 41/5136540CB1/ 1-252, 137-209, 137-412, 137-556, 137-575, 137-583, 137-597, 137-707, 137-738, 137-767, 145-191, 169-699,290- 1074 675, 298-791, 315-574, 417-901, 426-901, 428-1071, 428-1074, 431-518, 452-1026, 468-1062, 488-1048, 518-771, 518-795, 518-920, 518-1062, 521-1054, 523-773, 523-1068, 527-974, 536-980, 561-785, 574-1068, 595-1070, 595- 1071, 626-1071, 637-1071, 647-1058, 811-1071, 984-1068 42/3277403CB1/ 1-76, 1-632, 7-76, 19-71, 21-76, 119-426, 189-458, 234-750, 269-526, 381-2519, 472-1015, 667-1197, 994-1487, 2560 1224-1446, 1281-1385, 1453-1603, 1516-1790, 1516-1967, 1516-2010, 1620-2113, 1621-2213, 1677-1962, 1677- 2201, 1711-1976, 1711-1999, 1743-2271, 1858-2560, 1863-2066, 1865-2303, 2112-2358, 2528-2559 43/1517569CB1/ 1-541, 1-604, 12-686, 47-797, 124-507, 179-765, 198-661, 234-822, 237-811, 275-947, 377-1021, 414-1020, 430- 5833 909, 472-1022, 517-986, 547-1067, 640-1021, 713-1086, 790-1268, 793-1366, 793-1446, 797-1333, 797-1443, 797- 1453, 799-1225, 799-1333, 850-1493, 949-1544, 1064-1706, 1073-1570, 1122-1724, 1131-1704, 1137-1707, 1218- 1916, 1279-1535, 1392-1617, 1501-1559, 1505-1755, 1505-1971, 1522-1749, 1609-1871, 1609-1877, 1609-2052, 1824-2236, 1930-2502, 1963-2559, 1980-2641, 1981-2454, 2019-2590, 2038-2544, 2038-2672, 2038-2706, 2149- 2767, 2175-2494, 2200-2428, 2200-2692, 2201-2738, 2211-2858, 2220-2931, 2265-2968, 2267-2463, 2268-2480, 2296-2888, 2333-2588, 2352-2971, 2355-2614, 2478-3083, 2479-3121, 2487-3119, 2493-3096, 2523-3136, 2552- 3021, 2589-3194, 2591-3249, 2598-3150, 2608-3176, 2619-3303, 2627-3219, 2635;3357, 2638-3040, 2639-3049, 2639-3211, 2640-3052, 2643-3321, 2648-3147, 2677-3184, 2702-3275, 2712-2972, 2715-2986, 2715-3188, 2720- 3099, 2733-3428, 2789-3021, 2872-3480, 2882-3443, 2882-3571, 2884-3350, 2888-3388, 2888-3591, 2889-3167, 2890-3360, 2948-3681, 2954-3443, 2960-3664, 2975-3571, 2976-3689, 2986-3652; 2991-3692, 2997-3685, 3026- 3579, 3032-3667, 3048-3713, 3064-3530, 3080-3375, 3085-3729, 3109-3362, 3114-3548, 3118-3722, 3118-3726, 3119-3399, 3119-3722, 3120-3693, 3135-3738, 3136-3736, 3138-3736, 3143-3377, 3148-3739, 3153-3415, 3160- 3435, 3160-3670, 3160-3734, 3162-3713, 3162-3738, 3164-3422, 3173-3424, 3179-3688, 3183-3517, 3187-3739, 3188-3738, 3193-3728, 3206-3482, 3207-3741, 3209-3692, 3213-3420, 3231-3525, 3231-3725, 3231-3743, 3232- 3738, 3234-3738, 3243-3508, 3252-3741, 3292-3858, 3299-3858, 3699-4031, 3699-4088, 3718-4036, 3749-3968, 3749-4255, 3749-4285, 3814-4000, 3926-4281, 4087-4111, 4087-4115, 4087-4165, 4087-4196, 4087-4200, 4087- 4250, 4089-4170, 4094-4250, 4126-4250, 4128-4717, 4137-4250, 4141-4165, 4172-4316, 4172-4333, 4172-4335, 4179-4431, 4211-4385, 4211-4394, 4213-4335, 4222-4491, 4226-4250, 4257-4335, 4264-4335, 4296-4335, 4298- 4335, 4307-4335, 4311-4536, 4408-4674, 4408-4963, 4487-4797, 4664-4956, 4671-5297, 4871-5193, 4871-5396, 4957-5255, 5024-5292, 5024-5586, 5033-5297, 5085-5238, 5098-5365, 5158-5369, 5391-5630, 5406-5684, 5406- 5699, 5406-5700, 5406-5714, 5408-5691, 5442-5718, 5513-5740, 5542-5819, 5549-5698, 5584-5833, 5607-5833, 5665-5727 44/2415991CB1/ 1-707, 230-774, 245-538, 308-596, 351-1022, 419-681, 419-1022, 451-911, 451-959, 487-707, 487-727, 487-989, 2264 598-906, 599-933, 611-858, 620-833, 661-1022, 713-1308, 786-1423, 798-1084, 875-1107, 890-1681, 892-1474, 903-1172, 927-1197, 927-1227, 947-1173, 1009-1271, 1022-1291, 1171-1756, 1174-1435, 1175-1471, 1206-1423, 1244-1760, 1274-1463, 1298-1559, 1308-1539, 1308-1722, 1308-1884, 1310-1590, 1311-1521, 1321-1591, 1344- 1623, 1344-1997, 1359-1565, 1395-1654, 1453-1744, 1510-2164, 1528-2178, 1536-1819, 1539-1827, 1570-2221, 1592-2216, 1644-1875, 1644-2155, 1648-2225, 1698-1959, 1730-1959, 1747-2264, 1748-1914, 1757-2019, 1812- 2061, 1817-2043, 1893-2108, 1895-2166, 2037-2248, 2054-2264, 2063-2134 45/2735742CB1/ 1-625, 326-449, 326-502, 326-532, 326-533, 326-534, 326-544, 326-548, 326-549, 326-552, 326-557, 326-561, 326- 1638 568, 326-569, 326-571, 326-572, 326-573, 326-574, 326-575, 326-578, 326-579, 325-584, 326-587, 326-590, 326- 599, 326-601, 326-610, 326-662, 326-747, 326-771, 326-836, 326-848, 326-894, 345-566, 362-586, 362-595, 372- 624, 418-618, 460-719, 482-725, 516-675, 582-847, 588-715, 599-885, 601-803, 601-814, 627-986, 633-884, 646- 900, 653-972, 680-895, 680-904, 684-917, 711-1000, 738-945, 757-993, 763-1019, 764-995, 798-1042, 805-1053, 830-1101, 878-1102, 889-1286, 914-1526, 931-1157, 937-1152, 942-1201, 942-1519, 947-1156, 947-1321, 958- 1183, 965-1188, 965-1195, 965-1514, 997-1566, 1019-1292, 1033-1269, 1050-1262, 1085-1319, 1112-1389, 1133- 1369, 1146-1386, 1146-1475, 1146-1587, 1191-1381, 1191-1549, 1203-1330, 1350-1563, 1352-1612, 1363-1638, 1395-1582, 1395-1594 46/2768535CB1/ 1-520, 46-518, 46-520, 88-707, 129-472, 186-883, 187-765, 206-353, 421-1034, 505-1159, 623-908, 644-1251, 652- 4790 1211, 654-1195, 678-1221, 690-1269, 703-1254, 704-1393, 706-989, 762-1001, 770-1352, 781-1389, 797-1335, 813- 1420, 870-1413, 945-1256, 1050-1703, 1108-1788, 1114-1738, 1132-1698, 1173-1815, 1189-1796, 1195-1801, 1204- 1798, 1220-1719, 1248-1823, 1262-1921, 1266-1924, 1270-1883, 1272-1807, 1283-1664, 1283-1870, 1336-2021, 1425-2056, 1438-2076, 1527-2070, 1621-2136, 1676-2224, 1696-2084, 1750-2313, 1863-2252, 1918-2152, 1923- 2186, 1926-2568, 1964-2230, 1964-2464, 2072-2606, 2275-2500, 2401-3007, 2464-2726, 2470-2676, 2494-2785, 2533-2819, 2540-2809, 2595-3128, 2621-2839, 2640-2882, 2649-2884, 2654-2925, 2656-2930, 2698-2958, 2727- 2928, 2727-3213, 2782-2953, 2782-3400, 2853-3148, 2858-3045, 2889-3189, 2891-3338, 2891-3379, 2894-3205, 2934-3187, 2948-3209, 2972-3515, 2986-3244, 3000-3209, 3003-3246, 3027-3291, 3028-3230, 3028-3300, 3035- 3298, 3074-3268, 3074-3298, 3074-3666, 3106-3350, 3192-3404, 3192-3456, 3221-3449, 3223-3640, 3266-3531, 3266-3756, 3289-3860, 3292-3804, 3305-3643, 3308-3608, 3309-3598, 3361-3649, 3364-3659, 3400- 3643, 3406-3654, 3407-3672, 3411-3811, 3420-3867, 3421-3695, 3424-3703, 3428-3705, 3450-3787, 3454-3696, 3460-3739, 3473-3868, 3473-3875, 3487-3648, 3498-3745, 3503-3767, 3516-3753, 3533-3728, 3539-3762, 3599- 3809, 3601-3733, 3620-4123, 3638-3878, 3647-3669, 3647-3884, 3647-3919, 3647-4186, 3716-3988, 3724-3996, 3737-4008, 3746-3998, 3752-3983, 3755-4415, 3777-4010, 3777-4404, 3809-4098, 3823-4098, 3836-4109, 3857- 4095, 3858-4065, 3863-4367, 3875-4093, 3882-4128, 3900-4146, 3909-4147, 3984-4413, 3995-4242, 4025-4670, 4043-4296, 4056-4349, 4086-4123, 4100-4398, 4100-4593, 4100-4688, 4115-4333, 4116-4594, 4143-4696, 4147- 4677, 4152-4410, 4191-4680, 4202-4429, 4215-4494, 4221-4479, 4222-4509, 4277-4532, 4318-4682, 4322-4659, 4328-4543, 4380-4630, 4394-4669, 4422-4661, 4425-4667, 4439-4696, 4444-4696, 4450-4665, 4459-4696, 4472- 4676, 4494-4696, 4494-4790 47/6848851CB1/ 1-293, 136-477, 137-447, 170-482, 171-429, 171-477, 172-432, 172-446, 173-303, 173-433, 173-447, 174-416, 175- 3916 443, 180-393, 193-365, 193-447, 197-447, 202-447, 204-476, 206-476, 257-599, 366-599, 366-749, 386-429, 502- 684, 509-743, 600-749, 600-1197, 604-1073, 604-1184, 627-1215, 627-1308, 750-1197, 750-1603, 775-951, 921- 1562, 1143-1704, 1198-1603, 1198-1737, 1244-1601, 1293-1712, 1365-1613, 1596-1748, 1596-2025, 1604-1737, 1604-1858, 1605-1997, 1680-2413, 1728-2255, 1732-2340, 1749-1997, 1782-2357, 2040-2689, 2040-2690, 2059- 2331, 2254-2690, 2421-2777, 2421-2794, 2424-2824, 2435-3135, 2465-2742, 2480-2802, 2551-3204, 2571-2852, 2609-3171, 2637-2912, 2732-3429, 2946-3149, 2946-3219, 2989-3258, 2994-3238, 3162-3406, 3186-3436, 3187- 3610, 3214-3590, 3214-3620, 3226-3767, 3232-3512, 3235-3493, 3235-3616, 3254-3916, 3280-3916, 3378-3607 48/7040722CB1/ 1-1702, 5-561, 20-561, 107-167, 107-194, 107-240, 264-546, 420-852, 420-878, 420-1108, 420-1120, 424-1094, 947- 1702 1702, 952-988, 953-1702, 956-1702, 965-1702 49/6430290CB1/ 1-274, 27-274, 28-274, 29-274, 29-583, 40-682, 567-1426, 567-1429, 567-1448, 567-1458, 567-1462, 931-1211 1462 50/2640251CB1/ 1-282, 19-539, 73-658, 78-392, 83-598, 97-759, 106-624, 236-700, 335-611, 337-611, 375-634, 384-987, 404-759, 3958 489-700, 508-825, 523-790, 528-947, 594-899, 600-899, 600-902, 605-899, 668-931, 678-925, 685-899, 703-947, 746-983, 780-1061, 843-1073, 881-1389, 977-1275, 1043-1287, 1046-1323, 1111-1692, 1231-1506, 1322-1572, 1379-1630, 1408-1814, 1408-1873, 1433-2210, 1440-1692, 1563-2005, 1614-2034, 1626-2024, 1732-2034, 1750- 1972, 1820-2378, 1853-2417, 1975-2249, 2009-2210, 2043-2287, 2084-2626, 2091-2619, 2454-3008, 2468-3078, 2480-3019, 2584-3143, 2678-3169, 2687-3270, 2754-3231, 2901-3169, 2902-3169, 2936-3597, 3261-3958, 3382- 3686, 3382-3779 51/3839350CB1/ 1-296, 1-432, 1-450, 1-549, 1-563, 1-796, 3-360, 3-826, 102-826, 161-430, 190-798, 199-401, 221-736, 246-564, 826 254-773, 272-489, 299-436 52/6393813CB1/ 1-501, 18-719, 32-407, 32-493, 42-536, 51-302, 57-630, 58-305, 68-351, 68-608, 124-411, 173-710, 193-644, 208- 729 232, 216-516, 230-463, 230-716, 243-706, 266-706, 278-536, 283-729, 321-729, 334-717, 538-729, 594-655 53/5685755CB1/ 1-201, 76-697, 79-316, 197-478, 197-1448, 349-828, 351-803, 351-845, 353-846, 354-843, 358-845, 362-820, 363- 1610 828, 365-846, 366-846, 434-846, 459-846, 476-787, 479-1448, 480-1553, 530-816, 546-846, 606-846, 609-828, 839- 1279, 839-1333, 840-1331, 843-1210, 865-1323, 874-1051, 882-1321, 1252-1610 54/71728459CB1/ 1-337, 1-576, 1-617, 1-869, 120-487, 283-749, 283-750, 285-696, 286-739, 326-829, 327-828, 383-774, 420-819, 869 456-869 55/1904303CB1/ 1-515, 290-1414, 404-692, 416-828, 422-698, 429-676, 429-980, 530-747, 530-765, 530-1056, 586-858, 624-835, 2209 744-1052, 761-1021, 780-1070, 793-1288, 877-1193, 976-1439, 978-1330, 1018-1382, 1057-1255, 1057-1397, 1096- 1378, 1097-1412, 1097-1414, 1173-1451, 1203-1325, 1247-1687, 1247-1690, 1248-2190, 1254-1539, 1258-1414, 1298-1773, 1339-1918, 1345-1614, 1345-1880, 1345-1918, 1399-1618, 1434-1836, 1459-2128, 1500-2115, 1517- 1747, 1523-1786, 1582-2168, 1587-2209, 1590-2179, 1693-2200, 1719-2165, 1722-2208, 1725-2190, 1761-2184, 1763-2188, 1772-2189, 1774-2182, 1779-2187, 1788-2156, 1796-2187, 1812-2208, 1818-2182, 1820-2208, 1822- 2182, 1823-2192, 1825-2187, 1827-2182, 1833-2182, 1834-2182, 1846-2190, 1849-2192, 1858-2190, 1861-2184, 1863-2192, 1870-2182, 1871-2182, 1878-2180, 1879-2160, 1879-2180, 1897-2182, 1907-2187, 1928-2208, 2004- 2167, 2095-2182 56/2911343CB1/ 1-582, 1-1513, 43-138, 43-315, 43-573, 86-573, 101-347, 202-456, 465-569, 466-569, 523-996, 525-772, 528-1013, 1520 571-831, 571-838, 573-1124, 578-1373, 620-849, 658-806, 666-931, 666-1181, 732-1273, 732-1368, 735-1345, 774- 1377, 800-944, 829-1410, 830-1400, 834-1104, 885-1146, 933-1210, 939-1520, 942-1460, 970-1191, 999-1274, 1000-1411, 1051-1506, 1053-1514, 1053-1520, 1066-1520, 1067-1520, 1068-1514, 1075-1470, 1083-1448, 1098- 1520, 1108-1423, 1111-1493, 1138-1514, 1152-1437, 1163-1520, 1180-1520, 1187-1514, 1260-1520, 1274-1514 57/7500308CB1/ 1-1282, 4-295, 363-612, 363-888, 402-684, 402-707, 402-1050, 406-1001, 407-1018, 439-1006, 452-764, 454-859, 1282 463-718, 474-1001, 495-1035, 516-976, 580-1045, 646-1278, 748-1046, 748-1050, 835-1116, 887-1282, 1011-1243, 1060-1282 58/7501098CB1/ 1-252, 1-394, 1-397, 1-399, 1-1014, 87-193, 87-197, 87-198, 359-843, 363-843, 370-1010, 370-1016, 394-968, 410- 1228 1004, 430-990, 460-713, 460-862, 460-1024, 463-996, 465-715, 465-1228, 469-916, 537-1016, 568-1019, 580-1018 59/7503839CB1/ 1-128, 10-3582, 215-936, 270-739, 270-987, 293-883, 293-933, 293-1125, 441-617, 587-1256, 602-1405, 803-1370, 3582 909-1423, 959-1382, 1014-1803, 1031-1279, 1081-1663, 1262-1414, 1262-1691, 1279-2186, 1346-1720, 1347- 1654, 1347-1700, 1347-1705, 1347-1720, 1347-1868, 1347-2098, 1394-1922, 1394-2009, 1415-1663, 1446-2023, 1706-2355, 1706-2356, 1710-2355, 1717-2355, 1725-1999, 1779-2355, 1888-2355, 1909-2355, 1920-2355, 1923- 2355, 1976-2284, 2002-2355, 2034-2947, 2087-2443, 2087-2460, 2090-2490, 2101-2801, 2137-2265, 2137-2408, 2147-2468, 2217-2870, 2237-2518, 2275-2837, 2303-2578, 2334-2745, 2340-3263, 2341-2615, 2341-2879, 2341- 2920, 2341-2927, 2341-3008, 2341-3037, 2341-3051, 2341-3082, 2341-3088, 2341-3134, 2341-3233, 2346-3199, 2352-3252, 2384-2822, 2398-3095, 2423-2696, 2488-2721, 2489-3363, 2562-3289, 2612-2815, 2612-2885, 2614- 3559, 2632-3296, 2660-2904, 2661-2924, 2674-3520, 2710-3484, 2828-3072, 2853-3102, 2853-3275, 2874-3555, 2880-3256, 2898-3178, 2901-3159, 2901-3282, 2920-3582, 2946-3582, 3049-3273, 3142-3546, 3258-3449, 3258-3561, 3373-3501 60/7503698CB1/ 1-2043, 404-692, 416-828, 422-698, 429-676, 530-747, 530-765, 530-1056, 586-858, 624-835, 744-1052, 761-1021, 2063 780-1070, 897-1056, 963-1267, 1100-1540, 1100-1543, 1107-1392, 1111-1267, 1147-1267, 1151-1626, 1192-1771, 1198-1352, 1198-1467, 1198-1733, 1198-1800, 1236-1984, 1252-1471, 1312-1606, 1312-1981, 1370-1600, 1384- 1609, 1435-2021, 1440-2043, 1443-2032, 1517-1809, 1518-1743, 1546-2043, 1572-2018, 1575-2043, 1578-2063, 1580-2037, 1584-2039, 1614-2037, 1616-2041, 1617-1993, 1625-2042, 1627-2035, 1632-2040, 1649-2040, 1665- 2043, 1671-2035, 1673-2043, 1675-2035, 1676-2035, 1678-2040, 1680-2035, 1681-2040, 1686-2035, 1687-2035, 1699-2046, 1711-2047, 1714-2037, 1716-2034, 1720-2031, 1720-2033, 1720-2039, 1720-2063, 1723-2035, 1724- 2035, 1724-2039, 1729-2039, 1731-2013, 1731-2033, 1731-2039, 1732-2013, 1732-2031, 1732-2033, 1732-2039, 1750-2035, 1760-2040, 1781-2043, 1857-2020, 1871-2063, 1948-2035, 1980-2043

[0394] TABLE 5 Polynucleotide SEQ ID NO: Incyte Project ED: Representative Library 31 1895273CB1 THP1NOT03 32 70072222CB1 BRAIFEN05 33 3559223CB1 BRAHTDK01 34 3441255CB1 PLACNOB01 35 1958917CB1 BRSTNOT23 36 6219465CB1 BRAUNOR01 37 3576625CB1 NERDTDN03 38 4765758CB1 PLACNOT05 39 7236661CB1 BRAUNOR01 40 7714187CB1 BRAIHCT01 41 5136540CB1 UTREDIT07 42 3277403CB1 FIBRUNT02 43 1517569CB1 LUNGNOT18 44 2415991CB1 BRAINOT11 45 2735742CB1 LUNGFET03 46 2768535CB1 ADRENOT07 47 6848851CB1 BRAIFER05 48 7040722CB1 UTRSTMR02 49 6430290CB1 LUNGNON07 50 2640251CB1 BRAITUT03 51 3839350CB1 DENDTNT01 52 6393813CB1 KIDCTMT01 53 5685755CB1 BRAIUNT01 54 71728459CB1 BRAHNOT01 55 1904303CB1 OVARTUT10 56 2911343CB1 BSCNNOT03 57 7500308CB1 BRAYDIN03 58 7501098CB1 UTREDIT07 59 7503839CB1 BRAIFER05 60 7503698CB1 LUNGNOT02

[0395] TABLE 6 Library Vector Library Description ADRENOT07 pINCY Library was constructed using RNA isolated from adrenal tissue removed from a 61-year-old female during a bilateral adrenalectomy. Patient history included an unspecified disorder of the adrenal glands. BRAHNOT01 pINCY Library was constructed using RNA isolated from posterior hippocampus tissue removed from a 35-year-old Caucasian male who died from cardiac failure. Pathology indicated moderate leptomeningeal fibrosis and multiple micro- infarctions of the cerebral neocortex. Microscopically, the cerebral hemisphere revealed moderate fibrosis of the leptomeninges with focal calcifications. There was evidence of shrunken and slightly eosinophilic pyramidal neurons throughout the cerebral hemispheres. In addition, scattered throughout the cerebral cortex, there were multiple small microscopic areas of cavitation with surrounding gliosis. Patient history included dilated cardiomyopathy, congestive heart failure, cardiomegaly and an enlarged spleen and liver. BRAHTDK01 PSPORT1 This amplified and normalized library was constructed using pooled RNA isolated from archaecortex, anterior and posterior hippocampus tissue removed from a 55-year-old Caucasian female who died from cholangiocarcinoma. Pathology indicated mild meningeal fibrosis predominately over the convexities, scattered axonal spheroids in the white matter of the cingulate cortex and the thalamus, and a few scattered neurofibrillary tangles in the entorhinal cortex and the periaqueductal gray region. Pathology for the associated tumor tissue indicated well- differentiated cholangiocarcinoma of the liver with residual or relapsed tumor. Patient history included cholangiocarcinoma, post-operative Budd-Chiari syndrome, biliary ascites, hydrothorax, dehydration, malnutrition, oliguria and acute renal failure. Previous surgeries included cholecystectomy and resection of 85% of the liver. 7.6 × 10e5 independent clones from this amplified library were normalized in 1 round using conditions adapted Soares et al., PNAS (1994) 91:9228-9232 and Bonaldo et al., Genome Research (1996) 6:791, except that a significantly longer (48 hours/round) reannealing hybridization was used. BRAIFEN05 pINCY This normalized fetal brain tissue library was constructed from 3.26 million independent clones from a fetal brain library. Starting RNA was made from brain tissue removed from a Caucasian male fetus, who was stillborn with a hypoplastic left heart at 23 weeks' gestation. The library was normalized in 2 rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228 and Bonaldo et al., Genome Research (1996) 6:791, except that a significantly longer (48 hours/round) reannealing hybridization was used. BRAIFER05 pINCY Library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus who was stillborn with a hypoplastic left heart at 23 weeks' gestation. BRAIHCT01 pINCY Library was constructed using RNA isolated from diseased occipital lobe tissue removed from the brain of a 57-year-old Caucasian male, who died from a cerebrovascular accident. Patient history included Huntington's disease and emphysema. BRAINOT11 pINCY Library was constructed using RNA isolated from brain tissue removed from the right temporal lobe of a 5-year-old Caucasian male during a hemispherectomy. Pathology indicated extensive polymicrogyria and mild to moderate gliosis (predominantly subpial and subcortical), consistent with chronic seizure disorder. Family history included a cervical neoplasm. BRAITUT03 PSPORT1 Library was constructed using RNA isolated from brain tumor tissue removed from the left frontal lobe of a 17-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated a grade 4 fibrillary giant and small- cell astrocytoma. Family history included benign hypertension and cerebrovascular disease. BRAIUNT01 pINCY Library was constructed using RNA isolated from SK-N-MC, a neuroepithelioma cell line (ATCC HTB-10) derived from a 14-year-old Caucasian female with neuroepithelioma, with metastasis to the supra-orbital area. BRAUNOR01 pINCY This random primed library was constructed using RNA isolated from striatum, globus pallidus and posterior putamen tissue removed from an 81-year-old Caucasian female who died from a hemorrhage and ruptured thoracic aorta due to atherosclerosis. Pathology indicated moderate atherosclerosis involving the internal carotids, bilaterally; microscopic infarcts of the frontal cortex and hippocampus; and scattered diffuse amyloid plaques and neurofibrillary tangles, consistent with age. Grossly, the leptomeninges showed only mild thickening and hyalinization along the superior sagittal sinus. The remainder of the leptomeninges was thin and contained some congested blood vessels. Mild atrophy was found mostly in the frontal poles and lobes, and temporal lobes, bilaterally. Microscopically, there were pairs of Alzheimer type II astrocytes within the deep layers of the neocortex. There was increased satellitosis around neurons in the deep gray matter in the middle frontal cortex. The amygdala contained rare diffuse plaques and neurofibrillary tangles. The posterior hippocampus contained a microscopic area of cystic cavitation with hemosiderin-laden macrophages surrounded by reactive gliosis. Patient history included sepsis, cholangitis, post-operative atelectasis, pneumonia CAD, cardiomegaly due to left ventricular hypertrophy, splenomegaly, arteriolonephrosclerosis, nodular colloidal goiter, emphysema, CHF, hypothyroidism, and peripheral vascular disease. BRAYDIN03 pINCY This normalized library was constructed from 6.7 million independent clones from a brain tissue library. Starting RNA was made from RNA isolated from diseased hypothalamus tissue removed from a 57-year-old Caucasian male who died from a cerebrovascular accident. Patient history included Huntington's disease and emphysema. The library was normalized in 2 rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228 and Bonaldo et al., Genome Research (1996) 6:791, except that a significantly longer (48 -hours/round) reannealing hybridization was used. The library was linearized and recircularized to select for insert containing clones. BRSTNOT23 pINCY Library was constructed using RNA isolated from diseased breast tissue removed from a 35-year-old Caucasian female during a bilateral reduction mammoplasty. Pathology indicated nonproliferative fibrocystic disease. Family history included type II diabetes, atherosclerotic coronary artery disease, acute myocardial infarction, hyperlipidemia, and coronary artery bypass. BSCNNOT03 pINCY Library was constructed using RNA isolated from caudate nucleus tissue removed from the brain of a 92-year-old male. Pathology indicated several small cerebral infarcts but no senile plaques or neurofibrillary degeneration. Patient history included throat cancer which was treated with radiation. DENDTNT01 pINCY Library was constructed using RNA isolated from treated dendritic cells from peripheral blood. FIBRUNT02 pINCY Library was constructed using RNA isolated from an untreated MG-63 cell line derived from an osteosarcoma removed from a 14-year-old Caucasian male. KIDCTMT01 pINCY Library was constructed using RNA isolated from kidney cortex tissue removed from a 65-year-old male during nephroureterectomy. Pathology for the associated tumor tissue indicated grade 3 renal cell carcinoma within the mid-portion of the kidney and the renal capsule. LUNGFET03 pINCY Library was constructed using RNA isolated from lung tissue removed from a Caucasian female fetus, who died at 20 weeks' gestation. LUNGNON07 pINCY This normalized lung tissue library was constructed from 5.1 million independent clones from a lung tissue library. Starting RNA was made from RNA isolated from lung tissue. The library was normalized in two rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228-9232 and Bonaldo et al., Genome Research (1996) 6:791, except that a significantly longer (48 hours/round) reannealing hybridization was used. LUNGNOT02 PBLUESCRIPT Library was constructed using RNA isolated from the lung tissue of a 47-year-old Caucasian male, who died of a subarachnoid hemorrhage. LUNGNOT18 pINCY Library was constructed using RNA isolated from left upper lobe lung tissue removed from a 66-year-old Caucasian female. Pathology for the associated tumor tissue indicated a grade 2 adenocarcinoma. Patient history included cerebrovascular disease, atherosclerotic coronary artery disease, and pulmonary insufficiency. Family history included a myocardial infarction and atherosclerotic coronary artery disease. NERDTDN03 pINCY This normalized dorsal root ganglion tissue library was constructed from 1.05 million independent clones from a dorsal root ganglion tissue library. Starting RNA was made from dorsal root ganglion tissue removed from the cervical spine of a 32-year-old Caucasian male who died from acute pulmonary edema, acute bronchopneumonia, bilateral pleural effusions, pericardial effusion, and malignant lymphoma (natural killer cell type). The patient presented with pyrexia of unknown origin, malaise, fatigue, and gastrointestinal bleeding. Patient history included probable cytomegalovirus infection, liver congestion, and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, respiratory failure, pneumonia of the left lung, natural killer cell lymphoma of the pharynx, Bell's palsy, and tobacco and alcohol abuse. Previous surgeries included colonoscopy, closed colon biopsy, adenotonsillectomy, and nasopharyngeal endoscopy and biopsy. Patient medications included Diflucan (fluconazole), Deltasone (prednisone), hydrocodone, Lortab, Alprazolam, Reazodone, ProMace-Cytabom, Etoposide, Cisplatin, Cytarabine, and dexamethasone. The patient received radiation therapy and multiple blood transfusions. The library was normalized in 2 rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228-9232 and Bonaldo et al., Genome Research 6 (1996):791, except that a significantly longer (48 hours/round) reannealing hybridization was used. OVARTUT10 pINCY Library was constructed using RNA isolated from ovarian tumor tissue removed from the left ovary of a 58-year-old Caucasian female during a total abdominal hysterectomy, removal of a solitary ovary, and repair of inguinal hernia. Pathology indicated a metastatic grade 3 adenocarcinoma of colonic origin, forming a partially cystic and necrotic tumor mass in the left ovary, and an adenocarcinoma of colonic origin, forming a nodule in the left mesovarium. A single intramural leiomyoma was identified in the myometrium. The cervix showed mild chronic cystic cervicitis. Patient history included benign hypertension, follicular cyst of the ovary, colon cancer, benign colon neoplasm, and osteoarthritis. Family history included emphysema, myocardial infarction, atherosclerotic coronary artery disease, benign hypertension, and hyperlipidemia. PLACNOB01 PBLUESCRIPT Library was constructed using RNA isolated from placenta. PLACNOT05 pINCY Library was constructed using RNA isolated from placental tissue removed from a Caucasian male fetus, who died after 18 weeks' gestation from fetal demise. THP1NOT03 pINCY Library was constructed using RNA isolated from untreated THP-1 cells. THP-1 is a human promonocyte line derived from the peripheral blood of a 1-year-old Caucasian male with acute monocytic leukemia (ref: Int. J. Cancer (1980) 26:171). UTREDIT07 pINCY Library was constructed using RNA isolated from diseased endometrial tissue removed from a female during endometrial biopsy. Pathology indicated in phase endometrium with missing beta 3, Type II defects. UTRSTMR02 PCDNA2.1 This random primed library was constructed using pooled cDNA from two different donors. cDNA was generated using mRNA isolated from endometrial tissue removed from a 32-year-old female (donor A) and using mRNA isolated from myometrium removed from a 45-year-old female (donor B) during vaginal hysterectomy and bilateral salpingo- oophorectomy. In donor A, pathology indicated the endometrium was secretory phase. The cervix showed severe dysplasia (CIN III) focally involving the squamocolumnar junction at the 1, 6 and 7 o'clock positions. Mild koilocytotic dysplasia was also identified within the cervix. In donor B, pathology for the matched tumor tissue indicated multiple (23) subserosal, intramural, and submucosal leiomyomata. Patient history included stress incontinence, extrinsic asthma without status asthmaticus and normal delivery in donor B. Family history included cerebrovascular disease, depression, and atherosclerotic coronary artery disease in donor B.

[0396] TABLE 7 Program Description Reference Parameter Threshold ABI A program that removes Applied Biosystems, FACTURA vector sequences and Foster City, CA. masks ambiguous bases in nucleic acid sequences. ABI/PARACEL FDF A Fast Data Finder useful Applied Biosystems, Mismatch <50% in comparing and annotating Foster City, CA; amino acid or nucleic Paracel Inc., Pasadena, CA. acid sequences. ABI A program that assembles Applied Biosystems, AutoAssembler nucleic acid sequences. Foster City, CA. BLAST A Basic Local Alignment Altschul, S. F. et al. ESTs: Probability value = Search Tool useful in (1990) J. Mol. Biol. 1.0E−8 or less; Full sequence similarity search 215:403-410; Length sequences: for amino acid and nucleic Altschul, S. F. et al. (1997) Probability value = acid sequences. BLAST Nucleic Acids Res. 1.0E−10 or less includes five functions: 25:3389-3402. blastp, blastn, blastx, tblastn, and tblastx. FASTA A Pearson and Lipman Pearson, W. R. and D. J. ESTs: fasta E value = algorithm that searches for Lipman (1988) Proc. 1.06E−6; Assembled ESTs: similarity between a query Natl. Acad Sci. USA fasta Identity = sequence and a group of 85:2444-2448; Pearson, W. R. 95% or greater and Match sequences of the same type. (1990) Methods Enzymol. length = 200 bases or FASTA comprises as 183:63-98; and Smith, greater; fastx E value = least five functions: fasta, T. F. and M. S. Waterman 1.0E−8 or less; tfasta, fastx, tfastx, and (1981) Adv. Appl. Math. Full Length sequences: fastx ssearch. 2:482-489. score = 100 or greater BLIMPS A BLocks IMProved Searcher Henikoff, S. and J. G. Probability value = that matches a sequence Henikoff (1991) Nucleic 1.0E−3 or less against those in BLOCKS, Acids Res. 19:6565-6572; PRINTS, DOMO, PRODOM, Henikoff, J. G. and S. and PFAM databases to Henikoff (1996) Methods search for gene families, Enzymol. 266:88-105; sequence homology, and and Attwood, T. K. et structural fingerprint regions. al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424. HMMER An algorithm for searching Krogh, A. et al. (1994) J. PFAM, SMART or TIGRFAM a query sequence against Mol. Biol. 235:1501-1531; hits: Probability hidden Markov model Sonnhammer, E. L. L. et al. value = 1.0E−3 (HMM)-based databases of (1988) Nucleic Acids Res. or less; Signal peptide hits: protein family consensus 26:320-322; Durbin, R. et Score = 0 or greater sequences, such as PFAM, al. (1998) Our World View, SMART and TIGRFAM. in a Nutshell, Cambridge Univ. Press, pp. 1-350. ProfileScan An algorithm that searches Gribskov, M. et al. (1988) Normalized quality for structural and CABIOS 4:61-66; score ≧ GCG specified sequence motifs in protein Gribskov, M. et al. (1989) “HIGH” sequences that match Methods Enzymol. 183:146-159; value for that particular sequence patterns Bairoch, A. et al. (1997) Prosite motif. Generally, defined in Prosite. Nucleic Acids Res. 25:217-221. score = 1.4-2.1. Phred A base-calling algorithm Ewing, B. et al. (1998) that examines automated Genome Res. 8:175- sequencer traces with high 185; Ewing, B. and P. sensitivity and probability. Green (1998) Genome Res. 8:186-194. Phrap A Phils Revised Assembly Smith, T. F. and M. S. Score = 120 Program including SWAT and Waterman (1981) Adv. or greater; Match CrossMatch, programs Appl. Math. 2:482-489; length = 56 based on efficient Smith, T. F. and M. S. or greater implementation of the Waterman (1981) J. Mol. Smith-Waterman algorithm, Biol. 147:195- 197; and useful in searching Green, P., University of sequence homology and Washington, Seattle, WA. assembling DNA sequences. Consed A graphical tool for Gordon, D. et al. (1998) viewing and editing Phrap Genome Res. 8:195- assemblies. 202. SPScan A weight matrix analysis Nielson, H. et al. (1997) Score = 3.5 program that scans protein Protein Engineering or greater sequences for the presence 10:1-6; Claverie, of secretory signal J. M. and S. Audic (1997) peptides. CABIOS 12:431-439. TMAP A program that uses weight Persson, B. and P. Argos matrices to delineate (1994) J. Mol. Biol. transmembrane segments 237:182-192; Persson, on protein sequences and B. and P. Argos (1996) determine orientation. Protein Sci. 5:363-371. TMHMMER A program that uses a Sonnhammer, E. L. et al. hidden Markov model (HMM) (1998) Proc. Sixth Intl. to delineate transmembrane Conf. On Intelligent Systems segments on protein for Mol. Biol., Glasgow et sequences and determine al., eds., The Am. Assoc. orientation. for Artificial Intelligence (AAAI) Press, Menlo Park, CA, and MIT Press, Cambridge, MA, pp. 175-182. Motifs A program that searches Bairoch, A. et al. (1997) amino acid sequences for Nucleic Acids Res. 25:217-221; patterns that matched Wisconsin Package Program those defined in Prosite. Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.

[0397] TABLE 8 Caucasian African SEQ Allele 1 Allele 1 Asian Hispanic ID EST CB1 EST Allele Allele Amino fre- fre- Allele 1 Allele 1 NO: PID EST ID SNP ID SNP SNP Allele 1 2 Acid quency quency frequency frequency 57 7500308 6824818H1 SNP00058395 72 952 A A G noncoding n/d n/a n/a n/a 57 7500308 6824818H1 SNP00142506 233 791 A A G noncoding n/a n/a n/a n/a 57 7500308 6824818J1 SNP00058395 580 952 A A G noncoding n/d n/a n/a n/a 57 7500308 6824818J1 SNP00142506 419 791 A A G noncoding n/a n/a n/a n/a 59 7503839 1233581H1 SNP00105660 163 3212 A A G noncoding n/a n/a n/a n/a 59 7503839 1960883H1 SNP00051538 159 3011 C C T noncoding n/a n/a n/a n/a 59 7503839 2396122H2 SNP00051538 111 3011 C C T noncoding n/a n/a n/a n/a 59 7503839 2439231H1 SNP00051538 184 3011 C C T noncoding n/a n/a n/a n/a 59 7503839 3525859H1 SNP00051538 114 3011 C C T noncoding n/a n/a n/a n/a 59 7503839 5676172H1 SNP00021725 41 1071 C C A noncoding n/d n/d n/d n/d 59 7503839 6367830H1 SNP00003533 249 3361 C C T noncoding n/a n/a n/a n/a 59 7503839 7579662H1 SNP00021725 113 1071 C C A noncoding n/d n/d n/d n/d 59 7503839 7653343H1 SNP00021725 485 1071 C C A noncoding n/d n/d n/d n/d 59 7503839 7763335J1 SNP00051538 85 3011 C C T noncoding n/a n/a n/a n/a 59 7503839 8450847J1 SNP00003533 257 3361 C C T noncoding n/a n/a n/a n/a 59 7503839 8454173J1 SNP00003533 257 3361 C C T noncoding n/a n/a n/a n/a 59 7503839 8454612J1 SNP00003533 255 3361 C C T noncoding n/a n/a n/a n/a 60 7503698 1336111H1 SNP00151238 61 1312 A A G E297 n/a n/a n/a n/a 60 7503698 1904303H1 SNP00151238 115 1312 A A G E297 n/a n/a n/a n/a 60 7503698 3417040H1 SNP00151239 194 1563 C C T P381 n/a n/a n/a n/a 60 7503698 5943105H1 SNP00151239 45 1561 C C T S380 n/a n/a n/a n/a

[0398]

1 60 1 289 PRT Homo sapiens misc_feature Incyte ID No 1895273CD1 1 Met Trp Phe Leu Thr Thr Leu Leu Leu Trp Val Pro Val Asp Gly 1 5 10 15 Gln Val Gly Trp Leu Leu Leu Gln Val Ser Ser Arg Val Phe Thr 20 25 30 Glu Gly Glu Pro Leu Ala Leu Arg Cys His Ala Trp Lys Asp Lys 35 40 45 Leu Val Tyr Asn Val Leu Tyr Tyr Arg Asn Gly Lys Ala Phe Lys 50 55 60 Phe Phe His Trp Asn Ser Asn Leu Thr Ile Leu Lys Thr Asn Ile 65 70 75 Ser His Asn Gly Thr Tyr His Cys Ser Gly Met Gly Lys His Arg 80 85 90 Tyr Thr Ser Ala Gly Ile Ser Val Thr Val Lys Glu Leu Phe Pro 95 100 105 Ala Pro Val Leu Asn Ala Ser Val Thr Ser Pro Leu Leu Glu Gly 110 115 120 Asn Leu Val Thr Leu Ser Cys Glu Thr Lys Leu Leu Leu Gln Arg 125 130 135 Pro Gly Leu Gln Leu Tyr Phe Ser Phe Tyr Met Gly Ser Lys Thr 140 145 150 Leu Arg Gly Arg Asn Thr Ser Ser Glu Tyr Gln Ile Leu Thr Ala 155 160 165 Arg Arg Glu Asp Ser Gly Leu Tyr Trp Cys Glu Ala Ala Thr Glu 170 175 180 Asp Gly Asn Val Leu Lys Arg Ser Pro Glu Leu Glu Leu Gln Val 185 190 195 Leu Gly Leu Gln Leu Pro Thr Pro Val Trp Phe His Val Leu Phe 200 205 210 Tyr Leu Ala Val Gly Ile Met Phe Leu Val Asn Thr Val Leu Trp 215 220 225 Val Thr Ile Arg Lys Glu Leu Lys Arg Lys Lys Lys Trp Asn Leu 230 235 240 Glu Ile Ser Leu Asp Ser Gly His Glu Lys Lys Val Ile Ser Ser 245 250 255 Leu Gln Glu Asp Arg His Leu Glu Glu Glu Leu Lys Cys Gln Glu 260 265 270 Gln Lys Glu Glu Gln Leu Gln Glu Gly Val His Arg Lys Glu Pro 275 280 285 Gln Gly Ala Thr 2 159 PRT Homo sapiens misc_feature Incyte ID No 70072222CD1 2 Met Ser Gln Ala Trp Val Pro Gly Leu Ala Pro Thr Leu Leu Phe 1 5 10 15 Ser Leu Leu Ala Gly Pro Gln Lys Ile Ala Ala Lys Cys Gly Leu 20 25 30 Ile Leu Ala Cys Pro Lys Gly Phe Lys Cys Cys Gly Asp Ser Cys 35 40 45 Cys Gln Glu Asn Glu Leu Phe Pro Gly Pro Val Arg Ile Phe Val 50 55 60 Ile Ile Phe Leu Val Ile Leu Ser Val Phe Cys Ile Cys Gly Leu 65 70 75 Ala Lys Cys Phe Cys Arg Asn Cys Arg Glu Pro Glu Pro Asp Thr 80 85 90 Pro Val Asp Cys Arg Gly Pro Leu Glu Leu Pro Ser Ile Ile Pro 95 100 105 Pro Glu Arg Val Arg Val Ser Leu Ser Ala Pro Pro Pro Pro Tyr 110 115 120 Ser Glu Val Ile Leu Lys Pro Ser Leu Gly Pro Thr Pro Thr Glu 125 130 135 Pro Pro Pro Pro Tyr Ser Phe Arg Pro Glu Glu Tyr Thr Gly Asp 140 145 150 Gln Arg Gly Ile Asp Asn Pro Ala Phe 155 3 559 PRT Homo sapiens misc_feature Incyte ID No 3559223CD1 3 Met Ala Ala Ser Glu Asp Gly Ser Gly Cys Leu Val Ser Arg Gly 1 5 10 15 Arg Ser Gln Ser Asp Pro Ser Val Leu Thr Asp Ser Ser Ala Thr 20 25 30 Ser Ser Ala Asp Ala Gly Glu Asn Pro Asp Glu Met Asp Gln Thr 35 40 45 Pro Pro Ala Arg Pro Glu Tyr Leu Val Ser Gly Ile Arg Thr Pro 50 55 60 Pro Val Arg Arg Asn Ser Lys Leu Ala Thr Leu Gly Arg Ile Phe 65 70 75 Lys Pro Trp Lys Trp Arg Lys Lys Lys Asn Glu Lys Leu Lys Gln 80 85 90 Thr Thr Ser Ala Leu Glu Lys Lys Met Ala Gly Arg Gln Gly Arg 95 100 105 Glu Glu Leu Ile Lys Lys Gly Leu Leu Glu Met Met Glu Gln Asp 110 115 120 Ala Glu Ser Lys Thr Cys Asn Pro Asp Gly Gly Pro Arg Ser Val 125 130 135 Gln Ser Glu Pro Pro Thr Pro Lys Ser Glu Thr Leu Thr Ser Glu 140 145 150 Asp Ala Gln Pro Gly Ser Pro Leu Ala Thr Gly Thr Asp Gln Val 155 160 165 Ser Leu Asp Lys Pro Leu Ser Ser Ala Ala His Leu Asp Asp Ala 170 175 180 Ala Lys Met Pro Ser Ala Ser Ser Gly Glu Glu Ala Asp Ala Gly 185 190 195 Ser Leu Leu Pro Thr Thr Asn Glu Leu Ser Gln Ala Leu Ala Gly 200 205 210 Ala Asp Ser Leu Asp Ser Pro Pro Arg Pro Leu Glu Arg Ser Val 215 220 225 Gly Gln Leu Pro Ser Pro Pro Leu Leu Pro Thr Pro Pro Pro Lys 230 235 240 Ala Ser Ser Lys Thr Thr Lys Asn Val Thr Gly Gln Ala Thr Leu 245 250 255 Phe Gln Ala Ser Ser Met Lys Ser Ala Asp Pro Ser Leu Arg Gly 260 265 270 Gln Leu Ser Thr Pro Thr Gly Ser Pro His Leu Thr Thr Val His 275 280 285 Arg Pro Leu Pro Pro Ser Arg Val Ile Glu Glu Leu His Arg Ala 290 295 300 Leu Ala Thr Lys His Arg Gln Asp Ser Phe Gln Gly Arg Glu Ser 305 310 315 Lys Gly Ser Pro Lys Lys Arg Leu Asp Val Arg Leu Ser Arg Thr 320 325 330 Ser Ser Val Glu Arg Gly Lys Glu Arg Glu Glu Ala Trp Ser Phe 335 340 345 Asp Gly Ala Leu Glu Asn Lys Arg Thr Ala Ala Lys Glu Ser Glu 350 355 360 Glu Asn Lys Glu Asn Leu Ile Ile Asn Ser Glu Leu Lys Asp Asp 365 370 375 Leu Leu Leu Tyr Gln Asp Glu Glu Ala Leu Asn Asp Ser Ile Ile 380 385 390 Ser Gly Thr Leu Pro Arg Lys Cys Lys Lys Glu Leu Leu Ala Val 395 400 405 Lys Leu Arg Asn Arg Pro Ser Lys Gln Glu Leu Glu Asp Arg Asn 410 415 420 Ile Phe Pro Arg Arg Thr Asp Glu Glu Arg Gln Glu Ile Arg Gln 425 430 435 Gln Ile Glu Met Lys Leu Ser Lys Arg Leu Ser Gln Arg Pro Ala 440 445 450 Val Glu Glu Leu Glu Arg Arg Asn Ile Leu Lys Gln Arg Asn Asp 455 460 465 Gln Thr Glu Gln Glu Glu Arg Arg Glu Ile Lys Gln Arg Leu Thr 470 475 480 Arg Lys Leu Asn Gln Arg Pro Thr Val Asp Glu Leu Arg Asp Arg 485 490 495 Lys Ile Leu Ile Arg Phe Ser Asp Tyr Val Glu Val Ala Lys Ala 500 505 510 Gln Asp Tyr Asp Arg Arg Ala Asp Lys Pro Trp Thr Arg Leu Ser 515 520 525 Ala Ala Asp Lys Ala Ala Ile Arg Lys Glu Leu Asn Glu Tyr Lys 530 535 540 Ser Asn Glu Met Glu Val His Ala Ser Ser Lys His Leu Thr Arg 545 550 555 Phe His Arg Pro 4 1222 PRT Homo sapiens misc_feature Incyte ID No 3441255CD1 4 Met Pro Lys Gly Gly Ala Pro Pro Trp Ile Met Ala Leu Met Phe 1 5 10 15 Thr Gly His Leu Leu Phe Leu Ala Leu Leu Met Phe Ala Phe Ser 20 25 30 Thr Phe Glu Glu Ser Val Ser Asn Tyr Ser Glu Trp Ala Val Phe 35 40 45 Thr Asp Asp Ile Asp Gln Phe Lys Thr Gln Lys Val Gln Asp Phe 50 55 60 Arg Pro Asn Gln Lys Leu Lys Lys Ser Met Leu His Pro Ser Leu 65 70 75 Tyr Phe Asp Ala Gly Glu Ile Gln Ala Met Arg Gln Lys Ser Arg 80 85 90 Ala Ser His Leu His Leu Phe Arg Ala Ile Arg Ser Ala Val Thr 95 100 105 Val Met Leu Ser Asn Pro Thr Tyr Tyr Leu Pro Pro Pro Lys His 110 115 120 Ala Asp Phe Ala Ala Lys Trp Asn Glu Ile Tyr Gly Asn Asn Leu 125 130 135 Pro Pro Leu Ala Leu Tyr Cys Leu Leu Cys Pro Glu Asp Lys Val 140 145 150 Ala Phe Glu Phe Val Leu Glu Tyr Met Asp Arg Met Val Gly Tyr 155 160 165 Lys Asp Trp Leu Val Glu Asn Ala Pro Gly Asp Glu Val Pro Ile 170 175 180 Val His Ser Leu Thr Gly Phe Ala Thr Ala Phe Asp Phe Leu Tyr 185 190 195 Asn Leu Leu Asp Asn His Arg Arg Gln Lys Tyr Leu Glu Lys Ile 200 205 210 Trp Val Ile Thr Glu Glu Met Tyr Glu Tyr Ser Lys Val Arg Ser 215 220 225 Trp Gly Lys Gln Leu Leu His Asn His Gln Ala Thr Asn Met Ile 230 235 240 Ala Leu Leu Thr Gly Ala Leu Val Thr Gly Val Asp Lys Gly Ser 245 250 255 Lys Ala Asn Ile Trp Lys Gln Ala Val Val Asp Val Met Glu Lys 260 265 270 Thr Met Phe Leu Leu Asn His Ile Val Asp Gly Ser Leu Tyr Glu 275 280 285 Gly Val Ala Tyr Gly Ser Tyr Thr Ala Lys Ser Val Thr Gln Tyr 290 295 300 Val Phe Leu Ala Gln Arg His Phe Asn Ile Asn Asn Leu Asp Asn 305 310 315 Asn Trp Leu Lys Met His Phe Trp Phe Tyr Tyr Ala Thr Leu Leu 320 325 330 Pro Gly Phe Gln Arg Thr Val Gly Ile Ala Asp Ser Asn Tyr Asn 335 340 345 Trp Phe Tyr Gly Pro Glu Ser Gln Leu Val Phe Leu Asp Lys Phe 350 355 360 Ile Leu Lys Asn Gly Ala Gly Asn Trp Leu Ala Gln Gln Ile Arg 365 370 375 Lys His Arg Pro Lys Asp Gly Pro Met Val Pro Ser Thr Ala Gln 380 385 390 Arg Trp Ser Thr Leu His Thr Glu Tyr Ile Trp Tyr Asp Pro Gln 395 400 405 Leu Thr Pro Gln Pro Pro Ala Asp Tyr Gly Thr Ala Lys Ile His 410 415 420 Thr Phe Pro Asn Trp Gly Val Val Thr Tyr Gly Ala Gly Leu Pro 425 430 435 Asn Thr Gln Thr Asn Thr Phe Val Ser Phe Lys Ser Gly Lys Leu 440 445 450 Gly Gly Arg Ala Val Tyr Asp Ile Val His Phe Gln Pro Tyr Ser 455 460 465 Trp Ile Asp Gly Trp Arg Ser Phe Asn Pro Gly His Glu His Pro 470 475 480 Asp Gln Asn Ser Phe Thr Phe Ala Pro Asn Gly Gln Val Phe Val 485 490 495 Ser Glu Ala Leu Tyr Gly Pro Lys Leu Ser His Leu Asn Asn Val 500 505 510 Leu Val Phe Ala Pro Ser Pro Ser Ser Gln Cys Asn Lys Pro Trp 515 520 525 Glu Gly Gln Leu Gly Glu Cys Ala Gln Trp Leu Lys Trp Thr Gly 530 535 540 Glu Glu Val Gly Asp Ala Ala Gly Glu Ile Ile Thr Ala Ser Gln 545 550 555 His Gly Glu Met Val Phe Val Ser Gly Glu Ala Val Ser Ala Tyr 560 565 570 Ser Ser Ala Met Arg Leu Lys Ser Val Tyr Arg Ala Leu Leu Leu 575 580 585 Leu Asn Ser Gln Thr Leu Leu Val Val Asp His Ile Glu Arg Gln 590 595 600 Glu Asp Ser Pro Ile Asn Ser Val Ser Ala Phe Phe His Asn Leu 605 610 615 Asp Ile Asp Phe Lys Tyr Ile Pro Tyr Lys Phe Met Asn Arg Tyr 620 625 630 Asn Gly Ala Met Met Asp Val Trp Asp Ala His Tyr Lys Met Phe 635 640 645 Trp Phe Asp His His Gly Asn Ser Pro Met Ala Ser Ile Gln Glu 650 655 660 Ala Glu Gln Ala Ala Glu Phe Lys Lys Arg Trp Thr Gln Phe Val 665 670 675 Asn Val Thr Phe Gln Met Glu Pro Thr Ile Thr Arg Ile Ala Tyr 680 685 690 Val Phe Tyr Gly Pro Tyr Ile Asn Val Ser Ser Cys Arg Phe Ile 695 700 705 Asp Ser Ser Asn Pro Gly Leu Gln Ile Ser Leu Asn Val Asn Asn 710 715 720 Thr Glu His Val Val Ser Ile Val Thr Asp Tyr His Asn Leu Lys 725 730 735 Thr Arg Phe Asn Tyr Leu Gly Phe Gly Gly Phe Ala Ser Val Ala 740 745 750 Asp Gln Gly Gln Ile Thr Arg Phe Gly Leu Gly Thr Gln Ala Ile 755 760 765 Val Lys Pro Val Arg His Asp Arg Ile Ile Phe Pro Phe Gly Phe 770 775 780 Lys Phe Asn Ile Ala Val Gly Leu Ile Leu Cys Ile Ser Leu Val 785 790 795 Ile Leu Thr Phe Gln Trp Arg Phe Tyr Leu Ser Phe Arg Lys Leu 800 805 810 Met Arg Trp Ile Leu Ile Leu Val Ile Ala Leu Trp Phe Ile Glu 815 820 825 Leu Leu Asp Val Trp Ser Thr Cys Ser Gln Pro Ile Cys Ala Lys 830 835 840 Trp Thr Arg Thr Glu Ala Glu Gly Ser Lys Lys Ser Leu Ser Ser 845 850 855 Glu Gly His His Met Asp Leu Pro Asp Val Val Ile Thr Ser Leu 860 865 870 Pro Gly Ser Gly Ala Glu Ile Leu Lys Gln Leu Phe Phe Asn Ser 875 880 885 Ser Asp Phe Leu Tyr Ile Arg Val Pro Thr Ala Tyr Ile Asp Ile 890 895 900 Pro Glu Thr Glu Leu Glu Ile Asp Ser Phe Val Asp Ala Cys Glu 905 910 915 Trp Lys Val Ser Asp Ile Arg Ser Gly His Phe Arg Leu Leu Arg 920 925 930 Gly Trp Leu Gln Ser Leu Val Gln Asp Thr Lys Leu His Leu Gln 935 940 945 Asn Ile His Leu His Glu Pro Asn Arg Gly Lys Leu Ala Gln Tyr 950 955 960 Phe Ala Met Asn Lys Asp Lys Lys Arg Lys Phe Lys Arg Arg Glu 965 970 975 Ser Leu Pro Glu Gln Arg Ser Gln Met Lys Gly Ala Phe Asp Arg 980 985 990 Asp Ala Glu Tyr Ile Arg Ala Leu Arg Arg His Leu Val Tyr Tyr 995 1000 1005 Pro Ser Ala Arg Pro Val Leu Ser Leu Ser Ser Gly Ser Trp Thr 1010 1015 1020 Leu Lys Leu His Phe Phe Gln Glu Val Leu Gly Ala Ser Met Arg 1025 1030 1035 Ala Leu Tyr Ile Val Arg Asp Pro Arg Ala Trp Ile Tyr Ser Met 1040 1045 1050 Leu Tyr Asn Ser Lys Pro Ser Leu Tyr Ser Leu Lys Asn Val Pro 1055 1060 1065 Glu His Leu Ala Lys Leu Phe Lys Ile Glu Gly Gly Lys Gly Lys 1070 1075 1080 Cys Asn Leu Asn Ser Gly Tyr Ala Phe Glu Tyr Glu Pro Leu Arg 1085 1090 1095 Lys Glu Leu Ser Lys Ser Lys Ser Asn Ala Val Ser Leu Leu Ser 1100 1105 1110 His Leu Trp Leu Ala Asn Thr Ala Ala Ala Leu Arg Ile Asn Thr 1115 1120 1125 Asp Leu Leu Pro Thr Ser Tyr Gln Leu Val Lys Phe Glu Asp Ile 1130 1135 1140 Val His Phe Pro Gln Lys Thr Thr Glu Arg Ile Phe Ala Phe Leu 1145 1150 1155 Gly Ile Pro Leu Ser Pro Ala Ser Leu Asn Gln Ile Leu Phe Ala 1160 1165 1170 Thr Ser Thr Asn Leu Phe Tyr Leu Pro Tyr Glu Gly Glu Ile Ser 1175 1180 1185 Pro Thr Asn Thr Asn Val Trp Lys Gln Asn Leu Pro Arg Asp Glu 1190 1195 1200 Ile Lys Leu Ile Glu Asn Ile Cys Trp Thr Leu Met Asp Arg Leu 1205 1210 1215 Gly Tyr Pro Lys Phe Met Asp 1220 5 696 PRT Homo sapiens misc_feature Incyte ID No 1958917CD1 5 Met Ala Met Ala Arg Leu Gly Ser Trp Leu Gly Glu Ala Gln Trp 1 5 10 15 Leu Ala Leu Val Ser Leu Phe Val Ala Ala Leu Ala Thr Val Gly 20 25 30 Leu Tyr Leu Ala Gln Trp Ala Leu Ala Arg Ala Arg Pro Gln Pro 35 40 45 Gln Arg Arg Ala Val Glu Pro Gly Glu Gly Pro Arg Pro Gly Ser 50 55 60 Asp Ala Leu Leu Ser Trp Ile Leu Thr Leu Gly Ser Trp Arg Ser 65 70 75 Gln Trp Gln Ala Ala Trp Val Thr Ala Leu Asn Glu Glu Ala Glu 80 85 90 Arg Lys Gly Gly Pro Pro Phe Leu Ser Phe Glu Glu Gly Pro Arg 95 100 105 Gln Gln Ala Leu Glu Leu Val Val Gln Glu Val Ser Ser Val Leu 110 115 120 Arg Ser Ala Glu Glu Lys Val Val Val Cys His Val Val Gly Gln 125 130 135 Ala Ile Gln Phe Leu Val Ser Glu Thr Pro Ala Leu Gly Ala Gly 140 145 150 Cys Arg Leu Tyr Asp Met Arg Leu Ser Pro Phe His Leu Gln Leu 155 160 165 Glu Phe His Met Lys Glu Lys Arg Glu Asp Leu Gln Ile Ser Trp 170 175 180 Ser Phe Ile Ser Val Pro Glu Met Ala Val Asn Ile Gln Pro Lys 185 190 195 Ala Leu Gly Glu Asp Gln Val Ala Glu Thr Ser Ala Met Ser Asp 200 205 210 Val Leu Lys Asp Ile Leu Lys His Leu Ala Gly Ser Ala Ser Pro 215 220 225 Ser Val Val Leu Ile Thr Lys Pro Thr Thr Val Lys Glu Ala Gln 230 235 240 Asn Leu Gln Cys Ala Ala Ser Thr Ala Gln Glu Ser Cys Pro Pro 245 250 255 Lys Pro Pro Arg Ala His Glu Leu Lys Leu Leu Val Arg Asn Ile 260 265 270 His Val Leu Leu Leu Ser Glu Pro Gly Ala Ser Gly His Ile Asn 275 280 285 Ala Val Cys Val Val Gln Leu Asn Asp Pro Val Gln Arg Phe Ser 290 295 300 Ser Thr Leu Thr Lys Asn Thr Pro Asp Leu Met Trp Glu Glu Glu 305 310 315 Phe Thr Phe Glu Leu Asn Ala Lys Ser Lys Glu Leu His Leu Gln 320 325 330 Ile Ser Glu Ala Gly Arg Ser Ser Glu Gly Leu Leu Ala Thr Ala 335 340 345 Thr Val Pro Leu Asp Leu Phe Lys Lys Gln Pro Ser Gly Pro Gln 350 355 360 Ser Phe Thr Leu Thr Ser Gly Ser Ala Cys Gly Ser Ser Val Leu 365 370 375 Gly Ser Val Thr Ala Glu Phe Ser Tyr Met Glu Pro Gly Glu Leu 380 385 390 Lys Ser Trp Pro Ile Pro Pro Pro Val Pro Ala Ala Lys Ile Glu 395 400 405 Lys Asp Arg Thr Val Met Pro Cys Gly Thr Val Val Thr Thr Val 410 415 420 Thr Ala Val Lys Thr Lys Pro Arg Val Asp Val Gly Arg Ala Ser 425 430 435 Pro Leu Ser Ser Asp Ser Pro Val Lys Thr Pro Ile Lys Val Lys 440 445 450 Val Ile Glu Lys Asp Ile Ser Val Gln Ala Ile Ala Cys Arg Ser 455 460 465 Ala Pro Val Ser Lys Thr Leu Ser Ser Ser Asp Thr Glu Leu Leu 470 475 480 Val Leu Asn Gly Ser Asp Pro Val Ala Glu Val Ala Ile Arg Gln 485 490 495 Leu Ser Glu Ser Ser Lys Leu Lys Leu Lys Ser Pro Arg Lys Lys 500 505 510 Ser Thr Ile Ile Ile Ser Gly Ile Ser Lys Thr Ser Leu Ser Gln 515 520 525 Asp His Asp Ala Ala Leu Met Gln Gly Tyr Thr Ala Ser Val Asp 530 535 540 Ser Thr His Gln Glu Asp Ala Pro Ser His Pro Glu Arg Ala Ala 545 550 555 Ala Ser Ala Pro Pro Glu Glu Ala Glu Ser Ala Gln Ala Ser Leu 560 565 570 Ala Pro Lys Pro Gln Glu Asp Glu Leu Asp Ser Trp Asp Leu Glu 575 580 585 Lys Glu Pro Gln Ala Ala Ala Trp Ser Ser Gln Val Leu Leu Asp 590 595 600 Pro Asp Gly Asp Glu Leu Ser Glu Ser Ser Met Ser Val Leu Glu 605 610 615 Pro Gly Thr Ala Lys Lys His Lys Gly Gly Ile Leu Arg Lys Gly 620 625 630 Ala Lys Leu Phe Phe Arg Arg Arg His Gln Gln Lys Asp Pro Gly 635 640 645 Met Ser Gln Ser His Asn Asp Leu Val Phe Leu Glu Gln Pro Glu 650 655 660 Gly Ser Arg Arg Lys Gly Ile Thr Leu Thr Arg Ile Leu Asn Lys 665 670 675 Lys Leu Leu Ser Arg His Arg Asn Lys Asn Thr Met Asn Gly Ala 680 685 690 Pro Val Glu Pro Cys Thr 695 6 436 PRT Homo sapiens misc_feature Incyte ID No 6219465CD1 6 Met Gly Arg Ala Arg Pro Gly Gln Arg Gly Pro Pro Ser Pro Gly 1 5 10 15 Pro Ala Ala Gln Pro Pro Ala Pro Pro Arg Arg Arg Ala Arg Ser 20 25 30 Leu Ala Leu Leu Gly Ala Leu Leu Ala Ala Ala Ala Ala Ala Ala 35 40 45 Val Arg Val Cys Ala Arg His Ala Glu Ala Gln Ala Ala Ala Arg 50 55 60 Gln Glu Leu Ala Leu Lys Thr Leu Gly Thr Asp Gly Leu Phe Leu 65 70 75 Phe Ser Ser Leu Asp Thr Asp Gly Asp Met Tyr Ile Ser Pro Glu 80 85 90 Glu Phe Lys Pro Ile Ala Glu Lys Leu Thr Gly Ser Thr Pro Ala 95 100 105 Ala Ser Tyr Glu Glu Glu Glu Leu Pro Pro Asp Pro Ser Glu Glu 110 115 120 Thr Leu Thr Ile Glu Ala Arg Phe Gln Pro Leu Leu Pro Glu Thr 125 130 135 Met Thr Lys Ser Lys Asp Gly Phe Leu Gly Val Ser Arg Leu Ala 140 145 150 Leu Ser Gly Leu Arg Asn Trp Thr Ala Ala Ala Ser Pro Ser Ala 155 160 165 Val Phe Ala Thr Arg His Phe Gln Pro Phe Leu Pro Pro Pro Gly 170 175 180 Gln Glu Leu Gly Glu Pro Trp Trp Ile Ile Pro Ser Glu Leu Ser 185 190 195 Met Phe Thr Gly Tyr Leu Ser Asn Asn Arg Phe Tyr Pro Pro Pro 200 205 210 Pro Lys Gly Lys Glu Val Ile Ile His Arg Leu Leu Ser Met Phe 215 220 225 His Pro Arg Pro Phe Val Lys Thr Arg Phe Ala Pro Gln Gly Ala 230 235 240 Val Ala Cys Leu Thr Ala Ile Ser Asp Phe Tyr Tyr Thr Val Met 245 250 255 Phe Arg Ile His Ala Glu Phe Gln Leu Ser Glu Pro Pro Asp Phe 260 265 270 Pro Phe Trp Phe Ser Pro Ala Gln Phe Thr Gly His Ile Ile Leu 275 280 285 Ser Lys Asp Ala Thr His Val Arg Asp Phe Arg Leu Phe Val Pro 290 295 300 Asn His Arg Ser Leu Asn Val Asp Met Glu Trp Leu Tyr Gly Ala 305 310 315 Ser Glu Ser Ser Asn Met Glu Val Asp Ile Gly Tyr Ile Pro Gln 320 325 330 Val Ser Ala Gln Glu Ala Pro Ile Gln Met Glu Leu Glu Ala Thr 335 340 345 Gly Pro Ser Val Pro Ser Val Ile Leu Asp Glu Asp Gly Ser Met 350 355 360 Ile Asp Ser His Leu Pro Ser Gly Glu Pro Leu Gln Phe Val Phe 365 370 375 Glu Glu Ile Lys Trp Gln Gln Glu Leu Ser Trp Glu Glu Ala Ala 380 385 390 Arg Arg Leu Glu Val Ala Met Tyr Pro Phe Lys Lys Val Ser Tyr 395 400 405 Leu Pro Phe Thr Glu Ala Phe Asp Arg Ala Lys Ala Glu Asn Lys 410 415 420 Leu Val His Ser Ile Leu Leu Trp Gly Ala Leu Asp Asp Gln Ser 425 430 435 Cys 7 652 PRT Homo sapiens misc_feature Incyte ID No 3576625CD1 7 Met Ala Ala Ala Ala Leu Pro Pro Arg Pro Leu Leu Leu Leu Pro 1 5 10 15 Leu Val Leu Leu Leu Ser Gly Arg Pro Thr Arg Ala Asp Ser Lys 20 25 30 Val Phe Gly Asp Leu Asp Gln Val Arg Met Thr Ser Glu Gly Ser 35 40 45 Asp Cys Arg Cys Lys Cys Ile Met Arg Pro Leu Ser Lys Asp Ala 50 55 60 Cys Ser Arg Val Arg Ser Gly Arg Ala Arg Val Glu Asp Phe Tyr 65 70 75 Thr Val Glu Thr Val Ser Ser Gly Thr Asp Cys Arg Cys Ser Cys 80 85 90 Thr Ala Pro Pro Ser Ser Leu Asn Pro Cys Glu Asn Glu Trp Lys 95 100 105 Met Glu Lys Leu Lys Lys Gln Ala Pro Glu Leu Leu Lys Leu Gln 110 115 120 Ser Met Val Asp Leu Leu Glu Gly Thr Leu Tyr Ser Met Asp Leu 125 130 135 Met Lys Val His Ala Tyr Val His Lys Val Ala Ser Gln Met Asn 140 145 150 Thr Leu Glu Glu Ser Ile Lys Ala Asn Leu Ser Arg Glu Asn Glu 155 160 165 Val Val Lys Asp Ser Val Arg His Leu Ser Glu Gln Leu Arg His 170 175 180 Tyr Glu Asn His Ser Ala Ile Met Leu Gly Ile Lys Lys Glu Leu 185 190 195 Ser Arg Leu Gly Leu Gln Leu Leu Gln Lys Asp Ala Ala Ala Ala 200 205 210 Pro Ala Thr Pro Ala Thr Gly Thr Gly Ser Lys Ala Gln Asp Thr 215 220 225 Ala Arg Gly Lys Gly Lys Asp Ile Ser Lys Tyr Gly Ser Val Gln 230 235 240 Lys Ser Phe Ala Asp Arg Gly Leu Pro Lys Pro Pro Lys Glu Lys 245 250 255 Leu Leu Gln Val Glu Lys Leu Arg Lys Glu Ser Gly Lys Gly Ser 260 265 270 Phe Leu Gln Pro Thr Ala Lys Pro Arg Ala Leu Ala Gln Gln Gln 275 280 285 Ala Val Ile Arg Gly Phe Thr Tyr Tyr Lys Ala Gly Lys Gln Glu 290 295 300 Val Thr Glu Ala Val Ala Asp Asn Ala Leu Gln Gly Thr Ser Trp 305 310 315 Leu Glu Gln Leu Pro Pro Lys Val Glu Gly Arg Ser Asn Ser Ala 320 325 330 Glu Pro Asn Ser Ala Glu Gln Asp Glu Ala Glu Pro Arg Ser Ser 335 340 345 Glu Arg Val Asp Leu Ala Ser Gly Thr Pro Thr Ser Ile Pro Ala 350 355 360 Thr Thr Thr Thr Ala Thr Thr Thr Pro Thr Pro Thr Thr Ser Leu 365 370 375 Leu Pro Thr Glu Pro Pro Ser Gly Pro Glu Val Ser Ser Gln Gly 380 385 390 Arg Glu Ala Ser Cys Glu Gly Thr Leu Arg Ala Val Asp Pro Pro 395 400 405 Val Arg His His Ser Tyr Gly Arg His Glu Gly Ala Trp Met Lys 410 415 420 Asp Pro Ala Ala Arg Asp Asp Arg Ile Tyr Val Thr Asn Tyr Tyr 425 430 435 Tyr Gly Asn Ser Leu Val Glu Phe Arg Asn Leu Glu Asn Phe Lys 440 445 450 Gln Gly Arg Trp Ser Asn Met Tyr Lys Leu Pro Tyr Asn Trp Ile 455 460 465 Gly Thr Gly His Val Val Tyr Gln Gly Ala Phe Tyr Tyr Asn Arg 470 475 480 Ala Phe Thr Lys Asn Ile Ile Lys Tyr Asp Leu Arg Gln Arg Phe 485 490 495 Val Ala Ser Trp Ala Leu Leu Pro Asp Val Val Tyr Glu Asp Thr 500 505 510 Thr Pro Trp Lys Trp Arg Gly His Ser Asp Ile Asp Phe Ala Val 515 520 525 Asp Glu Ser Gly Leu Trp Val Ile Tyr Pro Ala Val Asp Asp Arg 530 535 540 Asp Glu Ala Gln Pro Glu Val Ile Val Leu Ser Arg Leu Asp Pro 545 550 555 Gly Asp Leu Ser Val His Arg Glu Thr Thr Trp Lys Thr Arg Leu 560 565 570 Arg Arg Asn Ser Tyr Gly Asn Cys Phe Leu Val Cys Gly Ile Leu 575 580 585 Tyr Ala Val Asp Thr Tyr Asn Gln Gln Glu Gly Gln Val Ala Tyr 590 595 600 Ala Phe Asp Thr His Thr Gly Thr Asp Ala Arg Pro Gln Leu Pro 605 610 615 Phe Leu Asn Glu His Ala Tyr Thr Thr Gln Ile Asp Tyr Asn Pro 620 625 630 Lys Glu Arg Val Leu Tyr Ala Trp Asp Asn Gly His Gln Leu Thr 635 640 645 Tyr Thr Leu His Phe Val Val 650 8 91 PRT Homo sapiens misc_feature Incyte ID No 4765758CD1 8 Met Trp Lys Leu Arg Glu Arg Leu Ala Asp Leu Pro Lys Val Thr 1 5 10 15 Val Ile Tyr Gln Met Gln Thr Gly Phe Glu Pro Arg Thr Leu Val 20 25 30 Leu Leu Ser Val Val Tyr Ala His Pro Ser Trp Ala Arg Gly Asp 35 40 45 His Arg Ala Ser Val His Arg His Lys Thr Arg Ala Gln Phe Pro 50 55 60 Asp Leu Gly Tyr Lys Asp Asp Ala Tyr Thr Gly Lys Thr Phe Lys 65 70 75 Ile Ser Phe Lys Asn Lys Ser Pro Arg Asp Ser Ala Trp Leu Cys 80 85 90 Leu 9 155 PRT Homo sapiens misc_feature Incyte ID No 7236661CD1 9 Met Trp Ser Gly His Ile Trp Leu Cys Phe Leu Ser His Val Ser 1 5 10 15 Trp Gly Ser Glu Ala Pro Val Ala Ser Phe Gly Gly Leu Cys Leu 20 25 30 Cys Pro Leu Val Ile Gln Gly Ser Val Ser Glu Thr Ser Trp His 35 40 45 Glu Thr Leu Trp Asp Pro His Trp Gly Ser Gly Ser Gly His Arg 50 55 60 Arg Ile Gln Gln Ile Lys Val Arg Gln Pro Val Leu Leu Pro Leu 65 70 75 Ser Lys Pro Phe Gln Trp Leu His Phe Ser Asp Leu Gly Leu Thr 80 85 90 Ser Lys Arg Lys Ser Phe Asp Ala Gly Phe Gln Leu Pro His Pro 95 100 105 Gly Glu Cys Ala Glu Glu Gly Glu Ala Thr Glu Val Asp Lys Arg 110 115 120 His Leu Ser Glu Ala Lys Ala Ala Val Arg Leu Ala Arg Lys Ser 125 130 135 Leu Lys Trp Leu Cys Ala Phe Arg Arg Val Ala Val Pro Trp Pro 140 145 150 Leu Trp Leu Ala Pro 155 10 765 PRT Homo sapiens misc_feature Incyte ID No 7714187CD1 10 Met Ile Trp Arg Ser Arg Ala Gly Ala Glu Leu Phe Ser Leu Met 1 5 10 15 Ala Leu Trp Glu Trp Ile Ala Leu Ser Leu His Cys Trp Val Leu 20 25 30 Ala Val Ala Ala Val Ser Asp Gln His Ala Thr Ser Pro Phe Asp 35 40 45 Trp Leu Leu Ser Asp Lys Gly Pro Phe His Arg Ser Gln Glu Tyr 50 55 60 Thr Asp Phe Val Asp Arg Ser Arg Gln Gly Phe Ser Thr Arg Tyr 65 70 75 Lys Ile Tyr Arg Glu Phe Gly Arg Trp Lys Val Asn Asn Leu Ala 80 85 90 Val Glu Arg Arg Asn Phe Leu Gly Ser Pro Leu Pro Leu Ala Pro 95 100 105 Glu Phe Phe Arg Asn Ile Arg Leu Leu Gly Arg Arg Pro Thr Leu 110 115 120 Gln Gln Ile Thr Glu Asn Leu Ile Lys Lys Tyr Gly Thr His Phe 125 130 135 Leu Leu Ser Ala Thr Leu Gly Gly Glu Glu Ser Leu Thr Ile Phe 140 145 150 Val Asp Lys Arg Lys Leu Ser Lys Arg Ala Glu Gly Ser Asp Ser 155 160 165 Thr Thr Asn Ser Ser Ser Val Thr Leu Glu Thr Leu His Gln Leu 170 175 180 Ala Ala Ser Tyr Phe Ile Asp Arg Asp Ser Thr Leu Arg Arg Leu 185 190 195 His His Ile Gln Ile Ala Ser Thr Ala Ile Lys Val Thr Glu Thr 200 205 210 Arg Thr Gly Pro Leu Gly Cys Ser Asn Tyr Asp Asn Leu Asp Ser 215 220 225 Val Ser Ser Val Leu Val Gln Ser Pro Glu Asn Lys Ile Gln Leu 230 235 240 Gln Gly Leu Gln Val Leu Leu Pro Asp Tyr Leu Gln Glu Arg Phe 245 250 255 Val Gln Ala Ala Leu Ser Tyr Ile Ala Cys Asn Ser Glu Gly Glu 260 265 270 Phe Ile Cys Lys Glu Asn Asp Cys Trp Cys His Cys Gly Pro Lys 275 280 285 Phe Pro Glu Cys Asn Cys Pro Ser Met Asp Ile Gln Ala Met Glu 290 295 300 Glu Asn Leu Leu Arg Ile Thr Glu Thr Trp Lys Ala Tyr Asn Ser 305 310 315 Asp Phe Glu Glu Ser Asp Glu Phe Lys Leu Phe Met Lys Arg Leu 320 325 330 Pro Met Asn Tyr Phe Leu Asn Thr Ser Thr Ile Met His Leu Trp 335 340 345 Thr Met Asp Ser Asn Phe Gln Arg Arg Tyr Glu Gln Leu Glu Asn 350 355 360 Ser Met Lys Gln Leu Phe Leu Lys Ala Gln Lys Ile Val His Lys 365 370 375 Leu Phe Ser Leu Ser Lys Arg Cys His Lys Gln Pro Leu Ile Ser 380 385 390 Leu Pro Arg Gln Arg Thr Ser Thr Tyr Trp Leu Thr Arg Ile Gln 395 400 405 Ser Phe Leu Tyr Cys Asn Glu Asn Gly Leu Leu Gly Ser Phe Ser 410 415 420 Glu Glu Thr His Ser Cys Thr Cys Pro Asn Asp Gln Val Val Cys 425 430 435 Thr Ala Phe Leu Pro Cys Thr Val Gly Asp Ala Ser Ala Cys Leu 440 445 450 Thr Cys Ala Pro Asp Asn Arg Thr Arg Cys Gly Thr Cys Asn Thr 455 460 465 Gly Tyr Met Leu Ser Gln Gly Leu Cys Lys Pro Glu Val Ala Glu 470 475 480 Ser Thr Asp His Tyr Ile Gly Phe Glu Thr Asp Leu Gln Asp Leu 485 490 495 Glu Met Lys Tyr Leu Leu Gln Lys Thr Asp Arg Arg Ile Glu Val 500 505 510 His Ala Ile Phe Ile Ser Asn Asp Met Arg Leu Asn Ser Trp Phe 515 520 525 Asp Pro Ser Trp Arg Lys Arg Met Leu Leu Thr Leu Lys Ser Asn 530 535 540 Lys Tyr Lys Ser Ser Leu Val His Met Ile Leu Gly Leu Ser Leu 545 550 555 Gln Ile Cys Leu Thr Lys Asn Ser Thr Leu Glu Pro Val Leu Ala 560 565 570 Val Tyr Val Asn Pro Phe Gly Gly Ser His Ser Glu Ser Trp Phe 575 580 585 Met Pro Val Asn Glu Asn Ser Phe Pro Asp Trp Glu Arg Thr Lys 590 595 600 Leu Asp Leu Pro Leu Gln Cys Tyr Asn Trp Thr Leu Thr Leu Gly 605 610 615 Asn Lys Trp Lys Thr Phe Phe Glu Thr Val His Ile Tyr Leu Arg 620 625 630 Ser Arg Ile Lys Ser Asn Gly Pro Asn Gly Asn Glu Ser Ile Tyr 635 640 645 Tyr Glu Pro Leu Glu Phe Ile Asp Pro Ser Arg Asn Leu Gly Tyr 650 655 660 Met Lys Ile Asn Asn Ile Gln Val Phe Gly Tyr Ser Met His Phe 665 670 675 Asp Pro Glu Ala Ile Arg Asp Leu Ile Leu Gln Leu Asp Tyr Pro 680 685 690 Tyr Thr Gln Gly Ser Gln Asp Ser Ala Leu Leu Gln Leu Leu Glu 695 700 705 Ile Arg Asp Arg Val Asn Lys Leu Ser Pro Pro Gly Gln Arg Arg 710 715 720 Leu Asp Leu Phe Ser Cys Leu Leu Arg His Arg Leu Lys Leu Ser 725 730 735 Thr Ser Glu Val Val Arg Ile Gln Ser Ala Leu Gln Ala Phe Asn 740 745 750 Ala Lys Leu Pro Asn Thr Met Asp Tyr Asp Thr Thr Lys Leu Cys 755 760 765 11 150 PRT Homo sapiens misc_feature Incyte ID No 5136540CD1 11 Met Phe Thr Leu Leu Val Leu Leu Ser Gln Leu Pro Thr Val Thr 1 5 10 15 Leu Gly Phe Pro His Cys Ala Arg Gly Pro Lys Ala Ser Lys His 20 25 30 Ala Gly Glu Glu Val Phe Thr Ser Lys Glu Glu Ala Asn Phe Phe 35 40 45 Ile His Arg Arg Leu Leu Tyr Asn Arg Phe Asp Leu Glu Leu Phe 50 55 60 Thr Pro Gly Asn Leu Glu Arg Glu Cys Asn Glu Glu Leu Cys Asn 65 70 75 Tyr Glu Glu Ala Arg Glu Ile Phe Val Asp Glu Asp Lys Thr Ile 80 85 90 Ala Phe Trp Gln Glu Tyr Ser Ala Lys Gly Pro Thr Thr Lys Ser 95 100 105 Ala Leu Gln Pro Ser Met Lys Gly Gly Gly Thr Leu Pro Pro Ser 110 115 120 Phe Ser Glu Asp Leu Arg Arg Leu Pro Cys Leu His Cys Arg Leu 125 130 135 Leu Trp Arg Met Gln Asp Tyr Leu Leu Met Asn Arg Gln Trp Arg 140 145 150 12 685 PRT Homo sapiens misc_feature Incyte ID No 3277403CD1 12 Met Leu Trp Phe Ser Gly Val Gly Ala Leu Ala Glu Arg Tyr Cys 1 5 10 15 Arg Arg Ser Pro Gly Ile Thr Cys Cys Val Leu Leu Leu Leu Asn 20 25 30 Cys Ser Gly Val Pro Met Ser Leu Ala Ser Ser Phe Leu Thr Gly 35 40 45 Ser Val Ala Lys Cys Glu Asn Glu Gly Glu Val Leu Gln Ile Pro 50 55 60 Phe Ile Thr Asp Asn Pro Cys Ile Met Cys Val Cys Leu Asn Lys 65 70 75 Glu Val Thr Cys Lys Arg Glu Lys Cys Pro Val Leu Ser Arg Asp 80 85 90 Cys Ala Leu Ala Ile Lys Gln Arg Gly Ala Cys Cys Glu Gln Cys 95 100 105 Lys Gly Cys Thr Tyr Glu Gly Asn Thr Tyr Asn Ser Ser Phe Lys 110 115 120 Trp Gln Ser Pro Ala Glu Pro Cys Val Leu Arg Gln Cys Gln Glu 125 130 135 Gly Val Val Thr Glu Ser Gly Val Arg Cys Val Val His Cys Lys 140 145 150 Asn Pro Leu Glu His Leu Gly Met Cys Cys Pro Thr Cys Pro Gly 155 160 165 Cys Val Phe Glu Gly Val Gln Tyr Gln Glu Gly Glu Glu Phe Gln 170 175 180 Pro Glu Gly Ser Lys Cys Thr Lys Cys Ser Cys Thr Gly Gly Arg 185 190 195 Thr Gln Cys Val Arg Glu Val Cys Pro Ile Leu Ser Cys Pro Gln 200 205 210 His Leu Ser His Ile Pro Pro Gly Gln Cys Cys Pro Lys Cys Leu 215 220 225 Gly Gln Arg Lys Val Phe Asp Leu Pro Phe Gly Ser Cys Leu Phe 230 235 240 Arg Ser Asp Val Tyr Asp Asn Gly Ser Ser Phe Leu Tyr Asp Asn 245 250 255 Cys Thr Ala Cys Thr Cys Arg Asp Ser Thr Val Val Cys Lys Arg 260 265 270 Lys Cys Ser His Pro Gly Gly Cys Asp Gln Gly Gln Glu Gly Cys 275 280 285 Cys Glu Glu Cys Leu Leu Arg Val Pro Pro Glu Asp Ile Lys Val 290 295 300 Cys Lys Phe Gly Asn Lys Ile Phe Gln Asp Gly Glu Met Trp Ser 305 310 315 Ser Ile Asn Cys Thr Ile Cys Ala Cys Val Lys Gly Arg Thr Glu 320 325 330 Cys Arg Asn Lys Gln Cys Ile Pro Ile Ser Ser Cys Pro Gln Gly 335 340 345 Lys Ile Leu Asn Arg Lys Gly Cys Cys Pro Ile Cys Thr Glu Lys 350 355 360 Pro Gly Val Cys Thr Val Phe Gly Asp Pro His Tyr Asn Thr Phe 365 370 375 Asp Gly Arg Thr Phe Asn Phe Gln Gly Thr Cys Gln Tyr Val Leu 380 385 390 Thr Lys Asp Cys Ser Ser Pro Ala Ser Pro Phe Gln Val Leu Val 395 400 405 Lys Asn Asp Ala Arg Arg Thr Arg Ser Phe Ser Trp Thr Lys Ser 410 415 420 Val Glu Leu Val Leu Gly Glu Ser Arg Val Ser Leu Gln Gln His 425 430 435 Leu Thr Val Arg Trp Asn Gly Ser Arg Ile Ala Leu Pro Cys Arg 440 445 450 Ala Pro His Phe His Ile Asp Leu Asp Gly Tyr Leu Leu Lys Val 455 460 465 Thr Thr Lys Ala Gly Leu Glu Ile Ser Trp Asp Gly Asp Ser Phe 470 475 480 Val Glu Val Met Ala Ala Pro His Leu Lys Gly Lys Leu Cys Gly 485 490 495 Leu Cys Gly Asn Tyr Asn Gly His Lys Arg Asp Asp Leu Ile Gly 500 505 510 Gly Asp Gly Asn Phe Lys Phe Asp Val Asp Asp Phe Ala Glu Ser 515 520 525 Trp Arg Val Glu Ser Asn Glu Phe Cys Asn Arg Pro Gln Arg Lys 530 535 540 Pro Val Pro Glu Leu Cys Gln Gly Thr Val Lys Val Lys Leu Arg 545 550 555 Ala His Arg Glu Cys Gln Lys Leu Lys Ser Trp Glu Phe Gln Thr 560 565 570 Cys His Ser Thr Val Asp Tyr Ala Thr Phe Tyr Arg Ser Cys Val 575 580 585 Thr Asp Met Cys Glu Cys Pro Val His Lys Asn Cys Tyr Cys Glu 590 595 600 Ser Phe Leu Ala Tyr Thr Arg Ala Cys Gln Arg Glu Gly Ile Lys 605 610 615 Val His Trp Glu Pro Gln Gln Asn Cys Ala Ala Thr Gln Cys Lys 620 625 630 His Gly Ala Val Tyr Asp Thr Cys Gly Pro Gly Cys Ile Lys Thr 635 640 645 Cys Asp Asn Trp Asn Glu Ile Gly Pro Cys Asn Lys Pro Cys Val 650 655 660 Ala Gly Cys His Cys Pro Ala Asn Leu Val Leu His Lys Gly Arg 665 670 675 Cys Ile Lys Pro Val Leu Cys Pro Gln Arg 680 685 13 126 PRT Homo sapiens misc_feature Incyte ID No 1517569CD1 13 Met Leu Leu Ser Ser Cys Leu Pro Pro Ala Asn Val Thr Thr Lys 1 5 10 15 Ala Ala Thr Pro Pro Pro Leu Val Leu Ser Leu Thr Thr Ala Asp 20 25 30 Pro Ala Gly Lys Pro Ala Pro Cys Arg Val Thr Leu Thr Leu Leu 35 40 45 Arg Ala Ser Ile Pro Ala Thr Lys Arg Ala Ser Phe Leu Ser Ser 50 55 60 Phe Ile Lys Met Phe Phe Glu Glu Leu Glu Tyr Ile Leu Gly Phe 65 70 75 Leu Ser Leu Leu Lys Phe His Val His Val Ser Val Tyr Ser Ala 80 85 90 Ile Cys His Phe Gln Lys Glu Gly Thr Gly Asn Ser Arg Ser Phe 95 100 105 Thr Cys Thr Pro Glu Leu Phe Pro Arg Leu Gln Thr His Leu Arg 110 115 120 Ala Glu Gly Gly Ala Gln 125 14 149 PRT Homo sapiens misc_feature Incyte ID No 2415991CD1 14 Met Asn Tyr Leu Phe Phe Phe Leu Thr Thr Ser Gly Leu Tyr Cys 1 5 10 15 Leu Ser Gly Ser His Gly Ser Asn Val Lys Tyr Ile Val Leu Thr 20 25 30 Tyr Phe Asn Cys Ser Trp Ser Leu Thr Ser Pro Gly Phe Arg Asp 35 40 45 Val Leu Lys Gly Ser Gln Leu Trp Gln Val Thr Asp Ser Trp Glu 50 55 60 Met Glu Arg Thr Lys Glu Tyr Ser Ser Cys Leu Thr Phe Leu Pro 65 70 75 Thr Ala Asp Ile Val Gln Ala Arg Val Met Glu Glu Leu Asn Leu 80 85 90 Leu Ala Ser Gln Ala Ala Pro Ile Pro Thr Ser Gln Cys Thr Ala 95 100 105 Pro Pro His Leu Phe Ser Pro Leu Ser Leu Thr Ser Pro Phe Ile 110 115 120 Met Ser His Lys Ser Gly Thr Val Gly Ser His Tyr Asn Leu Leu 125 130 135 Cys His Arg Asp Ser Ile Phe Leu Ile Ser Asn His Val Ser 140 145 15 114 PRT Homo sapiens misc_feature Incyte ID No 2735742CD1 15 Met Leu Ser Gly Ala Arg Cys Arg Leu Ala Ser Ala Leu Arg Gly 1 5 10 15 Thr Arg Ala Pro Pro Ser Ala Val Ala Arg Arg Cys Leu His Ala 20 25 30 Ser Gly Ser Arg Pro Leu Ala Asp Arg Gly Lys Lys Thr Glu Glu 35 40 45 Pro Pro Arg Asp Phe Asp Pro Ala Leu Leu Glu Phe Leu Val Cys 50 55 60 Pro Leu Ser Lys Lys Pro Leu Arg Tyr Glu Ala Ser Thr Asn Glu 65 70 75 Leu Ile Asn Glu Glu Leu Gly Ile Ala Tyr Pro Ile Ile Asp Gly 80 85 90 Ile Pro Asn Met Ile Pro Gln Ala Ala Arg Met Thr Arg Gln Ser 95 100 105 Lys Lys Gln Glu Glu Val Glu Gln Arg 110 16 519 PRT Homo sapiens misc_feature Incyte ID No 2768535CD1 16 Met Thr Cys Pro Asp Lys Pro Gly Gln Leu Ile Asn Trp Phe Ile 1 5 10 15 Cys Ser Leu Cys Val Pro Arg Val Arg Lys Leu Trp Ser Ser Arg 20 25 30 Arg Pro Arg Thr Arg Arg Asn Leu Leu Leu Gly Thr Ala Cys Ala 35 40 45 Ile Tyr Leu Gly Phe Leu Val Ser Gln Val Gly Arg Ala Ser Leu 50 55 60 Gln His Gly Gln Ala Ala Glu Lys Gly Pro His Arg Ser Arg Asp 65 70 75 Thr Ala Glu Pro Ser Phe Pro Glu Ile Pro Leu Asp Gly Thr Leu 80 85 90 Ala Pro Pro Glu Ser Gln Gly Asn Gly Ser Thr Leu Gln Pro Asn 95 100 105 Val Val Tyr Ile Thr Leu Arg Ser Lys Arg Ser Lys Pro Ala Asn 110 115 120 Ile Arg Gly Thr Val Lys Pro Lys Arg Arg Lys Lys His Ala Val 125 130 135 Ala Ser Ala Ala Pro Gly Gln Glu Ala Leu Val Gly Pro Ser Leu 140 145 150 Gln Pro Gln Glu Ala Ala Arg Glu Ala Asp Ala Val Ala Pro Gly 155 160 165 Tyr Ala Gln Gly Ala Asn Leu Val Lys Ile Gly Glu Arg Pro Trp 170 175 180 Arg Leu Val Arg Gly Pro Gly Val Arg Ala Gly Gly Pro Asp Phe 185 190 195 Leu Gln Pro Ser Ser Arg Glu Ser Asn Ile Arg Ile Tyr Ser Glu 200 205 210 Ser Ala Pro Ser Trp Leu Ser Lys Asp Asp Ile Arg Arg Met Arg 215 220 225 Leu Leu Ala Asp Ser Ala Val Ala Gly Leu Arg Pro Val Ser Ser 230 235 240 Arg Ser Gly Ala Arg Leu Leu Val Leu Glu Gly Gly Ala Pro Gly 245 250 255 Ala Val Leu Arg Cys Gly Pro Ser Pro Cys Gly Leu Leu Lys Gln 260 265 270 Pro Leu Asp Met Ser Glu Val Phe Ala Phe His Leu Asp Arg Ile 275 280 285 Leu Gly Leu Asn Arg Thr Leu Pro Ser Val Ser Arg Lys Ala Glu 290 295 300 Phe Ile Gln Asp Gly Arg Pro Cys Pro Ile Ile Leu Trp Asp Ala 305 310 315 Ser Leu Ser Ser Ala Ser Asn Asp Thr His Ser Ser Val Lys Leu 320 325 330 Thr Trp Gly Thr Tyr Gln Gln Leu Leu Lys Gln Lys Cys Trp Gln 335 340 345 Asn Gly Arg Val Pro Lys Pro Glu Ser Gly Cys Thr Glu Ile His 350 355 360 His His Glu Trp Ser Lys Met Ala Leu Phe Asp Phe Leu Leu Gln 365 370 375 Ile Tyr Asn Arg Leu Asp Thr Asn Cys Cys Gly Phe Arg Pro Arg 380 385 390 Lys Glu Asp Ala Cys Val Gln Asn Gly Leu Arg Pro Lys Cys Asp 395 400 405 Asp Gln Gly Ser Ala Ala Leu Ala His Ile Ile Gln Arg Lys His 410 415 420 Asp Pro Arg His Leu Val Phe Ile Asp Asn Lys Gly Phe Phe Asp 425 430 435 Arg Ser Glu Asp Asn Leu Asn Phe Lys Leu Leu Glu Gly Ile Lys 440 445 450 Glu Phe Pro Ala Ser Ala Val Ser Val Leu Lys Ser Gln His Leu 455 460 465 Arg Gln Lys Leu Leu Gln Ser Leu Phe Leu Asp Lys Val Tyr Trp 470 475 480 Glu Ser Gln Gly Gly Arg Gln Gly Ile Glu Lys Leu Ile Asp Val 485 490 495 Ile Glu His Arg Ala Lys Ile Leu Ile Thr Tyr Ile Asn Ala His 500 505 510 Gly Val Lys Val Leu Pro Met Asn Glu 515 17 1164 PRT Homo sapiens misc_feature Incyte ID No 6848851CD1 17 Met Ala Leu Phe Pro Ala Phe Ala Gly Leu Ser Glu Ala Pro Asp 1 5 10 15 Gly Gly Ser Ser Arg Lys Glu Leu Asp Trp Leu Ser Asn Pro Ser 20 25 30 Phe Cys Val Gly Ser Ile Thr Ser Leu Ser Gln Gln Thr Glu Ala 35 40 45 Ala Pro Ala His Val Ser Glu Gly Leu Pro Leu Thr Arg Ser His 50 55 60 Leu Lys Ser Glu Ser Ser Asp Glu Ser Asp Thr Asn Lys Lys Leu 65 70 75 Lys Gln Thr Ser Arg Lys Lys Lys Lys Glu Lys Lys Lys Lys Arg 80 85 90 Lys His Gln His His Lys Lys Thr Lys Arg Lys His Gly Pro Ser 95 100 105 Ser Ser Ser Arg Ser Glu Thr Asp Thr Asp Ser Glu Lys Asp Lys 110 115 120 Pro Ser Arg Gly Val Gly Gly Ser Lys Lys Glu Ser Glu Glu Pro 125 130 135 Asn Gln Gly Asn Asn Ala Ala Ala Asp Thr Gly His Arg Phe Val 140 145 150 Trp Leu Glu Asp Ile Gln Ala Val Thr Gly Glu Thr Phe Arg Thr 155 160 165 Asp Lys Lys Pro Asp Pro Ala Asn Trp Glu Tyr Lys Ser Leu Tyr 170 175 180 Arg Gly Asp Ile Ala Arg Tyr Lys Arg Lys Gly Asp Ser Cys Leu 185 190 195 Gly Ile Asn Pro Lys Lys Gln Cys Ile Ser Trp Glu Gly Thr Ser 200 205 210 Thr Glu Lys Lys His Ser Arg Lys Gln Val Glu Arg Tyr Phe Thr 215 220 225 Lys Lys Ser Val Gly Leu Met Asn Ile Asp Gly Val Ala Ile Ser 230 235 240 Ser Lys Thr Glu Pro Pro Ser Ser Glu Pro Ile Ser Phe Ile Pro 245 250 255 Val Lys Asp Leu Glu Asp Ala Ala Pro Val Thr Thr Trp Leu Asn 260 265 270 Pro Leu Gly Ile Tyr Asp Gln Ser Thr Thr His Trp Leu Gln Gly 275 280 285 Gln Gly Pro Pro Glu Gln Glu Ser Lys Gln Pro Asp Ala Gln Pro 290 295 300 Asp Ser Glu Ser Ala Ala Leu Lys Ala Lys Val Glu Glu Phe Asn 305 310 315 Arg Arg Val Arg Glu Asn Pro Arg Asp Thr Gln Leu Trp Met Ala 320 325 330 Phe Val Ala Phe Gln Asp Glu Val Met Lys Ser Pro Gly Leu Tyr 335 340 345 Ala Ile Glu Glu Gly Glu Gln Glu Lys Arg Lys Arg Ser Leu Lys 350 355 360 Leu Ile Leu Glu Lys Lys Leu Ala Ile Leu Glu Arg Ala Ile Glu 365 370 375 Ser Asn Gln Ser Ser Val Asp Leu Lys Leu Ala Lys Leu Lys Leu 380 385 390 Cys Thr Glu Phe Trp Glu Pro Ser Thr Leu Val Lys Glu Trp Gln 395 400 405 Lys Leu Ile Phe Leu His Pro Asn Asn Thr Ala Leu Trp Gln Lys 410 415 420 Tyr Leu Leu Phe Cys Gln Ser Gln Phe Ser Thr Phe Ser Ile Ser 425 430 435 Lys Ile His Ser Leu Tyr Gly Lys Cys Leu Ser Thr Leu Ser Ala 440 445 450 Val Lys Asp Gly Ser Ile Leu Ser His Pro Ala Leu Pro Gly Thr 455 460 465 Glu Glu Ala Met Phe Ala Leu Phe Leu Gln Gln Cys His Phe Leu 470 475 480 Arg Gln Ala Gly His Ser Glu Lys Ala Ile Ser Leu Phe Gln Ala 485 490 495 Met Val Asp Phe Thr Phe Phe Lys Pro Asp Ser Val Lys Asp Leu 500 505 510 Pro Thr Lys Gly Gln Val Glu Phe Phe Glu Pro Phe Trp Asp Ser 515 520 525 Gly Glu Pro Arg Ala Gly Glu Lys Gly Ala Arg Gly Trp Lys Ala 530 535 540 Trp Met His Gln Gln Glu Arg Gly Gly Trp Val Val Ile Asn Pro 545 550 555 Asp Glu Asp Asp Asp Glu Pro Glu Glu Asp Asp Gln Glu Ile Lys 560 565 570 Asp Lys Thr Leu Pro Arg Trp Gln Ile Trp Leu Ala Ala Glu Arg 575 580 585 Ser Arg Asp Gln Arg His Trp Arg Pro Trp Arg Pro Asp Lys Thr 590 595 600 Lys Lys Gln Thr Glu Glu Asp Cys Glu Asp Pro Glu Arg Gln Val 605 610 615 Leu Phe Asp Asp Ile Gly Gln Ser Leu Ile Arg Leu Ser Ser His 620 625 630 Asp Leu Gln Phe Gln Leu Val Glu Ala Phe Leu Gln Phe Leu Gly 635 640 645 Val Pro Ser Gly Phe Thr Pro Pro Ala Ser Cys Leu Tyr Leu Ala 650 655 660 Met Asp Glu Asn Ser Ile Phe Asp Asn Gly Leu Tyr Asp Glu Lys 665 670 675 Pro Leu Thr Phe Phe Asn Pro Leu Phe Ser Gly Ala Ser Cys Val 680 685 690 Gly Arg Met Asp Arg Leu Gly Tyr Pro Arg Trp Thr Arg Gly Gln 695 700 705 Asn Arg Glu Gly Glu Glu Phe Ile Arg Asn Val Phe His Leu Val 710 715 720 Met Pro Leu Phe Ser Gly Lys Glu Lys Ser Gln Leu Cys Phe Ser 725 730 735 Trp Leu Gln Tyr Glu Ile Ala Lys Val Ile Trp Cys Leu His Thr 740 745 750 Lys Asn Lys Lys Arg Leu Lys Ser Gln Gly Lys Asn Cys Lys Lys 755 760 765 Leu Ala Lys Asn Leu Leu Lys Glu Pro Glu Asn Cys Asn Asn Phe 770 775 780 Cys Leu Trp Lys Gln Tyr Ala His Leu Glu Trp Leu Leu Gly Asn 785 790 795 Thr Glu Asp Ala Arg Lys Val Phe Asp Thr Ala Leu Gly Met Ala 800 805 810 Gly Ser Arg Glu Leu Lys Asp Ser Asp Leu Cys Glu Leu Ser Leu 815 820 825 Leu Tyr Ala Glu Leu Glu Val Glu Leu Ser Pro Glu Val Arg Arg 830 835 840 Ala Ala Thr Ala Arg Ala Val His Ile Leu Thr Lys Leu Thr Glu 845 850 855 Ser Ser Pro Tyr Gly Pro Tyr Thr Gly Gln Val Leu Ala Val His 860 865 870 Ile Leu Lys Ala Arg Lys Ala Tyr Glu His Ala Leu Gln Asp Cys 875 880 885 Leu Gly Asp Ser Cys Val Ser Asn Pro Ala Pro Thr Asp Ser Cys 890 895 900 Ser Arg Leu Ile Ser Leu Ala Lys Cys Phe Met Leu Phe Gln Tyr 905 910 915 Leu Thr Ile Gly Ile Asp Ala Ala Val Gln Ile Tyr Glu Gln Val 920 925 930 Phe Ala Lys Leu Asn Ser Ser Val Phe Pro Glu Gly Ser Gly Glu 935 940 945 Gly Asp Ser Ala Ser Ser Gln Ser Trp Thr Ser Val Leu Glu Ala 950 955 960 Ile Thr Leu Met His Thr Ser Leu Leu Arg Phe His Met Lys Val 965 970 975 Ser Val Tyr Pro Leu Ala Pro Leu Arg Glu Ala Leu Ser Gln Ala 980 985 990 Leu Lys Leu Tyr Pro Gly Asn Gln Val Leu Trp Arg Ser Tyr Val 995 1000 1005 Gln Ile Gln Asn Lys Ser His Ser Ala Ser Lys Thr Arg Arg Phe 1010 1015 1020 Phe Asp Thr Ile Thr Arg Ser Ala Lys Pro Leu Glu Pro Trp Leu 1025 1030 1035 Phe Ala Ile Glu Ala Glu Lys Leu Arg Lys Arg Leu Val Glu Thr 1040 1045 1050 Val Gln Arg Leu Asp Gly Arg Glu Ile His Ala Thr Ile Pro Glu 1055 1060 1065 Thr Gly Leu Met His Arg Ile Gln Ala Leu Phe Glu Asn Ala Met 1070 1075 1080 Arg Ser Asp Ser Gly Ser Gln Cys Pro Leu Leu Trp Arg Met Tyr 1085 1090 1095 Leu Asn Phe Leu Val Ser Leu Gly Asn Lys Glu Arg Ser Lys Gly 1100 1105 1110 Val Phe Tyr Lys Ala Leu Gln Ser Cys Pro Trp Ala Lys Val Leu 1115 1120 1125 Tyr Leu Asp Ala Val Glu Tyr Phe Pro Asp Glu Met Gln Glu Ile 1130 1135 1140 Leu Asp Leu Met Thr Glu Lys Glu Leu Arg Val Arg Leu Pro Leu 1145 1150 1155 Glu Glu Leu Glu Leu Leu Leu Glu Asp 1160 18 112 PRT Homo sapiens misc_feature Incyte ID No 7040722CD1 18 Met Met Glu Glu Gly Arg Phe Leu Val Leu Gly Leu Thr Leu Thr 1 5 10 15 Leu Ser Gly Glu Gln Thr Leu Gly Asn Leu Val His Tyr Ser Gln 20 25 30 Gln Arg Ala Val Pro Val Leu Val Gly Gly Glu Gly Leu Gly Pro 35 40 45 Gly Leu Ile Cys Ala Asn Ser Leu Glu Gly Gly Gly Arg Arg Cys 50 55 60 Arg Gly Gly Ala Glu Ala Thr Lys Glu Thr Ala Pro Pro Ala Pro 65 70 75 Gly Leu Ser Ala Asp Ile Pro Gly Glu Ala Thr Gly Gly Asp Phe 80 85 90 Gly Tyr Pro Glu Lys Gln Lys Gly Asn Gly Met Ser Asn Lys Thr 95 100 105 Leu Ser Thr Ser Ser Leu Phe 110 19 170 PRT Homo sapiens misc_feature Incyte ID No 6430290CD1 19 Met Trp Leu Ser Ile Glu Gly Asn Ser Tyr Ala Asp Cys Gly Leu 1 5 10 15 Glu Asn Leu Gly Trp Leu Ser Cys Trp Leu Ser Arg Val Gly Trp 20 25 30 Phe Gly Ala Tyr Ser Gly Val Pro Cys Leu Pro Val Cys Leu Leu 35 40 45 Met Ile Leu Met Ser Ser Leu Arg Gly Gln Arg Leu Val Pro Gly 50 55 60 Ala Gly Pro Ser Cys Thr Leu Arg Phe Arg Trp Asp His Lys Gln 65 70 75 Arg Ser Thr Gly Gly Lys His Leu Cys Ala Ser Thr Leu His Ile 80 85 90 Asn Lys Leu Asp Gln Asn Met Glu Cys Thr Ser Leu Leu Arg Ile 95 100 105 Leu Glu Leu Ser Val Pro Pro Leu Gly Ala Pro Leu Trp Leu Lys 110 115 120 Thr Pro Pro Glu Ala Glu Gly Glu Glu Glu Ala Glu Arg Lys Glu 125 130 135 Asn Arg Arg Leu Gly Val Gly Ser Ser Arg Ala Glu Pro Ser Arg 140 145 150 Pro Ala Phe Leu Asp Ser Ser Gly Gly Ser Gly Asp Val Cys Cys 155 160 165 Gly Ser Gly Glu Trp 170 20 80 PRT Homo sapiens misc_feature Incyte ID No 2640251CD1 20 Met Trp Cys Thr Cys Arg Cys Arg Thr Gln Gln Pro Gly Met Pro 1 5 10 15 Ala Leu Met Pro Ser Pro Arg Asn Ala Phe Ser Ala Glu Trp Leu 20 25 30 Leu Ala Leu Ser Ser Thr Cys Gln His Ser Ser Ala Ala Ser Ala 35 40 45 Pro Cys Gln Gly Val Thr Arg Thr Arg Arg Ile Arg Lys His Gly 50 55 60 Gly Val Arg Lys His Trp Gln Ser Gln His Ile Cys Glu His Val 65 70 75 Thr His Gly Leu Ala 80 21 118 PRT Homo sapiens misc_feature Incyte ID No 3839350CD1 21 Met Glu Leu Leu Leu Thr Arg Ala Asp Leu Leu Leu Val Thr Tyr 1 5 10 15 Ser Trp Ala Lys Ser Glu Lys Pro Leu Pro Ala Leu Gly Lys Ala 20 25 30 Asp Gly Ala Ala Gln Gln Ala Gly Phe Ala His Arg Leu Arg Tyr 35 40 45 His Pro Thr Gln Ser Ala Arg Leu Cys Gly Pro Leu Ile Tyr Ile 50 55 60 Leu Ile Cys Gln Gln Asp Gly Val Gly Tyr Ala Val Phe Ala Gln 65 70 75 Arg Ser Asp Pro Arg Asp Ile Cys Val Gly Val Cys Pro Gly Ala 80 85 90 Ala Cys Leu Gln Val Gln Ile Gly Val Ser Phe Ala Gly Glu Cys 95 100 105 Gly Phe Leu Pro Trp His Gln Arg Arg Gly Leu Ala Asp 110 115 22 140 PRT Homo sapiens misc_feature Incyte ID No 6393813CD1 22 Met Ala Val Val Leu Pro Ala Val Val Glu Glu Leu Leu Ser Glu 1 5 10 15 Met Ala Ala Ala Val Gln Glu Ser Ala Arg Ile Pro Asp Glu Tyr 20 25 30 Leu Leu Ser Leu Lys Phe Leu Phe Gly Ser Ser Ala Thr Gln Ala 35 40 45 Leu Asp Leu Val Asp Arg Gln Ser Ile Thr Leu Ile Ser Ser Pro 50 55 60 Ser Gly Arg Arg Val Tyr Gln Val Leu Gly Ser Ser Ser Lys Thr 65 70 75 Tyr Thr Cys Leu Ala Ser Cys His Tyr Cys Ser Cys Pro Ala Phe 80 85 90 Ala Phe Ser Val Leu Arg Lys Ser Asp Ser Ile Leu Cys Lys His 95 100 105 Leu Leu Ala Val Tyr Leu Ser Gln Val Met Arg Thr Cys Gln Gln 110 115 120 Leu Ser Val Ser Asp Lys Gln Leu Thr Asp Ile Leu Leu Met Glu 125 130 135 Lys Lys Gln Glu Ala 140 23 478 PRT Homo sapiens misc_feature Incyte ID No 5685755CD1 23 Met Pro Arg Arg Gly Tyr Ser Lys Pro Gly Ser Trp Gly Ser Phe 1 5 10 15 Trp Ala Met Leu Thr Leu Val Gly Leu Val Thr His Ala Ala Gln 20 25 30 Arg Ala Asp Val Gly Gly Glu Ala Ala Gly Thr Ser Ile Asn His 35 40 45 Ser Gln Ala Val Leu Gln Arg Leu Gln Glu Leu Leu Arg Gln Gly 50 55 60 Asn Ala Ser Asp Val Val Leu Arg Val Gln Ala Ala Gly Thr Asp 65 70 75 Glu Val Arg Val Phe His Ala His Arg Leu Leu Leu Gly Leu His 80 85 90 Ser Glu Leu Phe Leu Glu Leu Leu Ser Asn Gln Ser Glu Ala Val 95 100 105 Leu Gln Glu Pro Gln Asp Cys Ala Ala Val Phe Asp Lys Phe Ile 110 115 120 Arg Tyr Leu Tyr Cys Gly Glu Leu Thr Val Leu Leu Thr Gln Ala 125 130 135 Ile Pro Leu His Arg Leu Ala Thr Lys Tyr Gly Val Ser Ser Leu 140 145 150 Gln Arg Gly Val Ala Asp Tyr Met Arg Ala His Leu Ala Gly Gly 155 160 165 Ala Gly Pro Ala Val Gly Trp Tyr His Tyr Ala Val Gly Thr Gly 170 175 180 Asp Glu Ala Leu Arg Glu Ser Cys Leu Gln Phe Leu Ala Trp Asn 185 190 195 Leu Ser Ala Val Ala Ala Ser Thr Glu Trp Gly Ala Val Ser Pro 200 205 210 Glu Leu Leu Trp Gln Leu Leu Gln Arg Ser Asp Leu Val Leu Gln 215 220 225 Asp Glu Leu Glu Leu Phe His Ala Leu Glu Ala Trp Leu Gly Arg 230 235 240 Ala Arg Pro Pro Pro Ala Val Ala Glu Arg Ala Leu Arg Ala Ile 245 250 255 Arg Tyr Pro Met Ile Pro Pro Ala Gln Leu Phe Gln Leu Gln Ala 260 265 270 Arg Ser Ala Ala Leu Ala Arg His Gly Pro Ala Val Ala Asp Leu 275 280 285 Leu Leu Gln Ala Tyr Gln Phe His Ala Ala Ser Pro Leu His Tyr 290 295 300 Ala Lys Phe Phe Asp Val Asn Gly Ser Ala Phe Leu Pro Arg Asn 305 310 315 Tyr Leu Ala Pro Ala Trp Gly Ala Pro Trp Val Ile Asn Asn Pro 320 325 330 Ala Arg Asp Asp Arg Ser Thr Ser Phe Gln Thr Gln Leu Gly Pro 335 340 345 Ser Gly His Asp Ala Gly Arg Arg Val Thr Trp Asn Val Leu Phe 350 355 360 Ser Pro Arg Trp Leu Pro Val Ser Leu Arg Pro Val Tyr Ala Asp 365 370 375 Ala Ala Gly Thr Ala Leu Pro Ala Ala Arg Pro Glu Asp Gly Arg 380 385 390 Pro Arg Leu Val Val Thr Pro Ala Ser Ser Gly Gly Asp Ala Ala 395 400 405 Gly Val Ser Phe Gln Lys Thr Val Leu Val Gly Ala Arg Gln Gln 410 415 420 Gly Arg Leu Leu Val Arg His Ala Tyr Ser Phe His Gln Ser Ser 425 430 435 Glu Glu Ala Gly Asp Phe Leu Ala His Ala Asp Leu Gln Arg Arg 440 445 450 Asn Ser Glu Tyr Leu Val Glu Asn Ala Leu His Leu His Leu Ile 455 460 465 Val Lys Pro Val Tyr His Thr Leu Ile Arg Thr Pro Lys 470 475 24 80 PRT Homo sapiens misc_feature Incyte ID No 71728459CD1 24 Met Lys Val Thr Ala Leu Leu Gly Ala Leu Ser Pro Val Phe Ala 1 5 10 15 Phe Val Ser Val Phe Ile Ser Trp Leu Ala Ser Phe Gly Asp Gln 20 25 30 Lys Ser Ile Asp Ser Pro Pro Asp Glu Gln Gln Ser Asn Ser Tyr 35 40 45 Thr Ser Gly Gln Ala Ala Ser Tyr Ser Gln Lys Ala Ile Gly Arg 50 55 60 Lys Gly Asn Trp Leu Pro Tyr Ser Leu His Asp Glu Ala Ala Leu 65 70 75 Gly Ser Gly Ser Trp 80 25 505 PRT Homo sapiens misc_feature Incyte ID No 1904303CD1 25 Met Ser Pro Trp Ser Trp Phe Leu Leu Gln Thr Leu Cys Leu Leu 1 5 10 15 Pro Thr Gly Ala Ala Ser Arg Arg Gly Ala Pro Gly Thr Ala Asn 20 25 30 Cys Glu Leu Lys Pro Gln Gln Ser Glu Leu Asn Ser Phe Leu Trp 35 40 45 Thr Ile Lys Arg Asp Pro Pro Ser Tyr Phe Phe Gly Thr Ile His 50 55 60 Val Pro Tyr Thr Arg Val Trp Asp Phe Ile Pro Asp Asn Ser Lys 65 70 75 Glu Ala Phe Leu Gln Ser Ser Ile Val Tyr Phe Glu Leu Asp Leu 80 85 90 Thr Asp Pro Tyr Thr Ile Ser Ala Leu Thr Ser Cys Gln Met Leu 95 100 105 Pro Gln Gly Glu Asn Leu Gln Asp Val Leu Pro Arg Asp Ile Tyr 110 115 120 Cys Arg Leu Lys Arg His Leu Glu Tyr Val Lys Leu Met Met Pro 125 130 135 Leu Trp Met Thr Pro Asp Gln Arg Gly Lys Gly Leu Tyr Ala Asp 140 145 150 Tyr Leu Phe Asn Ala Ile Ala Gly Asn Trp Glu Arg Lys Arg Pro 155 160 165 Val Trp Val Met Leu Met Val Asn Ser Leu Thr Glu Val Asp Ile 170 175 180 Lys Ser Arg Gly Val Pro Val Leu Asp Leu Phe Leu Ala Gln Glu 185 190 195 Ala Glu Arg Leu Arg Lys Gln Thr Gly Ala Val Glu Lys Val Glu 200 205 210 Glu Gln Cys His Pro Leu Asn Gly Leu Asn Phe Ser Gln Val Ile 215 220 225 Phe Ala Leu Asn Gln Thr Leu Leu Gln Gln Glu Ser Leu Arg Ala 230 235 240 Gly Ser Leu Gln Ile Pro Tyr Thr Thr Glu Asp Leu Ile Lys His 245 250 255 Tyr Asn Cys Gly Asp Leu Ser Ser Val Ile Leu Ser His Asp Ser 260 265 270 Ser Gln Val Pro Asn Phe Ile Asn Ala Thr Leu Pro Pro Gln Glu 275 280 285 Arg Ile Thr Ala Gln Glu Ile Asp Ser Tyr Leu Arg Arg Glu Leu 290 295 300 Ile Tyr Lys Arg Asn Glu Arg Ile Gly Lys Arg Val Lys Ala Leu 305 310 315 Leu Glu Glu Phe Pro Asp Lys Gly Phe Phe Phe Ala Phe Gly Ala 320 325 330 Gly His Phe Met Gly Asn Asn Thr Val Leu Asp Val Leu Arg Arg 335 340 345 Glu Gly Tyr Glu Val Glu His Ala Pro Ala Gly Arg Pro Ile His 350 355 360 Lys Gly Lys Ser Lys Lys Thr Ser Thr Arg Pro Thr Leu Ser Thr 365 370 375 Ile Phe Ala Pro Lys Val Pro Thr Leu Glu Val Pro Ala Pro Glu 380 385 390 Ala Val Ser Ser Gly His Ser Thr Leu Pro Pro Leu Val Ser Arg 395 400 405 Pro Gly Ser Ala Asp Thr Pro Ser Glu Ala Glu Gln Arg Phe Arg 410 415 420 Lys Lys Arg Arg Arg Ser Gln Arg Arg Pro Arg Leu Arg Gln Phe 425 430 435 Ser Asp Leu Trp Val Arg Leu Glu Glu Ser Asp Ile Val Pro Gln 440 445 450 Leu Gln Val Pro Val Leu Asp Arg His Ile Ser Thr Glu Leu Arg 455 460 465 Leu Pro Arg Arg Gly His Ser His His Ser Gln Met Val Ala Ser 470 475 480 Ser Ala Cys Leu Ser Leu Trp Thr Pro Val Phe Trp Val Leu Val 485 490 495 Leu Ala Phe Gln Thr Glu Thr Pro Leu Leu 500 505 26 321 PRT Homo sapiens misc_feature Incyte ID No 2911343CD1 26 Met Ser Gly Gly Lys Ser Ala Gln Gly Pro Glu Glu Gly Gly Val 1 5 10 15 Cys Ile Thr Glu Ala Leu Ile Thr Lys Arg Asn Leu Thr Phe Pro 20 25 30 Glu Asp Gly Glu Leu Ser Glu Lys Met Phe His Thr Leu Asp Glu 35 40 45 Leu Gln Thr Val Arg Leu Asp Arg Glu Gly Ile Thr Thr Ile Arg 50 55 60 Asn Leu Glu Gly Leu Gln Asn Leu His Ser Leu Tyr Leu Gln Gly 65 70 75 Asn Lys Ile Gln Gln Ile Glu Asn Leu Ala Cys Ile Pro Ser Leu 80 85 90 Arg Phe Leu Ser Leu Ala Gly Asn Gln Ile Arg Gln Val Glu Asn 95 100 105 Leu Leu Asp Leu Pro Cys Leu Gln Phe Leu Asp Leu Ser Glu Asn 110 115 120 Leu Ile Glu Thr Leu Lys Leu Asp Glu Phe Pro Gln Ser Leu Leu 125 130 135 Ile Leu Asn Leu Ser Gly Asn Ser Cys Thr Asn Gln Asp Gly Tyr 140 145 150 Arg Glu Leu Val Thr Glu Ala Leu Pro Leu Leu Leu Asp Leu Asp 155 160 165 Gly Gln Pro Val Val Glu Arg Trp Ile Ser Asp Glu Glu Asp Glu 170 175 180 Ala Ser Ser Asp Glu Glu Phe Pro Glu Leu Ser Gly Pro Phe Cys 185 190 195 Ser Glu Arg Gly Phe Leu Lys Glu Leu Glu Gln Glu Leu Ser Arg 200 205 210 His Arg Glu His Arg Gln Gln Thr Ala Leu Thr Glu His Leu Leu 215 220 225 Arg Met Glu Met Gln Pro Thr Leu Thr Asp Leu Pro Leu Leu Pro 230 235 240 Gly Val Pro Met Ala Gly Asp Ser Ser Pro Ser Ala Thr Pro Ala 245 250 255 Gln Gly Glu Glu Thr Val Pro Glu Ala Val Ser Ser Pro Gln Ala 260 265 270 Ser Ser Pro Thr Lys Lys Pro Cys Ser Leu Ile Pro Arg Gly His 275 280 285 Gln Ser Ser Phe Trp Gly Arg Lys Gly Ala Arg Ala Ala Thr Ala 290 295 300 Pro Lys Ala Ser Val Ala Glu Ala Pro Ser Thr Thr Lys Thr Thr 305 310 315 Ala Lys Arg Ser Lys Lys 320 27 60 PRT Homo sapiens misc_feature Incyte ID No 7500308CD1 27 Met Ser Gln Ala Trp Val Pro Gly Leu Ala Pro Thr Leu Leu Phe 1 5 10 15 Ser Leu Leu Ala Gly Pro Gln Lys Val Ile Leu Lys Pro Ser Leu 20 25 30 Gly Pro Thr Pro Thr Glu Pro Pro Pro Pro Tyr Ser Phe Arg Pro 35 40 45 Glu Glu Tyr Thr Gly Asp Gln Arg Gly Ile Asp Asn Pro Ala Phe 50 55 60 28 45 PRT Homo sapiens misc_feature Incyte ID No 7501098CD1 28 Met Phe Thr Leu Leu Val Leu Leu Ser Gln Leu Pro Thr Val Thr 1 5 10 15 Leu Gly Phe Pro His Cys Ala Arg Gly Pro Lys Ala Ser Lys His 20 25 30 Ala Gly Glu Glu Asp Leu Ile Trp Ser Ser Ser Leu Pro Ala Thr 35 40 45 29 43 PRT Homo sapiens misc_feature Incyte ID No 7503839CD1 29 Met Ala Leu Phe Pro Ala Phe Ala Gly Leu Ser Glu Ala Pro Asp 1 5 10 15 Gly Gly Ser Ser Arg Lys Val Lys Glu Ile Met Leu Gln Leu Ile 20 25 30 Leu Asp Ile Ala Leu Phe Gly Leu Arg Thr Phe Arg Leu 35 40 30 456 PRT Homo sapiens misc_feature Incyte ID No 7503698CD1 30 Met Ser Pro Trp Ser Trp Phe Leu Leu Gln Thr Leu Cys Leu Leu 1 5 10 15 Pro Thr Gly Ala Ala Ser Arg Arg Gly Ala Pro Gly Thr Ala Asn 20 25 30 Cys Glu Leu Lys Pro Gln Gln Ser Glu Leu Asn Ser Phe Leu Trp 35 40 45 Thr Ile Lys Arg Asp Pro Pro Ser Tyr Phe Phe Gly Thr Ile His 50 55 60 Val Pro Tyr Thr Arg Val Trp Asp Phe Ile Pro Asp Asn Ser Lys 65 70 75 Glu Ala Phe Leu Gln Ser Ser Ile Val Tyr Phe Glu Leu Asp Leu 80 85 90 Thr Asp Pro Tyr Thr Ile Ser Ala Leu Thr Ser Cys Gln Met Leu 95 100 105 Pro Gln Gly Glu Asn Leu Gln Asp Val Leu Pro Arg Asp Ile Tyr 110 115 120 Cys Arg Leu Lys Arg His Leu Glu Tyr Val Lys Leu Met Met Pro 125 130 135 Leu Trp Met Thr Pro Asp Gln Arg Gly Lys Gly Leu Tyr Ala Asp 140 145 150 Tyr Leu Phe Asn Ala Ile Ala Gly Asn Trp Glu Arg Lys Arg Pro 155 160 165 Val Trp Val Met Leu Met Val Asn Ser Leu Thr Glu Val Asp Ile 170 175 180 Lys Ser Arg Gly Val Pro Val Leu Asp Leu Phe Leu Ala Gln Glu 185 190 195 Ala Glu Arg Leu Arg Lys Gln Thr Gly Ala Val Glu Lys Val Glu 200 205 210 Glu Gln Cys His Pro Leu Asn Gly Leu Asn Phe Ser Gln Val Pro 215 220 225 Asn Phe Ile Asn Ala Thr Leu Pro Pro Gln Glu Arg Ile Thr Ala 230 235 240 Gln Glu Ile Asp Ser Tyr Leu Arg Arg Glu Leu Ile Tyr Lys Arg 245 250 255 Asn Glu Arg Ile Gly Lys Arg Val Lys Ala Leu Leu Glu Glu Phe 260 265 270 Pro Asp Lys Gly Phe Phe Phe Ala Phe Gly Ala Gly His Phe Met 275 280 285 Gly Asn Asn Thr Val Leu Asp Val Leu Arg Arg Glu Gly Tyr Glu 290 295 300 Val Glu His Ala Pro Ala Gly Arg Pro Ile His Lys Gly Lys Ser 305 310 315 Lys Lys Thr Ser Thr Arg Pro Thr Leu Ser Thr Ile Phe Ala Pro 320 325 330 Lys Val Pro Thr Leu Glu Val Pro Ala Pro Glu Ala Val Ser Ser 335 340 345 Gly His Ser Thr Leu Pro Pro Leu Val Ser Arg Pro Gly Ser Ala 350 355 360 Asp Thr Pro Ser Glu Ala Glu Gln Arg Phe Arg Lys Lys Arg Arg 365 370 375 Arg Ser Gln Arg Arg Pro Arg Leu Arg Gln Phe Ser Asp Leu Trp 380 385 390 Val Arg Leu Glu Glu Ser Asp Ile Val Pro Gln Leu Gln Val Pro 395 400 405 Val Leu Asp Arg His Ile Ser Thr Glu Leu Arg Leu Pro Arg Arg 410 415 420 Gly His Ser His His Ser Gln Met Val Ala Ser Ser Ala Cys Leu 425 430 435 Ser Leu Trp Thr Pro Val Phe Trp Val Leu Val Leu Ala Phe Gln 440 445 450 Thr Glu Thr Pro Leu Leu 455 31 1053 DNA Homo sapiens misc_feature Incyte ID No 1895273CB1 31 ccagcttgga gacaacatgt ggttcttgac aactctgctc ctttgggttc cagttgatgg 60 gcaagtgggc tggctactac tgcaggtctc cagcagagtc ttcacggaag gagaacctct 120 ggccttgagg tgtcatgcgt ggaaggataa gctggtgtac aatgtgcttt actatcgaaa 180 tggcaaagcc tttaagtttt tccactggaa ttctaacctc accattctga aaaccaacat 240 aagtcacaat ggcacctacc attgctcagg catgggaaag catcgctaca catcagcagg 300 aatatctgtc actgtgaaag agctatttcc agctccagtg ctgaatgcat ctgtgacatc 360 cccactcctg gaggggaatc tggtcaccct gagctgtgaa acaaagttgc tcttgcagag 420 gcctggtttg cagctttact tctccttcta catgggcagc aagaccctgc gaggcaggaa 480 cacatcctct gaataccaaa tactaactgc tagaagagaa gactctgggt tatactggtg 540 cgaggctgcc acagaggatg gaaatgtcct taagcgcagc cctgagttgg agcttcaagt 600 gcttggcctc cagttaccaa ctcctgtctg gtttcatgtc cttttctatc tggcagtggg 660 aataatgttt ttagtgaaca ctgttctctg ggtgacaata cgtaaagaac tgaaaagaaa 720 gaaaaagtgg aatttagaaa tctctttgga ttctggtcat gagaagaagg taatttccag 780 ccttcaagaa gacagacatt tagaagaaga gctgaaatgt caggaacaaa aagaagaaca 840 gctgcaggaa ggggtgcacc ggaaggagcc ccagggggcc acgtagcagc ggctcagtgg 900 gtggccatcg atctggaccg tcccctgccc acttgctccc cgtgagcact gcgtacaaac 960 atccaaaagt tcaacaacac cagaactgtg tgtctcatgg tatataactc ttaaagcaaa 1020 taaatgaact gacttcaaaa aaaaaaaaaa agg 1053 32 1579 DNA Homo sapiens misc_feature Incyte ID No 70072222CB1 32 agcccctgca gcagggtggg agcattagga catgtccaca cgtcttcaag ggaaaatggc 60 taagggctgt cagagaggcc cagggaagag gcctgggtag gggcgagcag ggagcagaca 120 atcacttgtt gaaggaagat ccaagtccag gaaggaacgt agggcagttt ggtgtcatgg 180 aaggaactgg gggcccagcc gaggggctca agagcccttc agactctgcc tgagcgaggg 240 tggtgctctg tcacccaggc tggagtgtag tggtgtgatc tcagctcact gcagccttga 300 actcctaggc tcaagtgatc ctcctacctc aacctccaga gtaactggga ctacaggaaa 360 gctcagtggc ccccaagcca ggatgtccca agcttgggtc cccggcctcg cgcccacctt 420 gctgttcagc ctgctggctg gcccccaaaa gattgcagcc aaatgtggtc tcatccttgc 480 ctgccccaaa ggattcaaat gctgtggtga cagctgctgc caggagaacg agctcttccc 540 tggccccgtg aggatcttcg tcatcatctt cctggtcatc ctgtccgtct tttgcatctg 600 tggcctggct aagtgcttct gtcgcaactg cagagagccg gagccagaca ccccagtgga 660 ttgccggggg cccctggaac tgccctccat catcccccca gagagggtca gagtatccct 720 ttctgcgccc ccacccccct acagtgaggt gattctgaag cccagcctgg gcccaactcc 780 cacagagcca ccccctccct acagcttcag gcctgaagaa tataccgggg atcagagggg 840 cattgacaac ccggccttct gagtcacctc ctgcctggaa tcttgccatc agcaacctcc 900 tccccagtgc ctcctggatc aagctagaga ctgctggcac cccaggaatg tccctgccca 960 tcctgccgtg tctctgttca ttcttggatt taacttatta ctttttctgc ttctgtttcc 1020 accccagctg cctctcttgt cctgagggtt aggctggagt gacagtttcc gcccaccccc 1080 cagcccaaga aagaggctgc cggaaagaaa atgctgacca ttggaggtgc ccaacagtag 1140 aatgggctac tgtgaggggt agtaagagcc ccatttctgg aggtatgcga atcttgactg 1200 gacagccagc tctgagattt tatcagggca cttctatacc tgtgggacat tggactggat 1260 gagccctgag ccagcttcca ctcctacctg aatagagaac tcactgcacc cacccacaac 1320 acatgataaa cacatgtcct cactgaatgt tactgattgc ggctgagggc ctgcctctgg 1380 ctgtgtgggg aggtgggtgg agaggtgagc ccaggcactg ctgaggggtg cggtgatggg 1440 gtcgctgcgc cgcaatccca ccactgatga gccacctggg aggtctggga ggccagtcca 1500 tccatgggcc gccctcggag agaggcttgt tctagatgta ttggctgtct gttttttgat 1560 gtctctgtgt gccaaacag 1579 33 2440 DNA Homo sapiens misc_feature Incyte ID No 3559223CB1 33 agcagtcctt gacgacgagg aatttttttt tttttttttt tttttttttt taattttctt 60 ttttaaaaag acgccccctc cagccccctc gccggtgacc ttggccgcct cggatgctct 120 gattccacgc ggctcgctct aacttgcccc cgcgccggcc gggcccatgg ccgcgtcgga 180 ggacgggagc ggctgcctcg tgtcgcgggg ccgctcgcag agtgacccca gcgtcctcac 240 cgactcctcg gccacctcct ccgcggacgc cggggagaac ccagatgaga tggaccaaac 300 gcccccggcg cgtcctgaat atctggtctc agggattcga actccccctg tgaggaggaa 360 cagcaaactg gccaccctgg gcaggatctt caaaccctgg aaatggagga aaaagaaaaa 420 cgaaaaactg aagcagacaa cgtcagcgct ggagaagaag atggccggca ggcaaggccg 480 agaggagctc atcaagaagg ggctgctgga gatgatggag caggatgctg aaagcaaaac 540 ttgcaacccc gatggaggac cccgatctgt acagagtgaa ccacccactc ccaagtcgga 600 gacgctgact tcagaagatg cccagcccgg aagccccttg gccactggga cggaccaggt 660 ctccctggac aagccactgt cctcagctgc ccacttggac gatgcagcca agatgccttc 720 tgcatccagt ggtgaagaag cagacgctgg cagcctcctg cccaccacca atgagctctc 780 ccaagcctta gctggggctg actccctgga cagtcctccc agacctctgg agagatccgt 840 gggccagctc cccagccccc cactgctgcc cactccgcca cccaaggcaa gctccaaaac 900 cacaaaaaat gtcacaggcc aagccacact cttccaagcc tccagcatga agagtgccga 960 cccttccctc cggggccagc tctccacacc cacggggtct ccgcatctca ccacggtcca 1020 ccggcctctt cccccaagcc gcgtcattga ggagctgcac agggcgctgg ccacgaagca 1080 ccgccaggac agttttcaag gaagagaaag taaagggtct ccaaagaagc ggctggatgt 1140 ccgtctgtcg agaacgtcca gcgtggagcg gggcaaggag agggaggagg cttggagctt 1200 tgacggggca ttggagaaca agcgaactgc cgctaaggaa tctgaggaga acaaggagaa 1260 cctgatcata aattctgaac tcaaagacga cttgcttttg tatcaggacg aggaggcgct 1320 gaacgactcc attatttctg gaacactgcc acggaaatgc aagaaggagc tcctggccgt 1380 gaagctaagg aaccggccaa gcaaacagga actagaagac cggaacattt tccccagaag 1440 gactgatgaa gaaagacagg agatccggca gcagatcgag atgaagcttt ccaaacggct 1500 gagccaaaga cctgccgtgg aagagctgga gagaagaaat atcttgaaac aaaggaatga 1560 tcagacagag caggaagaaa gaagagaaat caagcaaaga ttgacaagaa agcttaatca 1620 gagacccact gttgatgaat taagagacag aaaaattctg atacgattca gtgattacgt 1680 ggaagtagca aaagcgcagg actatgacag gagggcagac aaaccctgga cgagactgtc 1740 agcagcagat aaggcagcaa ttcgtaaaga attaaatgag tacaaaagta atgaaatgga 1800 ggtacatgca tcaagcaagc acttgacaag attccacagg ccatagagat tttcttctga 1860 gaagaatttg tgtttaattt tttgatacca acactgaaca ttcatcaggg aactttcctg 1920 aagttcagct caagactacc ctacctgctg tgtttgtgag aagagtagga tcacacacac 1980 aggtgcaatc ttgaccacac ttacctgcaa gaggagtaac cagaggacac acttccttcc 2040 ttctttggtg tctgaggagt gtgaactgtt ggggtcagtt aagacccaac ataactctat 2100 cagaagaaaa ctgttgtttg cctttcaacc ttgttttaca gttctgcagt gtaatggagg 2160 acgggcaacg tgcatgtgca ggctcaccac tcccaggcct ctgacatgag ggacatgtga 2220 cagtgtcatt cagtattatg ttcaaaagac atttttatcc tgatcataat taatttgaaa 2280 actctttaag ttcatgttat acaagatgat ttactgtatt atacttttcc ttttttatat 2340 aatgtctaac aaaaaataca gctgcaacat tttgattcct gttaattttg ttctttaatt 2400 aaatgactac ttattgcagg aaaaaaaaaa aaaaaaaaaa 2440 34 4133 DNA Homo sapiens misc_feature Incyte ID No 3441255CB1 34 cttctttggg caaacataca caaatgcatc atacatgtgt ggtgagctta tcaccagtga 60 tggttttctg tgctagaaat gactcttaat ttgaattttg gagtgctttt tctctttttt 120 tacaatgtgt gttccaactc tttgtgttaa atagatttaa gtaaaggagg taaatgctaa 180 attcatagtg ttttttacct gtatcacttc cctgtgtatt atggaaaaat tagagatttt 240 aacgttattc aaagttttac tggaagcaaa actgtgccag ggacagagat atacaattta 300 agttttctct ttttggcaac tgcacttgct taaaatgtac tgaatgtcag ctggatttca 360 cagcatatca gatttacagt ctttgtctta tcaaggcctt tactgtatgt tttatactaa 420 ccagatggga aacacattga gcatcatatc tgacatgtat gcctaaggga ggagctcccc 480 catggatcat ggcgttaatg tttacaggac atttactatt cttagcatta ttgatgtttg 540 ctttctctac ttttgaggaa tctgtgagca attattccga atgggcagtt ttcacagatg 600 atatagatca gtttaaaaca cagaaagtgc aagatttcag acccaaccaa aagctgaaga 660 aaagtatgct tcatccaagt ttatattttg atgctggaga aatccaagca atgagacaaa 720 agtctcgtgc aagccatttg catcttttta gagctatcag aagtgcagtg acagttatgc 780 tgtccaaccc aacatactac ctacctccac caaagcatgc tgattttgct gccaagtgga 840 atgaaattta tggtaacaat ctgcctcctt tagcattgta ctgtttgtta tgcccagaag 900 acaaagttgc ctttgaattt gtcttggaat atatggacag gatggttggc tacaaagact 960 ggctagtaga gaatgcacca ggagatgagg ttccaattgt ccattcctta acaggttttg 1020 ccactgcctt tgacttttta tataacttat tagataatca tcgaagacaa aaatacctgg 1080 aaaaaatatg ggttattact gaggaaatgt acgagtattc caaggtccgc tcatggggca 1140 aacagcttct ccataaccac caagccacta atatgatagc attactcaca ggggccttgg 1200 tgactggagt agataaagga tctaaagcaa atatatggaa acaggctgta gtggatgtca 1260 tggaaaagac aatgtttcta ttgaatcata ttgttgatgg ttctttggat gaaggtgtgg 1320 cctatggaag ctacacagct aaatccgtca cacagtatgt ttttctggcc cagcgccatt 1380 ttaatatcaa caacttggat aataactggt taaagatgca cttttggttc tattatgcca 1440 cccttttacc tggcttccaa agaactgtgg gtatagcaga ttccaattat aattggtttt 1500 atggtccaga aagccagcta gttttcttgg ataagttcat cttaaagaat ggagctggaa 1560 attggttagc tcagcaaatt agaaagcacc gacctaaaga tggaccgatg gttccttcaa 1620 ctgcccaaag gtggagtact cttcacactg aatacatctg gtatgatccc cagctcacac 1680 cacagccacc tgctgattat ggtactgcaa aaatacacac attccctaac tggggtgtgg 1740 ttacttatgg ggctgggttg ccaaacacac agaccaacac ctttgtgtct tttaaatctg 1800 ggaagctggg gggacgagct gtgtatgaca tagttcattt tcagccatat tcctggattg 1860 atgggtggag aagttttaac ccaggacatg agcatccaga tcagaactca tttacttttg 1920 cccccaatgg acaagtattt gtttctgaag ctctctatgg acccaagttg agccacctta 1980 acaatgtatt ggtgtttgct ccatcaccct caagccagtg taataagccc tgggaaggtc 2040 aactgggaga atgtgcgcag tggcttaagt ggactggcga ggaggttggt gatgcagctg 2100 gggaaataat cactgcctct caacatgggg aaatggtatt tgtgagtggg gaagccgtgt 2160 ctgcttattc ttcagcaatg agactgaaaa gtgtatatcg tgctttgctt ctcttaaatt 2220 cccaaactct gctagttgtt gatcatattg agaggcaaga agattcccca ataaattctg 2280 tcagtgcctt ctttcataat ttggatattg attttaaata tatcccatat aagtttatga 2340 ataggtataa tggtgccatg atggatgtgt gggatgcaca ttacaaaatg ttttggtttg 2400 atcatcatgg caatagtccc atggccagta tacaggaagc agagcaagct gctgaattta 2460 aaaaacgatg gactcaattt gttaatgtta cttttcagat ggaacccaca atcacaagaa 2520 ttgcatatgt cttttatggg ccatatatca atgtctccag ctgcagattt attgatagtt 2580 ccaatcctgg acttcagatt tctctcaatg tcaataatac tgaacatgtt gtttctattg 2640 taactgatta ccataacctg aagacaagat tcaattatct gggattcggt ggctttgcca 2700 gtgtggctga tcaaggccaa ataacccgat ttggtttggg cactcaagca atagtaaagc 2760 ctgtaagaca tgataggatt attttcccct ttggatttaa atttaatata gcagttggat 2820 taattttgtg cattagcttg gtgattttaa ctttccaatg gcgtttttac ctttctttta 2880 gaaaactaat gcgatggata ttaatacttg ttattgcctt gtggtttatt gagcttttgg 2940 atgtgtggag cacttgtagt cagcccattt gtgcaaaatg gacaaggaca gaggctgagg 3000 gaagcaagaa gtctttgtct tctgaagggc accacatgga tcttcctgat gttgtcatta 3060 cctcacttcc tggttcagga gctgaaattc tcaaacaact ttttttcaac agtagtgatt 3120 ttctctacat cagggttcct acagcctaca ttgatattcc tgaaactgag ttggaaatcg 3180 actcatttgt agatgcttgt gaatggaagg tgtcagatat ccgcagtggg cattttcgtt 3240 tactccgagg ctggttgcag tctttagtcc aggacacaaa attacatttg caaaacatcc 3300 atctgcatga acccaatagg ggtaaactgg cccaatattt tgcaatgaat aaggacaaaa 3360 aaagaaaatt taaaaggaga gagtctttgc cagaacaaag aagtcaaatg aaaggcgcct 3420 ttgatagaga tgctgaatat attagggctt tgaggagaca cctggtttac tatccaagtg 3480 cacgtcctgt gctcagttta agcagtggaa gctggacgtt aaagcttcat ttttttcagg 3540 aagttttagg agcttcgatg agggcattgt acatagtaag agaccctcgg gcatggattt 3600 attcaatgtt gtacaatagt aaaccaagtc tttattcttt gaagaatgta ccagagcatt 3660 tagcaaaatt gtttaaaata gagggaggta aaggcaaatg taacttaaat tcgggttatg 3720 ctttcgagta tgaaccattg aggaaagaat tatcaaaatc caaatcaaat gcagtgtccc 3780 tcttgtctca cttgtggcta gcaaatacag cagcagcctt gagaataaat acagatttgc 3840 tgcctactag ctaccagctg gtcaagtttg aagatattgt gcattttcct cagaaaacta 3900 ctgaaaggat ttttgccttt cttggaattc ctttgtctcc tgctagttta aaccaaatat 3960 tgtttgccac ctctacaaac cttttttacc ttccctatga aggggaaata tcaccaacta 4020 atactaatgt ttggaaacag aacttgccta gagatgaaat taaactaatt gaaaacatct 4080 gctggactct gatggatcgc ctaggatatc caaagtttat ggactaaaat aaa 4133 35 4689 DNA Homo sapiens misc_feature Incyte ID No 1958917CB1 35 cgcgcgtttc ctccccgctt gcccgcccag aggcccccgg ccacgctcct cgccgggctc 60 cgaccccgcc gcgccccctc cacgccccca gcgcgctgtg gccgcagcca gcgcgtgtcc 120 tgagtccgcc gttccggccc ggggctgccg gggaagttgg ggcgaggcgg gccggggatg 180 cgccatggcc atggcccggc tgggctcgtg gctcggggag gcgcagtggc tcgcgctggt 240 gtcgctcttc gtcgcggccc tggccacggt aggcctgtac ctggcgcagt gggcgctggc 300 cagggcgcga ccccagcccc agcggcgggc ggtggagcct ggagaggggc cgcgcccggg 360 gtccgacgcg ctgctctcct ggatcctgac gctgggcagc tggaggagcc agtggcaggc 420 ggcctgggtg accgccctga acgaggaggc cgagaggaaa gggggcccac ctttcctgtc 480 ctttgaggag ggcccgcggc agcaggcact ggagctggtg gtgcaggagg tctccagcgt 540 gctcaggtcg gcggaggaga aggtggtggt ctgtcacgtg gtgggccagg ctattcagtt 600 cttggtcagc gagacgcctg ccttgggtgc tggatgccgg ctgtacgaca tgcggctctc 660 ccctttccat ttacagctgg agttccacat gaaggagaag agagaggacc tccagattag 720 ctggtctttc atcagtgtgc cggaaatggc cgttaatatc cagcccaaag cactggggga 780 ggaccaggtg gctgagacaa gtgcgatgtc tgacgttctc aaggacatct tgaagcattt 840 ggctggttct gcctctccat cagtggttct gattaccaag cccacgactg taaaggaagc 900 tcagaactta cagtgtgctg catctactgc tcaggaatcc tgtcctccta aacctccaag 960 ggctcacgag ctgaagctac tggtgaggaa catccacgtc ttgctgctca gcgagcccgg 1020 tgcctcaggc cacattaatg cagtgtgcgt cgtgcagctg aacgatcctg ttcagaggtt 1080 ctccagcacc ctgacgaaaa acactccgga cctcatgtgg gaagaggaat tcaccttcga 1140 gttgaatgcc aagtcgaagg agttacacct gcagatttca gaggctgggc gatcctcaga 1200 aggtctgctg gcgacggcga cagttcctct ggacttattt aagaagcagc cttctgggcc 1260 acagagcttc acgctgacca gcgggtctgc ctgcggcagc tcggtgctgg gctcggtcac 1320 ggcagagttc tcttacatgg aacctggtga attgaaatcc tggcccatcc ctccccctgt 1380 tcctgctgca aaaatagaaa aggaccgcac ggtgatgccc tgtgggactg tggtcactac 1440 tgtcactgct gtgaagacca agcctcgcgt cgacgtgggg agggcgtccc cgctgagctc 1500 tgattctccg gtgaagactc ccatcaaggt gaaggtgatc gagaaggaca tctctgtcca 1560 ggccatcgcc tgccgcagcg cccccgtcag caaaacactc tcttcttcag acacagaatt 1620 gttggtgttg aatggttcgg atccagtggc tgaagtggcc attcgacagc tcagtgaatc 1680 ttcaaagctg aaactcaagt cgccacggaa gaaaagcact attatcatat cagggatctc 1740 caagacctca ctatctcagg accacgacgc tgccctgatg cagggctaca cggcctctgt 1800 ggacagcacc caccaggagg acgccccatc ccatccggag agggcggcag cctctgcccc 1860 gccagaggaa gccgagtcag cccaggcatc ccttgccccc aagccccagg aggacgagct 1920 agactcctgg gacttggaga aggagccaca ggccgcggca tggagcagcc aggtcctgct 1980 ggaccccgac ggtgatgagc tgtcagagag ctccatgagt gtcttggagc cgggcactgc 2040 caaaaagcat aaaggaggaa ttctaaggaa aggtgcaaag ctgttcttcc gccggcggca 2100 tcaacagaaa gacccaggca tgagtcagtc acacaatgac cttgtgttcc tggagcagcc 2160 agagggttcc cggaggaaag gcatcaccct caccaggatc ctgaacaaga agctgctctc 2220 caggcacaga aacaagaaca ccatgaacgg tgcccccgtg gagccctgca cgtagggcct 2280 gaggtcatca cctccaagcc agaagacgtg cacccatgtt aactaccctc accaggacgc 2340 agccagtgtg tccgccggat gtccagatgc cccgcttgtc ttgctgggtt tcttccaacc 2400 atctcgtcat ttaaagggaa aacaaaatct gagtctccag ccaggaggct tctcccagag 2460 aggacaaaaa agcccaactt gccaccagat gctaaatgag acttgacagc tgcagagctt 2520 gggctgtgct catagctaag ggttagggtt caatattaga aggagattaa cattataagt 2580 gaaataatat gctctaatag attgtggagg gcaggtttga gggacttagt ttacctattc 2640 tacactaaca agtgttgttt tgggtccatg cctggaccat gtcacaaaaa ggaggtgccc 2700 ccctgtgctg tcactgtgaa tggaaaggat gggtcacctc tcttcatctg ctgcttggaa 2760 taaaaaatgc agctggccct gagtacaggg aagtggaaca taggcaggat tttggattaa 2820 tagagaaatt ttgataagaa tggagacgct acgacagatg taggaagtca tctacctttg 2880 atattagcca tagaacttga acactaacta tatcctatgc atagtatgca gaacactttt 2940 ctaagtttac tttgagccta cttgcaagtg gaagatatat atattctcac atggttttta 3000 catttttctc tatcgtgtta gaagctctaa taatgctagt ggagcagttg acatccaggg 3060 ttttttttcc tgcctgtcat acttgctaaa caagagcaca gcgggcctgt cagatgaagt 3120 caggagccat acgtgaccgc tcgtagaaca cagtaaccaa acacatacat ggattttgcc 3180 aagtgctgcc agtagccaaa acaaagtctt tttagggcaa tagaggaaat tattttgtgt 3240 ctcaggtgtc agtcttagga atggaagttt aataacaaat gggccaaact cgcaggacat 3300 tccttctatg agcgcttcag aattttgctg tgaacagtcc tcttggacac aggttggggt 3360 gcccttgttt gggtttgttt tggtggaaaa catcacaaac ctggcacacc atttgaatat 3420 ccctaatatc attccagtcg ctttcctcat cagttgcctt tctatttcag ttcattcaca 3480 gatctcactt ctgaatgtgc cacttccagt agacatgctg gtcaaagagc agtcatcatt 3540 ggggtgaagt gttcttgaca gtttaatatg attcactttt ctccaaagac atgtaaaagg 3600 ctgttacgaa agcttggctt ctgtcatgga gacggaaatg ggcaagcttc cttccgtagc 3660 ctcttgttaa tccttaaaca ttaaatattt cgggggtaat agagccactg gtgagtaaaa 3720 acctatataa aaaccaaaat tataggattt tttctttttt agtaaaaacc tgtatcaaaa 3780 ccaaaattat aggatttttt tcttttttag taaaaaccta tataaaaacc aaaattatag 3840 gattttttct tttttagtaa aaacctatat gaaaaccaaa attataggat ttttttcttt 3900 tttagtaaaa acctgtataa aaaccaaaat tataggattt ttttttcttc ttttttagag 3960 agagagatta gaaaacgaca ttaggaattt cactttaaaa tgcgcattac aaacttctta 4020 ggtgttccag gaattatcaa gtgactttaa aatgactttt ccaacctgct ttgtttttaa 4080 aaattatatt ccagttttaa tcattgtaaa aaaagcacct ggagtttcaa aacatgtgaa 4140 tactaccaag tttctgtccc caaagtcagg catcactgct agtcttttgg gacagatggg 4200 acagatgttc actttaatgt tttacttgaa gttttactgc tctttgccat gtggtaaaaa 4260 gaggctgaga catatttaag aattccaaga ggatattatg tgtcagaatt tcagacactg 4320 atgagaagtt tttaattgtt cttttttatt tgattttgga attcaggtgc actctattca 4380 agtgcaagga tatcagaagt ttttttttat ttaaaaaatt tttttttcga gatggagttt 4440 cactctgttg cccaggctgg agtgcaatgg cagcttactg caacctccac ctcctggttc 4500 aagcgattct cctgcctcag cctcccaagt agctgggatt acaggcacgc gccaccacac 4560 ctggctaatt ctatttagta gaaatggagt ctcaccatgt tggtcaggct ggtctcgaac 4620 tcctgacctc aggtgatcca cccaccttgg cacttacata aaccgcggtc gnccttgcgg 4680 atttattat 4689 36 3294 DNA Homo sapiens misc_feature Incyte ID No 6219465CB1 36 atgggccggg cccggccggg ccaacgcggg ccgcccagcc ccggccccgc cgcgcagcct 60 cccgcgccac cgcgccgccg cgcccgttcc ctggcgctgc tcggagccct gctggccgcc 120 gccgctgccg ccgccgtccg ggtctgcgcc cgccacgccg aggcccaggc ggccgcgcgg 180 caggaactgg cgctgaagac cctggggaca gatggccttt ttctcttttc ctccttggac 240 actgacgggg atatgtacat cagccctgag gagttcaaac ccattgctga gaagctaaca 300 gggtcaactc ccgcggccag ctacgaggag gaggagttgc cccctgaccc tagcgaggag 360 acgctcacca tagaagcccg attccagcct ctgctcccgg agaccatgac caagagcaaa 420 gatggcttcc taggggtctc ccgcctcgcc ctgtccggcc tccgaaactg gacagccgcc 480 gcctcaccaa gtgcagtgtt tgccacccgc cacttccagc ccttccttcc cccgccaggc 540 caggagctgg gtgagccctg gtggatcatc cccagtgagc tgagcatgtt cactggctac 600 ctgtccaaca accgcttcta tccaccgccg cccaagggca aggaggtcat catccaccgg 660 ctcctgagca tgttccaccc tcggcccttt gtgaagaccc gctttgcccc tcagggagct 720 gtggcctgcc tgactgccat cagcgacttc tactacactg tgatgttccg gatccatgcc 780 gagttccagc tcagtgagcc gcccgacttc cccttttggt tctcccctgc tcagttcacc 840 ggccacatca tcctctccaa agacgccacc cacgtccgcg acttccggct cttcgtgccc 900 aaccacaggt ctctgaatgt ggacatggag tggctttacg gggccagtga aagcagcaac 960 atggaggtgg acatcggcta cataccccag gtgagcgcac aggaggctcc catccagatg 1020 gagctggagg ccacgggccc ctctgtgccc tccgtgatcc tggatgagga tggcagcatg 1080 atcgacagcc acctgccctc aggggagccc ctgcagtttg tgtttgagga gatcaagtgg 1140 cagcaggagc tgagctggga ggaggctgcc cggcgcctgg aggtggccat gtaccccttc 1200 aagaaggtct cctacttgcc gttcactgag gccttcgacc gagccaaggc tgagaacaag 1260 ctggtgcact caatcctgct gtggggggcc ctggatgacc agtcctgctg aggttcaggg 1320 cggactctcc gggagactgt cctggaaagt tcgcccatcc tcaccctgct caacgagagc 1380 ttcatcagca cctggtccct ggtgaaggag ctggaggaac tgcagaacaa acaggagaac 1440 tcgtcccacc agaagctggc tggcctgcac ctggagaagt acagcttccc cgtggagatg 1500 atgatctgcc tgcccaatgg caccgtggtc catcacatca atgccaacta cttcttggac 1560 atcacctccg tgaagcccga ggaaatcgag agcaatctct tcagcttctc atccaccttt 1620 gaagacccgt ccacggccac ctacatgcag ttcctgaagg agggactccg gcgtggcctg 1680 cccctcctcc agccctagag tgcctggacg ggatctgatg cacaggcccc cacgcctcag 1740 agccagagtg gtcctcagcc catttcagac tgcagatgcc gcccactccc accccactcc 1800 taggctgcct tggagggtac aagatccact gagggtggcc accacagcct tggctccatg 1860 gtggcgggta gacaagggat gcctgggctg actgggcaga ggaacctcta gctctgactg 1920 tcactcggct ctccctaccc atttggctct ggaagctgct tggccccccc agatcagggc 1980 ctgggtgaac tccctggacc tttcctagcc agccgcacag tctaggccct tgtggggtga 2040 agaatggagg gaggagcagg ctaggaagac ggggccacca ccctctcctt gctttcagcc 2100 cttcccacag gaaacatcaa gaagccccag ccaggagggg ccaggctgcc aaggcggctc 2160 ccctgtttat ctagagcctt cgttcctggc cataccccgg actgccctcc tgtgcctgat 2220 gtccccagct ggggtcagtc tcaacaggag ccagtcttct ggagcctctg ggcagaaccc 2280 tccatcagag tggaaatcag acgggacccc ctgcagcttc cctgaccacg ccactgacca 2340 gctatctggg gaagtttact gtgaaggggt ttctgccttt agcaatgggg ttcactaagg 2400 gggttcccga ggcccagggc caaggcactc ccaccgccta ccttagcaca gggtctctgc 2460 aggactgcgg gagccagcgc tcctgccgcc cctcttgccc ctcagacctt gcatccacag 2520 aagcacaacc cagccaaaca ccacagcctt ctccagagcc ggcactgtcc cggcaaccag 2580 gggtgcccca ggctagctct tctacctctg gggcaccacg gactcccctt ggccactctt 2640 gggactttgg tccacgtcct gagccactga ccacggccag tctctctttt tatatgtgca 2700 gaaaagtgtt tttacacaaa ctttctcatg gtttgtaggt atttttttat aaccccagtg 2760 ctgaggagaa aggaggggca gtggcttccc cggcagcagc cccatgatgg ctgaatccga 2820 aatcctcgat gggtccagct tgatgtcttt gcagctgcac ctatgggaag aagtagtcct 2880 ctcttccttc tcctcttcag ctttttaaaa acagtcctca gaggatccat gatccccagc 2940 actgtcccat cctccacaaa ggcccacagg catgcctgta ctctctttca ttaaggtctt 3000 gaagtcaggc tgccccctcc ccagccccca gttctctccc caccccctca ccccacccgg 3060 ggctcactca gcctggcaga ggaagaagga aggcagacat ctccgcagcc actcctgggc 3120 cttttatgtg ccgagttacc ccacttgcct tgggcgtgtc cactgagcct tccccagcca 3180 gtcttgttct caattttgtt ttgttttgtt ttgttttgag acggagtctt gctctgtcac 3240 ccaggctgga gtgctatggc tcgatcttgg ctcactgcaa cctccacctc ccag 3294 37 3635 DNA Homo sapiens misc_feature Incyte ID No 3576625CB1 37 atggccgctg ccgccctccc gccccggccg ctgctccttc tgccgctagt gctgctgctg 60 agcggccgcc ccacgcgcgc cgacagtaag gtgtttgggg acctggacca ggtgaggatg 120 acctcggagg gctccgactg ccgttgcaag tgcatcatgc ggcccctgag caaggacgcg 180 tgtagccgag tgcgcagtgg gcgggcacgc gtggaggact tctacacggt ggagactgtg 240 agctcgggca ctgactgccg ctgctcctgt accgcacctc cctcctctct caacccctgt 300 gagaacgagt ggaagatgga gaaactcaaa aagcaggcgc ccgagctcct caagctgcag 360 tccatggtgg atctcctgga gggcaccctg tacagcatgg acttgatgaa ggtgcacgcc 420 tacgtccaca aggtggcctc ccagatgaac acactggaag agagcatcaa ggccaacctg 480 agccgggaga atgaggtggt gaaggacagc gtgcgccacc tcagtgagca gttgaggcac 540 tatgagaatc actctgccat catgctgggc atcaagaagg agctgtcccg cctgggcctc 600 cagctgctgc agaaggatgc cgccgccgcc cctgccaccc ctgccacggg cactggtagc 660 aaggcccagg acacagctag aggaaaaggc aaggacatca gcaagtatgg cagtgtgcag 720 aaaagctttg cagacagagg cctcccaaaa cctcccaagg agaagctgct tcaggtggag 780 aagctgagaa aggagagcgg caagggcagt ttcctccagc ccacagccaa gccccgcgcc 840 ctggcccagc agcaggctgt gatccggggc ttcacctact acaaggcagg caagcaggag 900 gtgaccgagg cggtggcaga caacgccctc cagggcactt cctggctgga gcaactgccg 960 cccaaggtgg agggcaggtc caactccgca gagcccaact ccgcagagca ggatgaggct 1020 gagcccaggt cctccgagcg agtggacctg gcttctggca cccccacttc aatccctgcc 1080 accaccacca ccgccaccac caccccaacc cccaccacca gtctcctgcc caccgagcca 1140 ccttcaggtc cagaagtctc cagccaaggc agagaggcga gctgtgaggg caccctccgg 1200 gctgtggacc cccctgtgag gcaccacagc tatgggcgcc acgagggagc ctggatgaag 1260 gaccctgcag ctcgagacga caggatctat gtcaccaact actactatgg aaacagcctg 1320 gtggagttcc gcaacctgga aaacttcaag caaggccgct ggagtaacat gtacaagcta 1380 ccctacaact ggatcggcac aggccacgtg gtgtaccagg gcgccttcta ctacaaccgc 1440 gccttcacca agaacatcat caagtacgac ctacggcagc gcttcgtggc ctcctgggcg 1500 ctgctgcccg acgtggtata tgaggacacc acaccttgga agtggcgcgg acactcggac 1560 attgactttg ccgtggatga gagcggcctg tgggtcatct accccgccgt ggacgaccgc 1620 gatgaggccc agcccgaggt gatcgtcctg agtcgcttgg accccggcga tctctccgtg 1680 caccgggaga ccacgtggaa gacacggctg cggcggaact cctacgggaa ctgcttcctg 1740 gtgtgcggca tcctgtatgc cgtggacacg tacaaccagc aggaaggcca ggtcgcctac 1800 gctttcgaca cgcacacggg caccgacgca cgcccccagc tgccgttcct caacgagcac 1860 gcctacacca cccagatcga ctacaacccc aaggagcggg tgctgtacgc ctgggacaat 1920 ggccaccagc tcacctacac cctccacttc gtggtctgag tggagacctg tgctcccggg 1980 agaggggcag cagtgcggga ggggctttgc acagcagctc ctgcaactga cccagtccgc 2040 aaatatttat tgggggccag cccagggctg ggactgggca tgaggtggtc accaggattg 2100 agcttcctca gcacccagtg ggtaatactt gcttccactt gcagagcacc gtgccaagca 2160 cttcccacac acttacccgt ttgattctcc tagcacctcc cttggaggta gagatcatga 2220 acccatttaa cagacgagga gacaggctca gagaggcacc gtcccttgcc taacacctca 2280 gttgtgatca ggcaggctgt gctctcagga cagccccatt ttagggatga ggagacttca 2340 ccacgccctc ccctccctgc cctcccccat ctcccctggt ctcccttgtt ctctcaaccc 2400 agtctccctt cccagggcca ctcagaacca gaggtcttta gggccagtgt actggtgtgg 2460 ggtggaggcc ctggctctgc ctgccatcct agggccctgt tctggctgag ctgttggtgg 2520 ccctgggctt tgggcccctt agccaatgtc cttgtctctt gtctttggcc agccccctca 2580 gcccagccca ccccacccgc tgtccggcca cattccaaac ctctaccgtc acctagctgc 2640 tgagcagaaa ccgcaccccg agagaaaatc ccatcctctg ttccaaggcc cctgtctgct 2700 ctatgctcat ttttattttc tcttattctt catcagtgcc gtcatttgtt tctgcagcag 2760 cagctgagaa ggcagccggc agctctgcca gggtggggag ctgagctgag gctccctctc 2820 cacccagaag cactggcgtt gttcacatag tcaggccttg ggtcccctcc ctggttcatc 2880 ccagagcctt tgggcctgga gtccgccttg tcctttttct ctgggctttc aaacccacaa 2940 cctttacaca ctcagggata cctccgggtc tgccatgaat aagaccctag gcccaagtct 3000 ggtgtggtgc caggatggca cagtttccct cttccttgcc agccctgacc tggtcactgg 3060 gcaggctggc ccagcagcct gggggctgca gaagacatgg tgtgagtagt tgggtccagg 3120 ggaggcatca ggccttcttc tggttgcagg agagaaccag agggtgggaa cggggaggga 3180 agaactgagg gtctgcagac tggacttttc ctggctcgac ccaggacttg ggttgaggat 3240 gcacgggggc caccttgccc ggggccactg gtggctcccc agagcctcag acccacacag 3300 cccagaggac gaggccttca agcctgcccc tcttctgctt ttttagacag tatttttaga 3360 gctggaaaga aattttctag cccaactccc tgtttcatga aagagaaaag aggctcagaa 3420 aagtttagag agcagctcag tgtcacactg ggagctgggc acagccgatc tccttccaga 3480 agggttctgt ctgtatcctt tattctccgc accattccca tcacccgtga agagaagcct 3540 gctgtcaccg cagcccccaa gaaatagatg ccctttcttg aattgcattt tttaaaacaa 3600 gaaagtttcc ccaccagtga atgaaagtct tgtga 3635 38 635 DNA Homo sapiens misc_feature Incyte ID No 4765758CB1 38 caacaatgta ggttttaatt ttcacatttt atagatgtgg aaattgagag agaggttagc 60 tgacttaccc aaagtcacag taatatatca aatgcagaca ggatttgaac ccaggactct 120 agttctgttg tccgtggttt atgctcatcc ttcctgggct agaggagacc acagggcctc 180 cgttcacagg cataagacaa gagcccagtt tccagatctg gggtacaagg atgatgcata 240 cactgggaaa acttttaaga tttctttcaa gaacaagagt cctagagatt cggcctggct 300 gtgtctgtaa gtaagaatgt aatggctcta gagtgggaaa ttaaagttgc taagcaggtc 360 cttatccaca tttaatttca cccttcctca caatgacagc ttttttctca cttgctagtg 420 attaagtgca tggacttgaa gtcatatgaa cttggttgga aatgctgttt cataccctta 480 ctagctgcgt ggtcataggt aagttactta acctctctga gccctagctt tctcatctgc 540 agggctggta tctcacagga ttgtgaagag tcagtgagga ctgtgttgac atgtttatcc 600 taggcacagg ttgtcaggtc aacttagttg ttcat 635 39 793 DNA Homo sapiens misc_feature Incyte ID No 7236661CB1 39 ggcgcccgtg gcttgtgtgt gtggtttccc ttctggtgcc ctactcggga ggttgttgct 60 ttgccccatg acaggaagga tcagcgtttc tcctcttagc aaactgtgag gctggatgca 120 gagattcaga tactgctttt gtagatgtgg tcggggcata tctggttgtg ttttctctcc 180 catgtttcat ggggaagtga agctcccgtg gcctcctttg ggggcctttg cctctgtccg 240 ctggtgatac aggggtcggt atcagagacc tcttggcacg aaaccttgtg ggacccacat 300 tggggctctg gctctgggca cagaaggata caacaaatca aagttcggca gcctgtgctt 360 ctgccattaa gtaaaccctt tcagtggctg catttttctg atctgggttt aacctcaaag 420 aggaagagct ttgacgccgg gttccagctt cctcatcctg gtgagtgtgc cgaagaggga 480 gaagcaacgg aggtggacaa acggcacctg tcagaggcga aagctgctgt cagattggcg 540 aggaagtcct taaaatggtt gtgtgctttc cgccgggtgg ctgtgccatg gcctctctgg 600 ttggcacctt gatggcagcc cgcccccagg taccatgttg ccatggcgtc tccatgcagg 660 agcacaccct tcatgaccac agctccggga agcagggtct ctgttccttg tcccgagaga 720 cccacggaaa aaattcctct tcctcatggc aagagggact cctctcccac gggggaggct 780 cacagacgtc tgt 793 40 2741 DNA Homo sapiens misc_feature Incyte ID No 7714187CB1 40 ctctgatggc tgttctccta gtccccaaga gttgaaccgg agaggctttt actttgcacc 60 aggtcgagaa cgtgatcagc cctttagaga aggaacctcc ttgtaacagg aattctgctg 120 ggaaacgccg tgtaggcact acctccgaag ataagatgca tgtttggagc tgtgtaaaat 180 gcccactggc tgtttgaaag aaggaaaagg tgactagggt tgcaaattaa ccttagtatc 240 acttaaaaat attctatcta gtcaaatgta cgtaagcaaa gaagagagca ccaggatata 300 aaactgccac agcagcttgg aagacagatg attcagattt tggggacttt cttttgcgtg 360 ttacatagat ttgtttgtca tcatgcagtt aagcaggtgt tgagggaaag ctgagagaat 420 gaaggctcta aatccccagt ggaagcatga tatggcgaag cagagctggt gctgaattgt 480 tctctctgat ggctctatgg gagtggatag cactgagtct tcattgctgg gttttagcgg 540 ttgctgctgt ttcggatcag catgccacaa gccccttcga ctggctcctc tctgataagg 600 gacccttcca tcgctcacag gaatacacag attttgtgga cagaagccgg cagggattta 660 gcacaagata caagatatac agggagtttg gccgctggaa agtaaataac cttgcagttg 720 agagaagaaa tttccttggc tctcctctgc ctcttgcccc tgaattcttc cgcaacataa 780 gacttttggg acgtcgacct acccttcagc aaatcacaga aaaccttatc aagaaatatg 840 ggacacattt cttgctatct gctactctgg gaggagagga gtcactcaca atttttgtgg 900 acaagcggaa gttgagcaaa cgagctgaag gaagtgattc caccaccaat agctcttcgg 960 tcactctgga gacgctacat cagctagccg cttcttattt cattgacagg gacagcaccc 1020 ttcggagact tcaccacatt caaattgcat ccactgccat aaaggtaaca gaaacacgga 1080 ctggtcctct tggctgcagt aactatgaca acctagattc tgtcagttct gttctggttc 1140 agagtcctga gaataagatt cagttgcaag ggcttcaagt acttctccca gactatcttc 1200 aggaacgttt tgtacaagca gctttgagct acattgcttg caattcagag ggagagttta 1260 tctgcaagga aaatgactgc tggtgtcact gtggtcccaa atttccagaa tgcaactgcc 1320 cctccatgga cattcaagcc atggaagaga atcttcttcg aataactgaa acctggaaag 1380 cttacaacag tgactttgag gaatcagatg aattcaagtt atttatgaaa aggctaccta 1440 tgaattattt cctcaacaca tctactataa tgcatttgtg gacaatggat tctaattttc 1500 agcgccgtta tgaacaactg gagaacagca tgaaacaact tttcctaaag gcgcagaaaa 1560 ttgtacacaa gctttttagc cttagcaaga ggtgtcataa acaacccctc atcagcctgc 1620 caagacaaag aacctcaacc tactggctta ctcgcatcca gtcttttctc tactgcaatg 1680 agaacggcct cctaggcagc ttttcagaag agacgcactc gtgcacgtgt ccgaatgacc 1740 aggtggtctg caccgcgttc ctgccctgca cagtgggaga cgcctctgcc tgcctgacat 1800 gcgcaccaga caaccgcacc cgctgcggca cctgcaacac cggctacatg ctcagccagg 1860 ggctctgcaa gcctgaagtc gccgagtcca ccgatcacta tattggcttt gaaactgacc 1920 tgcaagatct cgagatgaaa tatctgctgc agaaaacgga cagacgaata gaagtccatg 1980 ccatttttat cagcaatgac atgcgcctca atagctggtt tgatccctcc tggcgtaagc 2040 ggatgctcct caccttgaag agcaataagt acaagtcaag tctggtccat atgattttgg 2100 gtctctcttt acagatttgc ttaactaaaa acagcacctt ggagccagtg ttggctgttt 2160 atgtcaatcc cttcggaggc agccactctg agagctggtt tatgcctgtg aatgaaaaca 2220 gctttccaga ctgggagcgg actaagttgg acctacccct gcagtgttat aactggacat 2280 taactctggg gaacaaatgg aagacatttt ttgagacagt acacatctac ctgagaagtc 2340 gcatcaagtc caatggtccc aatggtaatg agagcattta ctatgaacct ctggagttta 2400 ttgacccttc ccggaacctg ggctatatga aaatcaataa cattcaagtg tttggctaca 2460 gcatgcactt tgaccctgaa gcaattcggg acctgatttt gcagctggac tacccctata 2520 ctcagggatc ccaggattca gcacttttgc aactactaga gatcagagac cgtgtaaata 2580 aactctcccc acctggtcag cgtcgtctag atcttttctc ttgcttgctt cgtcatagac 2640 tcaagctgtc tactagtgag gtggtgagga tccaatctgc tctgcaggcg tttaatgcca 2700 aattgccaaa cacaatggat tatgacacga ccaaattatg t 2741 41 1074 DNA Homo sapiens misc_feature Incyte ID No 5136540CB1 41 gcgaacccca ggcccttccc aggtttgcgc gcggtggcca tccagaccct gcggagagcg 60 aggcccggag cgtcgccgag gtttgagggc gccggagacc gagggcctgg cggccgaagg 120 aaccgcccca agaagagcct ctggcccggg ggctgctgga acatgtgcgg ggggacacag 180 tttgtttgac agttgccaga ctatgtttac gcttctggtt ctactcagcc aactgcccac 240 agttaccctg gggtttcctc attgcgcaag aggtccaaag gcttctaagc atgcgggaga 300 agaagtgttt acatcaaaag aagaagcaaa ctttttcata catagacgcc ttctgtataa 360 tagatttgat ctggagctct tcactcccgg caacctagaa agagagtgca atgaagaact 420 ttgcaattat gaggaagcca gagagatttt tgtggatgaa gataaaacga ttgcattttg 480 gcaggaatat tcagctaaag gaccaaccac aaaatcagct cttcagccgt ctatgaaagg 540 gggaggcaca ctccctccat cattttcaga agacctgagg aggctgcctt gtctccattg 600 ccgccttctg tggaggatgc aggattacct tcttatgaac aggcagtggc gctgaccaga 660 aaacacagtg tttcaccacc accaccatat cctgggcaca caaaaggatt tagggtattt 720 aaaaaatcta tgtctctccc atctcactga ctaccttgtc attttggtat aagaaatttg 780 tgttatttga taggccgggc atggtggctc atgcctgtaa tcccagcact ttgggaggcc 840 aggagttcga gaccagcctg gccaacatgg tgaaacccgg tctctactaa aaattcaaaa 900 attacctagg cgtcatgggg catgcctgta gtcccaccta cttgggaggc tgaagcagga 960 gaattgctcg aacctgggag gcagaggttg cagtaagctg agatcacgcc actgcattcc 1020 agcctgggcg acagagcaag actccatctc aaaaataaaa taaaaaaaaa aggg 1074 42 2560 DNA Homo sapiens misc_feature Incyte ID No 3277403CB1 42 gcggcagctg agcagaggcg gcggcgcggg acctgcagtc gccaggattc cctccaggtg 60 acgatgctct ggttctccgg cgtcggggct ctggctgagc gttactgccg ccgctcgcct 120 gggattacgt gctgcgtctt gctgctactc aattgctcgg gggtccccat gtctctggct 180 tcctccttct tgacaggttc tgttgcaaaa tgtgaaaatg aaggtgaagt cctccagatt 240 ccatttatca cagacaaccc ttgcataatg tgtgtctgct tgaacaagga agtgacatgt 300 aagagagaga agtgccccgt gctgtcccga gactgtgccc tggccatcaa gcagagggga 360 gcctgttgtg aacagtgcaa aggttgcacc tatgaaggaa atacctataa cagctccttc 420 aaatggcaga gcccggctga gccttgtgtt ctacgccagt gccaggaggg cgttgtcaca 480 gagtctgggg tgcgctgtgt tgttcattgt aaaaaccctt tggagcatct gggaatgtgc 540 tgccccacat gtccaggctg tgtgtttgag ggtgtgcagt atcaagaagg ggaggaattt 600 cagccagaag gaagcaaatg taccaagtgt tcctgcactg gaggcaggac acaatgtgtg 660 agagaagtct gtcccattct ctcctgtccc cagcacctta gtcacatacc cccaggacag 720 tgctgcccca aatgtttggg tcagaggaaa gtgtttgacc tcccttttgg gagctgcctc 780 tttcgaagtg atgtttatga caatggatcc tcatttctgt acgataactg cacagcttgt 840 acctgcaggg actctactgt ggtttgcaag aggaagtgct cccaccctgg tggctgtgac 900 caaggccagg agggctgttg tgaagagtgc ctcctacgag tgcccccaga agacatcaaa 960 gtatgcaaat ttggcaacaa gattttccag gatggagaga tgtggtcctc tatcaattgt 1020 accatctgtg cttgtgtgaa aggcaggacg gagtgtcgca ataagcagtg cattcccatc 1080 agtagctgcc cacagggcaa aattctcaac agaaaaggat gctgtcctat ttgcactgaa 1140 aagcccggcg tttgcacggt gtttggagat ccccactaca acacttttga cggtcggaca 1200 tttaactttc aggggacgtg tcagtacgtt ttgacaaaag actgctcctc ccctgcctcg 1260 cccttccagg tgctggtgaa gaacgacgcc cgccggacac gctccttctc gtggaccaag 1320 tcggtggagc tggtgctggg cgagagcagg gtcagcctgc agcagcacct caccgtgcgc 1380 tggaacggct cgcgcatcgc gctcccctgc cgcgcgccac acttccacat cgacctggat 1440 ggctacctct tgaaagtgac caccaaagca ggtttggaaa tatcttggga tggagacagt 1500 tttgtagaag tcatggctgc gccgcatctc aagggcaagc tctgtggtct ttgtggcaac 1560 tacaatggac ataaacgtga tgacttaatt ggtggagatg gaaacttcaa gtttgatgtg 1620 gatgactttg ctgaatcttg gagggtggag tccaatgagt tctgcaacag acctcagaga 1680 aagccagtgc ctgaactgtg tcaagggaca gtcaaggtaa agctccgggc ccatcgagaa 1740 tgccaaaagc tcaaatcctg ggagtttcag acctgccact cgactgtgga ctacgccact 1800 ttctaccggt cctgtgtgac agacatgtgt gaatgtccag tccataaaaa ctgttattgc 1860 gagtcatttt tggcatatac ccgggcctgc cagagagagg gcatcaaagt ccactgggag 1920 cctcagcaga attgtgcagc cacccagtgt aagcatggtg ctgtgtacga tacctgtggt 1980 ccgggatgta tcaagacctg tgacaactgg aatgaaattg gtccatgcaa caagccgtgc 2040 gttgctgggt gccactgtcc agcaaacttg gtccttcaca agggaaggtg catcaagcca 2100 gtcctttgtc cccagcggtg acctttgttt cgatccttaa gactctgaaa tctggtgact 2160 ttgacactga agcggaagag ccaatgaagg actgcagtat ttgtgtgccc gattctgtaa 2220 acacacacac acagagtata tatgtgtata tatatataga tatattcaaa aacattgcat 2280 catttatatg aactataggg ggattattat atgtatattt tttgctataa gacatgtatt 2340 gtttctagga tcctaacctg taagccattg aacatgttgt ataaatacac caggtgtttt 2400 taatttaata aggtggcatg cagatacatt ggatagtgtt aacatcacat acatttgtca 2460 tttttaagga agttttctaa gagccctcaa ttgcctgcct gtattaattt tagttttgat 2520 caggagttgg gggatccact atttaacgcc gcacccgtgt 2560 43 5833 DNA Homo sapiens misc_feature Incyte ID No 1517569CB1 43 ctcctctcag aaatcgatga gtgccggtct cagccgtgcc tgcatggggg ctcttgtcag 60 gaccgcgttg ctgggtacct gtgcctctgc agcacaggct atgagggcgc ccactgtgag 120 ctggagaggg atgagtgccg agctcacccg tgcagaaatg gagggtcctg caggaacctc 180 ccaggggcct atgtctgccg gtgccctgca ggcttcgttg gagtccactg tgagacaggt 240 aggggctccc tccagtgggc cccacatgca gagcctgggc ctctggaaga tcagagagga 300 ggtggggcat ccccacattc cctgctgggc aggccacctg gggagaggga cccccagggc 360 tgcggccacc ttgggaggga ggggtggagg tgagggtgct ggggagggct gaggggcggg 420 acctgcccac tgcccctctc tcctggcctc cgcccctaga ctcctccttt cccttcttcc 480 cgctgtcctc tcctccctcc cccagactcc ccccttgcag cttgggccca ctctctgggt 540 gttctccaga ggtggacgcc tgcgactcca gcccctgcca gcatggaggc cggtgtgaga 600 gcggcggcgg ggcctacctg tgcgtctgcc cagagagctt cttcggctac cactgcgaga 660 cagtgagtga cccctgcttc tccagcccct gtgggggccg tggctattgc ctggccagca 720 acggctccca cagctgcacc tgcaaagtgg gctacacggg cgaggactgc gccaaagagc 780 tcttcccacc gacggccctc aagatggaga gagtggagga gagtggggtc tctatctcct 840 ggaacccgcc caatggtcca gccgccaggc agatgcttga tggctacgcg gtcacctacg 900 tctcctccga cggctcctac cgccgcacgg actttgtgga caggacccgc tcctcgcacc 960 agctccaggc cctggcggcc ggcagggcct acaacatctc cgtcttctca gtgaagcgaa 1020 acagtaacaa caagaatgac atcagcaggc ctgccgtgct gctggcccgc acgcgacccc 1080 gccctgtgga aggcttcgag gtcaccaatg tgacggctag caccatctca gtgcagtggg 1140 ccctgcacag gatccgccat gccaccgtca gtggggtccg tgtgtccatc cgccaccctg 1200 aggccctcag ggaccaggcc accgatgtgg acaggagtgt ggacaggttc acctttaggg 1260 ccctgctgcc tgggaagagg tacaccatcc agctgaccac cctcagtggg ctcaggggag 1320 aggagcaccc cacagagagc ctggccaccg cgccgacgca cgtgtggacc cggcccctgc 1380 ctccagcaaa cctgaccgcc gcccgagtca ctgccacctc tgcccacgtg gtctgggatg 1440 ccccgactcc aggcagcttg ctggaggctt atgtcatcaa tgtgaccacc agccagagca 1500 ccaagagccg ctatgtcccc aacgggaagc tggcgtccta cacggtgcgc gacctgctgc 1560 cgggacggcg gtaccagctc tctgtgatag cagtgcagag cacggagctc gggccgcagc 1620 acagcgagcc cgcccacctc tacatcatca cctcccccag ggatggcgct gacagacgct 1680 ggcaccaggg aggacaccac cctcgggtgc tcaagaacag accgcccccg gcgcgcctgc 1740 cggagctgcg cctgctcaat gaccacagcg cccccgagac ccccacccag ccccccaggt 1800 tctcggagct tgtggacggc agaggaagag tgagcgccag gttcggtggc tcacccagca 1860 aagcagccac cgtgagatca caacccacag cctcggcgca gctcgagaac atggaggaag 1920 cccccaagcg ggtcagcctg gccctccagc tccctgaaca cggcagcaag gacatcggaa 1980 acgtccctgg caactgttca gaaaacccct gtcagaacgg aggcacttgt gtgccgggcg 2040 cagacgccca cagctgtgac tgcgggccag ggttcaaagg cagacgctgc gagctcgcct 2100 gtataaaggt gtcccgcccc tgcacaaggc tgttctccga gacaaaggcc tttccagtct 2160 gggagggagg cgtctgtcac cacgtgtata aaagagtcta ccgagttcac caagacatct 2220 gcttcaaaga gagctgtgaa agcacaagcc tcaagaagac cccaaacagg aaacaaagta 2280 agagtcagac actggagaaa tcttaaggat ttaagacgtt cttgttacac tccaccaacc 2340 tcacgagttt ctaacaccca ggaagatgag gtctaaaaac tggatgaaaa aggacaccct 2400 gagaaaaggt cctagctgga gtcagtcccc tctgtgacct ctctcctcag gcctctagag 2460 gacagatggc caggcctgtg cacacaccag cccaccctga gagacccctc tgggaccaac 2520 cacctgtgag tcctgcgatg cgtttaagca gcctgtgccc tcacccaagc tgcagttcct 2580 gaaggtgtag tctgtgtctc tgcggatgag atgacagctc gccattcccc ggaatcagtg 2640 aggctgtcag tcagccacgc ttctgcagta tgcagaaacc tgttcttaga ctccaaagcc 2700 agagaaagaa ttctcccttc gaggcccaac aaattgagaa ggaactgtga tggaccactt 2760 ccaaaacaga gacgggggca ggggctgaag ggcagagacc aggtgatgtc agaaggaaag 2820 ccgggttgca gacacagccg cccctgctct ggtcctccag cgtgtttatg acgctcgtgc 2880 aggtcgacga gccatcctat ggactagtta acactaaggt ggagttcaga cttttttaga 2940 caacggcgcg actggcagcc tttctctatc aagggtcaga cggtaaacgt tttcagcttt 3000 gcagaccaga ggtccctgtg gctacagtag cgcagacaca gccacaggca tgtcattgaa 3060 tggctgcggc tatgttccaa taaaaactta tttacaataa caggtggtgg ccaaattggc 3120 ccatgggcct tatttggtga accctgttct atgagatcac ctaggcttca gccttaaaca 3180 gtggaagcca tcccctgaat gacaagtcac aagggtatca aagaaagacc cctgaatttt 3240 catggaaaaa gctattcaga cccctgcttg gaaagctaag gcacactgcc acgaagcagc 3300 aaggacgcct tacaagtctc agtgcaacag agatggacac ctgggctggg ctggacaatg 3360 tttaaggttc cttttagtcc atgactcaag tgatactgtt ttaggctatc aggtagtaaa 3420 cacgatctta gacatcccca tctttgtaag cagaacagta cggcacttca ccacatctgc 3480 ttcccaccat gcttctaagc agctgtcttc cccctgctaa tgttacaacc aaagcagcca 3540 ccccacctcc tctcgtgttg agcctcacga ccgctgaccc agctggaaag ccagcgccct 3600 gccgcgtcac cctgactctg ctcagagcca gcattccagc cacaaagagg gcctccttcc 3660 tttcctcttt cataaaaatg ttttttgaag agttagagta tattttaggc tttttatctt 3720 tattaaaatt tcatgtgcat gtgtctgtgt attctgcaat ttgtcatttt cagaaagaag 3780 gaacaggcaa ttcgcgaagt ttcacctgta ctcccgagct gttccccagg ctccagaccc 3840 acttgagagc agaaggtgga gctcaatgaa gggtctcgag ctcagcgaag ggtcactggg 3900 tgaactgaga gaaaccacgt tcacaaacgc gtactgcgga cttcctgccg ccctgggacc 3960 tgtcactgtt tgtccatgta agctacagca ttactagcag atgctaagat cgagtgatat 4020 cactggaaaa gtaggtgaat cctactagga aactttctac tccctactag gacctcaagc 4080 ccctcagcca cacagcaaat gctaatatgc tccagtgtta gcttagaagc cttgtgtcaa 4140 caagaactgg ctcctgagtc ccaagcttgg tgccacacag caaatgctaa tatgctccag 4200 tgttagctta gaagccttgt gtcaacaaga actggctcct gagtcccaag cttggtgcca 4260 cacagcaaat gctaatatgc tccagtgtta gcttagaagc cttgtgtcaa caagaactgg 4320 ctcctgagtc ccaagtgctg tcacaggact tgcccattgg gatgttttcc acattaaata 4380 tcaagtaaaa agacttcctg gtgctcagga attacagttc gttcttgaaa cattccaaag 4440 aggccaccac agcttttccc atgtggcttc ttttaaaaac tcaaatggct tccttgaaaa 4500 tactcaaagt ccacccaagg aaattagtaa taatagaatc agaaaactgt caggagcata 4560 aagatttctg tatcaaaatg aaagaagcaa tcctgagttg ctgaattacc catctgctaa 4620 tgaaaccggg atggactgat catctaacca agtgcagact gaggattcta cttagtcctc 4680 cgactgggta caacaacagc ctaggttcta gggagggtgg cagtgaccgg gatgccacaa 4740 tggaagagaa aatgaaaaca ctggcacagt gaaatgtctc atttccaaac agttttgcct 4800 atggccaagc aaggcaataa agacaaactc tcccttttcc ccattgcgtg tgggctgcca 4860 ggtacaagta agggaatctt tgctgtgccc actgtcctcc agtagagaac ccaacaggca 4920 agggccccac tcaggtatca gctcacctcc tgcacctccc cttagcagga actccttcca 4980 ctggcaaagg actgccactg ccatctgact caactgtggc gatgtggacg gagtcaccga 5040 gctgcttttc ttttgcaaaa caaaagtctt tttctttgca gtcacgctgt aagacgaggc 5100 tgctggagaa aacaaaagca cctagatttc agtgctgaat ccccacaatt gcatgcagct 5160 cacacctacc aggggtattc cagtgcatag gggaaaggaa cccggctgaa aaaccagctc 5220 cttatttttc ttttaaataa aataatacga tcctaagtcc atttaccatc tgaagttgtc 5280 acgagtgaac agtcacatta ctgttgtgga ccaggcctta gatgagtttc tcaggctcag 5340 cactgacatt ctgggccgga tcatcctctc ttgtgggacc atcctgtgca ctgcaggatg 5400 tttcacagca cccctggcct ctacccacta gaatcctaca atctaccaga tcctaggatc 5460 tagttgatcc tagaatgcta ccaaggagac ttgaattttg gtcccatcat caaaaatgcc 5520 ttctgcatca atcctatgcc agtttcccct aaaagagggc taactggaat gttctaggat 5580 gtaccaatcc tccaggaccc tcttagagct catgccatca gagacaggcc tctatctcag 5640 ggatcacccc ggctgacatc aaattcctct tctcttttcc caacatttca aattgttctt 5700 cggactcatt gagttcccta aggtgacacc cccccccccc ccccacaccc accttggggg 5760 gtcacggatt gctccctgtg gccctggctt cagcccacct gctccatgac cccatgctct 5820 tctcctctgg ttc 5833 44 2264 DNA Homo sapiens misc_feature Incyte ID No 2415991CB1 44 gtaagcccta atatacacta cataaaaacg ttagggctgc ctgtaatccc agcactttgg 60 gaagctgagg tgggtagatc acttgaggtc aggagttcga gaccagcctg gccaacatgg 120 cgaaaccctg tctctactaa aaatacaaaa ttttagctgg gtgttatggt gggcacctgt 180 aatcccagct actttgaaga tgaggtagca gactcacttg aaccagggag gcggaggttg 240 cagtgagcca agattttgcc actgcactcc agcctgggtg acagagcaag actctgtctc 300 acaaaaaaaa aaaaaaaagg gggctgtaca taggcagcaa actaagctgc agtgatgttg 360 cctatattta aattttctca aatggccaag ctctgatggt ctactttatt tgagcaatag 420 ttgagactta taattgccta taaataaaca aacaaatgaa ctatttgttt ttttttctca 480 caacatctgg cctatattgt ctgtcaggaa gccatggctc caatgtaaag tacatagttc 540 ttacatactt caactgcagc tggtccctga cctcaccagg tttcagagat gttcttaaag 600 gaagccagct gtggcaggtc acagattcat gggaaatgga aagaaccaag gaatatagct 660 cttgcctcac ctttctaccc actgcagata tagttcaagc cagagtaatg gaagaactta 720 acttactagc ctctcaggct gctcctatcc ctacctccca gtgtacagcc cctccccatc 780 tctttagtcc cctttccctc acttcccctt ttataatgtc acacaaatca gggacagtag 840 gatcacatta taacctactt tgtcataggg attcgatttt tcttatatca aatcatgttt 900 cctgaaaccc agctggggca tatgcactca atgtctaata catacttatt aatgtaccgg 960 atattggcct tgcccctgga tatcagcaat atattataaa aggttccagt agatgagacg 1020 attgagtctg aatacaattg cagtaaattg tgccaataaa gatattgtac tgttacggtc 1080 ttagagttaa agccgcttga atgcagcatg cacattcatg taaacagaca atcagggtag 1140 gcctagaata accacaaaaa ttctattggc cttactgcag ccacctatat gtagaacaat 1200 ggaggagata gtttgtggtc cattattgta ccctgtttca tccattagca tcagaatctc 1260 tctttcaggt catttattaa atatgattga aatgtttaaa agttcctgaa catgattcat 1320 gatgattaaa atatcataca actgataaaa gactttaaga actttatata tttcctgttg 1380 cctcaaaatg taacagaaat tattcttaga gctttgattt tagctatcct aattactgca 1440 aataaatatt tgttcttata gttttaaatc aaaaagaaaa gtcttgttat aaaaccttaa 1500 gcttgaaatc atattaataa aatgtattgt acatagtgga aaattttcag tagctaattt 1560 aaaatttcag aaaatgctat taaagaattt tgattcaagt atttaaactg tttagttatg 1620 catgcttctt attaaccgaa aatgataata ccatttagtt tagtgatcag tatgagaagc 1680 aatacctaat cctatgttgc tattgtattt tttcctagtt ggtgtgcctg ctcagaaaaa 1740 catatactgt atgtgtatac atacctgtgt atatataaaa ggtcaattta tatatttttc 1800 tataggaaaa tggagtaaca agttccctat ctcccatatt tatttgtcca tagtaaaatg 1860 gccacattga tgataatttc tagaactagt ttctgagatt gtcagccctt tgtctaaaat 1920 aatggcagta ttaatgattg acttctgtca ctgccatagt tacctggatt gtcagccttg 1980 gtagcctttg tctaaagtcc taaagagttc caaaaaaaat gtgttgaaat ttaattgcta 2040 aatagtggtt ggtgattctt tacagtagga attgtaataa ttttcttgca aataagttat 2100 ttactgctat tgatattgaa taatttgtct tttattcaga tatatttcaa aaagcatgaa 2160 tatatgatta ttcataaatt gtatacttta ccagtaagtt ttcagaggaa ataaagactt 2220 ttaaatcctt aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 2264 45 1638 DNA Homo sapiens misc_feature Incyte ID No 2735742CB1 45 tcgagctggc cactattacg gcgcagtgtg ctggaaaggg tctgaatcta aagcagaggc 60 agcataacta tcttcacgac tcctgtttgt tgttgttgct ttaaatctag aataccctgt 120 catgatggaa attgactata atacaactgt aattttaaat agcacattaa attattatgt 180 acctatcact tttgtgcgtg ctagtgtatc aaaaaggtat tgttatacat atactaaata 240 tatgacattt gagaaacact gttggtattt tacttctgta gaataattca gatgagacta 300 aaggccttat aagtctactt attttgctgc ggtgaggcct ggtctccggc tgccagacca 360 tgctgagtgg agcacgctgc aggctcgcct cagcgctgcg gggaacgcgc gcgccgccgt 420 ccgcggtcgc ccgtaggtgc ctgcacgcgt cggggtcgcg gcctttggcc gaccggggca 480 agaagactga ggagccgccc cgcgacttcg atccggcgct gctggagttc ctggtgtgcc 540 cgctctccaa gaagccgctc agatatgaag catcaacaaa tgaattgatt aatgaagagt 600 tgggaatagc ttatccaatc attgatggga tccctaatat gataccacag gcagctagga 660 tgacacgtca aagtaagaag caagaagaag tggagcagcg ctagttcata atttaaaaaa 720 attaaaaaaa cgcaacagcc aacttttctt aataccatat accttttaaa acacagtggc 780 aggtaataag tggaagagaa gaatgtttct gtctcttcct acgttgactg ttcttattcc 840 actggtttct ttagcaggac tgttctactc agcctctgtg gaagaaaact tcccacaggg 900 ctgcactagc acagccagcc tttgctttta cagcctgctc ttgcctatta ccataccagt 960 gtatgtattc ttccaccttt ggacttggat gggtattaaa ctcttcaggc ataattgatg 1020 caactagagt caatatgctg tatatattaa tgatagctct tgggcatcga tctctgaaag 1080 ctcaaatgga tggaatttag tttgcgggaa agaggctttg ctttgcgcat atcaggctta 1140 ggactgtggg aggcttaagt tgcagatgct tcttttattg tactcttgtt ctgcccttgt 1200 tttttgaagg ctctgactta taactgctgt atcagaagaa acattttgac agtgtcttgg 1260 ttggagatga acatccctaa ttgacatgtg atgactattt cttattccat tcatctaaga 1320 gtcattgaaa ttttgttttg cttgtttgtt tagcttcaag gtctttggta aagtcacatg 1380 ttaaggatga ctgaaataat tccaaaggag tgatgttgga atagtccctc taagggagag 1440 aaatgcattt gaacgaatgt gatataaaac cacataatca aatagaaact tcatgtactt 1500 acaaaaactg agtttgtaaa attaccttca tttctttgac attaaatgct tatattagca 1560 ataaacatgt tgacactttc ctataaaaaa taaaccagtt tgcagtaaaa aaaaaaaaaa 1620 agggcggccg ccgactag 1638 46 4790 DNA Homo sapiens misc_feature Incyte ID No 2768535CB1 46 gacgtctttc ttaccttttt ttctgaactt ctaggccttc tctttccaga actggtggaa 60 gacaaatgaa acggccaaga tggtaagaaa caagccgcat ttctccttgg ggagactgat 120 aatttaaaag gtttgttgtg tcagaaacat tcccagcttc atcaccaacc ctttccttcc 180 acctctgccc actggagacc acttacatcc cgaagcggac gcggcagctg aagtcaggaa 240 accatgcatc acattagcag gagccaactg cagactttaa actccgttca acatgtggat 300 gcggcagaga aatgacctgt ccagacaagc cggggcagct cataaactgg ttcatctgct 360 ccctgtgcgt cccgcgggtg cgtaagctct ggagcagccg gcgtccaagg acccggagaa 420 accttctgct gggcactgcg tgtgccatct acttgggctt cctggtgagc caggtgggga 480 gggcctctct ccagcatgga caggcggctg agaaggggcc acatcgcagc cgcgacaccg 540 ccgagccatc cttccctgag atacccctgg atggtaccct ggcccctcca gagtcccagg 600 gcaatgggtc cactctgcag cccaatgtgg tgtacattac cctacgctcc aagcgcagca 660 agccggccaa tatccgtggc accgtgaagc ccaagcgcag gaaaaagcat gcagtggcat 720 cggctgcccc agggcaggag gctttggtcg gaccatccct tcagccgcag gaagcggcaa 780 gggaagctga tgctgtagca cctgggtacg ctcagggagc aaacctggtt aagattggag 840 agcgaccctg gaggttggtg cggggtccgg gagtgcgagc cgggggccca gacttcctgc 900 agcccagctc cagggagagc aacattagga tctacagcga gagcgccccc tcctggctga 960 gcaaagatga catccgaaga atgcgactct tggcggacag cgcagtggca gggctccggc 1020 ctgtgtcctc taggagcgga gcccgtttgc tggtgctgga ggggggcgca cctggcgctg 1080 tgctccgctg tggccctagc ccctgtgggc ttctcaagca gcccttggac atgagtgagg 1140 tgtttgcctt ccacctagac aggatcctgg ggctcaacag gaccctgccg tctgtgagca 1200 ggaaagcaga gttcatccaa gatggccgcc catgccccat cattctttgg gatgcatctt 1260 tatcttcagc aagtaatgac acccattctt ctgttaagct cacctgggga acttatcagc 1320 agttgctgaa acagaaatgc tggcagaatg gccgagtacc caagcctgaa tcaggttgta 1380 ctgaaataca tcatcatgag tggtccaaga tggcactctt tgattttttg ttacagattt 1440 ataatcgctt agatacaaat tgctgtggat tcagacctcg caaggaagat gcctgtgtac 1500 agaatggatt gaggccaaaa tgtgatgacc aaggttctgc ggctctagca cacattatcc 1560 agcgaaagca tgacccaagg catttggttt ttatagacaa caagggtttc tttgacagga 1620 gtgaagataa cttaaacttc aaattgttag aaggcatcaa agagtttcca gcttctgcag 1680 tttctgtttt gaagagccag cacttacggc agaaacttct tcagtctctg tttcttgata 1740 aagtgtattg ggaaagtcaa ggaggtagac aaggaattga aaagcttatc gatgtaatag 1800 aacacagagc caaaattctt atcacctata tcaatgcaca cggggtcaaa gtattaccta 1860 tgaatgaatg acaaaagaat cttctggcta gggtgttaga tatatttatg catttttggt 1920 tttgttttta aatcaagcac atcaacctca agcccgttta gcaatgaggc agtgtagatg 1980 aatacgtaaa ataaatgact ttaaccaagt agctataatg ggacttagca ctgtatgcat 2040 acttaaaaag gttttgaaaa acaaactact tgagaaatat ttgtttatat ttttctctaa 2100 catcatgcta tgtgtcagtc tgaacatctg acaacagaaa tttcagttat tattctagct 2160 aagttttgaa aacatttgtc atgctgttta atagaaaact gcaaaccaga gatactgact 2220 ccattaataa accatatttt gtgccgtttt gactgttctg accaaatact aatgggaaca 2280 attcttgacg tttttctgtt gctgattgtt aacatagagc agtctctaca ctaccctgag 2340 gcaactctac attggaacac tgaggcttac agcctgcaag agcatcagag ctgaccatac 2400 atttaaacag aaatgctggt ttatttgcaa aatcaccagt atattttcta ttgtgtctat 2460 aaaaaatcag tcatttaagt acaagaatca tattttccat tcctttttag aaatttattt 2520 tgttgtccct atggaaatca ttcacatctg acaatttata tgttaaagag ttttactctc 2580 tctattttgg tccaatttgt atctagtggc tgagaaatta aataattcta aagtatgaag 2640 ttacctatct gaaaatgtac ttacagagta tcattttaaa atggatgtct ctttaaaaat 2700 tttgttactt ttaccaacaa tgtaatataa tttatgtata ttttattaat aatagtgaat 2760 tccttaaaat ttgttctatg tacttatatt taatttgatt taatggttac tgcccagata 2820 ttgagaaatg gttcaaatat tgagtgtgtt tcaatatatt atctggctta tttcaacatg 2880 agtaatatga gcaaaataag ttaaaacctg cgtctgatca attttcctca tgactagaac 2940 taaaacagta aatttggaca atattaagcc tcaaataatc atctccaaac tccttctaac 3000 actttttaaa tcagattgga agacatggac aaatcaggtt catgtgttgc atctttatgt 3060 cctttgccaa tatccaagat catcacatat ggtagatatt cacatggagt ttcaaattca 3120 gaatagatta ccattacctt cctgccctta cacatcctac tccttattta aaagttctat 3180 ttgtgacttt tcatttcctg aaagtttaaa aatacaattt gagaatgttt ataatacatt 3240 ctctcctgtc ttttcacggt tacgtctgtt attgctgaaa tacaccacat tttctttgtt 3300 ctggtcaagg ttaactcaat atctgtgtga aagagaacta ctaacaacgt tacaatagag 3360 gctagatttg aaaaaaaaaa tctatagatc taattgatac aattgtagaa caaaatgtca 3420 aaataatgtt ttaagtataa gagaagatgg accaaggaga gagagatcat ttgaaaatct 3480 aattgtagct tttctaggct cacattcatg tactactttt agcaccctta tgggctgtgc 3540 tcgccccctg gacagttgag ctttggatta tcttcctctt caattttccc tctattgacc 3600 cgagtgtctc cctctgcttc tacagattta tagtactcct tggctctttt gagtctccac 3660 ttttactcac tgtctctggg atttttaaga tccttttctt ctcttataaa tcatcctctt 3720 aatgaaaatt agcctaacaa aagtttggag actggaatcc tactttgagc cactgacttg 3780 aaataactct tttggcaagt tgcctgacat cctgtcttac caaggtggca tatttgcatt 3840 tttactgctt aaaacatttt ttttttttta ccatctttat ccaaatttat catattgatg 3900 gtaggactaa caggcttttt agaagctggc tttaactttg agtctcaagc tacaatgctg 3960 ttgggcagcc tggtcttccc acgtgagggt ttaactttgt ttatttgcct ccagttattc 4020 caaaatgctt attaaatgaa aggcccagga acatgtttat tttagtcacc tttgcttttt 4080 aacaattttg ttttgtaatc aatgagtaat tcatgatgaa ttatttttga ctaatggata 4140 gccgaaggcc aagcttttaa ttctaatagg taatgttctt cttttgtctt attgaaacaa 4200 tgagaatact ctgtgcattt caaatgcact ccgattatgc tgtggtttta ttcacataag 4260 cacaatatgt gttttattta taacttcata acaaacttat aatataataa tttaccttag 4320 cagacatgca aaagcttatt cttgtgtgac ttactttctt taagctaata atataaaaat 4380 aaatatgtat cttaaaaatc tataataaaa cattagaaat taaagatatg tgctttttat 4440 tttgcagatg agttcatttg cttctgtaga tgtgttttca gagctaggta cagaggaatg 4500 tttgctacct ttagcggtga aaaaagaaag agagtcaaga attttgttgg attgtgtttg 4560 tgtgtgcata tatttgatat catcattata tttgtaatct ttggacttgt aatcatagcc 4620 tgtttattct actgtgccat taaatatact ttaccttata cataacgaat aaaataccta 4680 gatgtagatt tatttacaca ctgtcttatg aaattcttat gtttatgtca gcacagaaca 4740 agcacacatt tagagcattc atctgaanat tatatggaaa ttgaccatgg 4790 47 3916 DNA Homo sapiens misc_feature Incyte ID No 6848851CB1 47 tgccccgccg cgccccagtc ccttgacgac cctcctctct gggccccgcc cctcccgctt 60 cggggtcaag ccccagagag cgccgcgaaa accacatttc ccagagtgca ccgcgacggc 120 aggggtcctc agaccggcgc tcgctcgccg gcgccatccc tatagagaag aacggaggta 180 cggcctgtgg tcatggcgct gttcccagcc tttgcggggc ttagtgaggc tcccgatggc 240 gggagctcca ggaaagagtt agactggctg agcaacccaa gcttttgtgt tggatccata 300 acgtccctga gccaacaaac tgaagcagct ccagcccatg tttctgaagg gttaccgctg 360 acaaggagtc atctgaaatc agagtcttca gatgaaagtg acactaacaa aaagctcaaa 420 caaacaagta gaaaaaagaa gaaagagaaa aagaaaaaaa ggaagcatca gcatcataag 480 aaaacaaaga ggaagcatgg gccgtcgagt agcagcaggt ctgagacaga caccgattct 540 gaaaaggaca aaccttccag aggcgttgga ggcagtaaaa aggaatctga ggaaccgaat 600 caaggaaata atgctgcagc tgatactgga catcgctttg tttggcttga ggacattcag 660 gctgtgacgg gagaaacctt cagaacagat aagaaaccag atcctgcgaa ctgggagtac 720 aagtctctct accgagggga tatagcaaga tacaagagga aaggagactc ctgccttggc 780 attaacccta agaagcagtg catatcttgg gaagggactt ccacagagaa gaagcattca 840 cgcaagcagg ttgaacgcta ttttactaag aagagtgtgg gattaatgaa catcgatgga 900 gttgccatta gcagtaaaac tgaacctccc tcatctgagc ccatctcctt tataccagtg 960 aaggacttgg aagatgcggc tcctgttaca acctggttga atcctctggg gatttatgat 1020 cagtcaacca cacattggct acaaggacag ggtcctccag agcaggaatc aaagcagcca 1080 gacgcacagc cagacagcga gagtgcggct ctcaaggcca aggtggagga gtttaacagg 1140 agggtgcggg agaatcctcg ggatacgcag ctgtggatgg catttgttgc ttttcaggac 1200 gaggtcatga aaagtcctgg cctgtatgcc atcgaggaag gagagcagga aaagcgaaag 1260 aggtccctga agctcattct ggagaagaag ctggccattc tggagcgggc cattgagagc 1320 aaccagagca gtgtggatct gaaactggcc aagctgaagc tctgcacaga gttctgggag 1380 ccctccactc tggtcaaaga gtggcagaaa ctgatatttt tgcatcccaa taatacagcc 1440 ctttggcaga aatacctttt attttgccag agccagttta gtaccttttc gatatcaaaa 1500 attcacagtc tttatggaaa atgcttgagc actttgtctg ctgttaagga cggcagcatc 1560 ttatctcacc ctgcgttgcc tggcacggaa gaggccatgt ttgcactctt tcttcagcag 1620 tgccactttc tgcggcaggc tggccactct gagaaggcca tctcattgtt ccaggccatg 1680 gtggacttca ccttcttcaa acccgacagc gtgaaagatc tgcctaccaa aggacaggtg 1740 gaattctttg aacccttttg ggacagtgga gagccccggg ctggggagaa gggagcccga 1800 ggctggaagg cgtggatgca ccagcaggaa cgaggtggct gggtggtcat caacccagat 1860 gaggatgacg atgaaccaga agaggatgac caggaaataa aagataagac tctgcccagg 1920 tggcagatct ggcttgctgc tgagcgttcc cgtgaccaga ggcactggcg gccctggcgc 1980 cctgataaga ccaagaagca aaccgaggaa gactgtgagg atcccgagag acaggtgttg 2040 tttgatgata ttgggcaatc tttgatcaga ctttccagcc atgatcttca gttccagctg 2100 gtggaggcct tcctgcagtt cttgggtgtg ccttctggct ttactcctcc agcctcctgt 2160 ctttatctgg ccatggatga gaacagcatc tttgataatg gactttatga tgaaaagccc 2220 ttgacttttt tcaacccttt gttttctggg gctagctgtg ttggccgcat ggataggttg 2280 ggctatcctc gctggaccag gggtcagaac cgagagggcg aggagttcat ccgcaatgtc 2340 ttccaccttg tcatgccttt attttcaggc aaagagaagt cccagctctg cttctcctgg 2400 ttacagtatg agattgcaaa ggtcatttgg tgcctgcaca ctaaaaacaa gaagagatta 2460 aagtctcaag ggaagaactg caaaaaacta gccaagaatc tccttaagga gccagaaaac 2520 tgcaacaact tttgcctgtg gaagcagtat gcacatctgg agtggttgct tggcaacacg 2580 gaggatgcca gaaaagtttt tgacacagca cttggcatgg caggaagcag agaactgaaa 2640 gactctgacc tctgtgagct cagtctgctc tatgctgagc tggaggtgga gctgtcgcca 2700 gaagtgagaa gggctgccac agctcgagct gttcacatat taaccaagct gactgagagc 2760 agcccctatg ggccctacac tggacaggtg ttggctgttc acattttgaa agcgcgaaag 2820 gcttatgagc acgcactgca ggactgtttg ggtgacagct gtgtctccaa tccagctccc 2880 accgattcct gtagccgcct aattagcctg gctaaatgct tcatgctctt ccagtatttg 2940 accataggga ttgatgctgc tgtgcagata tacgaacagg tgtttgcaaa actgaacagt 3000 tctgttttcc cagaaggctc tggcgagggg gacagtgcca gctcccagag ttggaccagt 3060 gttctcgaag ccatcacact gatgcacacg agcctgctga gattccacat gaaagtgagt 3120 gtttacccgc tggcccctct gcgagaggca ctctcacagg ctttaaagtt gtatccaggc 3180 aaccaggttc tttggaggtc ctatgtacag attcagaata agtcccacag tgccagcaaa 3240 accaggagat tttttgacac aatcaccagg tctgccaaac ccttggagcc ttggttgttt 3300 gcaattgaag ctgagaaact gaggaagaga ctggtggaaa ctgtccagag gttagacggt 3360 agagagatcc acgccacaat tcctgagacc ggcttaatgc atcggatcca agccctgttt 3420 gaaaatgcca tgcgcagcga cagtggcagc cagtgcccct tgctgtggag gatgtatttg 3480 aactttctgg tttccttagg aaataaagaa agaagcaaag gtgtattcta caaagcactt 3540 cagagttgcc cttgggcaaa ggtgttgtac ctggacgccg tggagtattt ccccgatgag 3600 atgcaggaga tcctggacct gatgactgag aaggagctcc gggtgcgcct gccgctggag 3660 gagctggagc tgctgctgga ggattagaga gcagtgggaa aacgggctgt gcctgcgagg 3720 ccaagttgcc caccctgcgg agctaggagg cgcgagcaga gaacgtgtgt gttaggagaa 3780 ctcggctttt gaaatgttct ttctcgatag taataatgtg ggctgccagc ctctcacatc 3840 ttgcacactt tttgggtgtg taaatgacac aaaagttatt tacatattat atatgataat 3900 acgcgtgtat atgaca 3916 48 1702 DNA Homo sapiens misc_feature Incyte ID No 7040722CB1 48 ctccctgagc ccacgggacg ctgggaacca gccagccatg gtgggagggg tcccacctgc 60 gttggggtag gaggaggaca cagtaccagt tcccttcaaa cactcaccgg tgctggggtt 120 gtaaacatcc ccgtcgttca ccagcacttt gttaaagagg acaacgcccc catcactggg 180 gaaaggcttc tgggtgagcc ccgcagaaaa agacaccaga gaaggcaccg gagctcctgg 240 agcagagaaa ggatggaatg gattgacccg ggtgcttctg tcctccaggg ggagggcctg 300 gaaaactgag gcctacgtgc caggcccagg tgccaggccc attttatttc acccaaagtg 360 gtgaagcaaa ctcctcatgc ccaacagcca gagggttccc tgtctgaggg atcagcaggc 420 aggacagctg aggaatctga gaaaccggac agactcttgt taggagggtg tgtgtgaggc 480 tgggcatgta agcatatgag atgagcatgt gtatgtgcgt gtgagtgtgt gcacacactt 540 gtgagcacac atattaggag gccaggccag gcagtgggtg catcatcatc tagggagctg 600 cttccttact aataaatcag taaaacctgg agccccagga agctcatcag gaccacacaa 660 gggcagaggc ccacccagtg atccccttgg gaaactcaat gagctgggat gatggaggag 720 ggaagattcc ttgtcttggg cctgactctg accctctctg gggagcaaac cttggggaat 780 ttggtccact atagtcagca gagggctgtc ccagtgctgg tgggtgggga agggctgggc 840 ccaggcttga tttgtgctaa tagcctggag ggaggaggca ggagatgcag aggaggggca 900 gaggccacca aggagaccgc tcctcctgct cctggtctct cagcagacat acctggggaa 960 gctacaggag gtgacttcgg gtatcctgaa aaacagaaag gaaatggcat gtcaaacaag 1020 accctaagca ccagctcctt gttctgagcc ccctttttcc tctgctcctc acaagttcaa 1080 atcgagtctt cactactata gaaacagaca tagaacaagg gcacccactg tcactgccct 1140 ccttcaagca gaggcacatt tgtaccagcc cgtccctgct tcctcactag cccatttatc 1200 ctggcgggga agagggcact gagggcaagc tggctgcagg aaagaaagag atgggcactg 1260 gagccttgga gacttctctg tgactgagag agtcacacaa gccaactaac atttgccctc 1320 tagcagtgtt atctgttcaa gagctctacc ttcaactaga ctgaatgcag tacttattaa 1380 atggaggcat ggatgggtgg gtgcagaagt ggagggacaa atagatggat gagtggatgc 1440 acgcagggaa gagtgcacgg cttgatgtgt ggaaggatgt gcacatgcat aggtgggtgg 1500 acagatatgt gcatggatac atgggtgggt gggtccctgg ggtgccccag cctctgcata 1560 tgaggatgca tatgtgggtg gatggatgta tcgatgggtg gatacacgga tacatgtgtg 1620 ggtgggtggc tggatggaag gatggatgga agggatacac ggatagatgc atgggtgagt 1680 gctgcatgca cggaagggtg cg 1702 49 1462 DNA Homo sapiens misc_feature Incyte ID No 6430290CB1 49 aagaccctgt ctcaaaaaaa agaaaaaaat cagttgcaga tgtccatacc ttatgatgat 60 tagccaagga ctggtgacac acctcatggc agattgcacg tcagggtcga gagccagtgg 120 ctgaggacag ctctatgctc aggcttgtgt ttccccagcg tgttgtgccc tctgcagccc 180 tcttgtgccc agacacagag tagttaaaaa cagcagtaca gagggcaaga catggaactg 240 cctacttttt tgctcagtgg gaaaagtgct tgggtgagac atgtggctgt ccattgaagg 300 gaacagctat gctgactgtg ggttggaaaa tctaggctgg ctgtcttgct ggctgtcccg 360 tgttggctgg tttggtgcct acagtggagt cccttgtctg cctgtgtgtc tcttaatgat 420 tctgatgtca tctctgcgag gtcagaggtt ggttcccggg gcaggcccat cttgcaccct 480 gaggttcaga tgggaccaca agcagcgtag cacaggggga aaacacttgt gcgcgtcgac 540 cttgcacatc aacaagttag accagaacat ggagtgcacc agccttctca gaattcttga 600 gctctctgta ccaccactag gggctcctct gtggctcaag acccctcctg aggcagaggg 660 tgaggaggag gcagaaagaa aagagaacag gagacttgga gtgggcagca gtagagcgga 720 acccagcagg cccgcctttt tggattcctc tgggggctct ggggatgtgt gttgtgggag 780 tggagagtgg tgacgagcag aggacggaca gctgctgaaa gcgatcattc ctctccttgt 840 ggggcatcct gggaagaaca tgggtgatct ctgcagtcag gcagcgcagt cctcgtgggg 900 ccttatgggg cggctctggg tgtctgcatt ctaatccctg gcaacaaatg gggctgcaag 960 gctgggctcc tggtagatgc tcaggaaggg ttgttccact cctcaccccc tcctgagctg 1020 ctttctagcc tcgcagcccc gtctttggat ccctttttgg cactctgctg ggctcagagc 1080 ttccgtggca ggagcagagg ctgctctctc ctgggttcct ctgggagcta ccatggagct 1140 tgggcagttc cttctattgt tgcgattctg ggttcaaagc cacaggcctc tcagacagct 1200 gtgacttccc ggcaggcagt agggatgggg tgggggtgga ggcgttgggg ccctgcagct 1260 tccctcgctt gcctctgtcc ttgctaggca gtgagttgga ggcgcctggg ctcagctgat 1320 gttctccaag gaggacttgg aatgaacccg agacacaaag ggtgaggtca gtggtttgct 1380 cagcaagaag gctgagttag tgacaacctg tcacagctcc caggatccct ggctgcagtc 1440 cctggctccg aatcctcccc ct 1462 50 3958 DNA Homo sapiens misc_feature Incyte ID No 2640251CB1 50 tttttttttt tttttttcta aagtttcagt cagttttatt acatccagtc cagtaagctg 60 tgctgtctag tggtatccac acatacttta ttagttttat ctttgttcag cccaccaaca 120 aaaatttgga aagattgcta cacatgacag agcgacagta ccctagggtg acatgacagc 180 ccatatatca gttctctgtt tcacattaaa aagttaccat tcattcggtc caaacatcca 240 cccaatccac acgttctctc aaagactagc atggttctgt ccaatacctt gctctaattc 300 caattcattc gttctcataa cttatttgaa aaggcacatt tggtcagtct gatgtcattc 360 ttagggcatc tttgctctct cctggccatt actgcttgct tttatgtact gaaaagtcat 420 ccattgaatg gtctgttcct gaatgtcgcc acaaagcagt ctgtaaaacc cactcacttt 480 ccctccttaa attacctccc tccaggtctg tttcctcaaa gatcgtccct tagtgggtca 540 cagtaatcat gaaccctggg tacaattgat acaggctgag aagtaagaat tcactgttca 600 cttagagcaa ctcattccct gacctgaacc gggtgtgttc cacccttgcc catggttaga 660 tctctttcct tgatagaaca agcaaaagag gggctgatcc atctcccgtg aacatctgtt 720 gactgtgggc ggcctgggcc agccttgctg tgtttgcctc agatgcgagt aaggaagctc 780 cagttgtagc cttggcacag ctgaggccat gccattgcta cccggaagct ggctctgcag 840 cgttgtgact tagacacttt acaagtctga gccatcccgt actagttcat caactttcct 900 tcctcatgat ctgcaaagat acagagagaa tggcattcca aaattccatg gatgactttt 960 ctgaatgtcc tagaatgttt ggcaaagatc tggctaaaac tagtactatg gaatagaaaa 1020 ggaaaagtga catttgtgta atttattttg gaaatgcaaa ggaattatta tgcagcaatc 1080 ttaactttgt gtacatacca ctcacctccc ttaaaattca gcagaaccag aggtgccaga 1140 aatgtcaaaa aatatctagt cattccaata tgtaaaacaa gactgccttg ttttaaaaaa 1200 acaaattaaa tgtaaaaatt gtatgactct tacccagtga aaagctttac taacacagcc 1260 ctgggtgcta tttccagata ctgaaaagat ctaagtaggt gcttaagaac tgctttttaa 1320 cccattcaca accttcatat taaactagga tgaggctgca ggagctgagg aaggaaggcc 1380 tgggtgggaa cctggatgtc ctttcctgga gaacagcttt gctatttcac tggtaactcc 1440 gaaacttcaa aatattgact gtacaaatta ctcaagttta ttttggccta attattctta 1500 agaaaggtgg ttctttttta gaaaagggaa gcagaagcta attgaaattc cattactcag 1560 gcctctagta agtgccccct tcatgtagtc actattcact gagggccatg agggtgaggc 1620 cctgctgggg gggcagggca gggctgtgag ctcaggagcc catccctgtg ctcagagaga 1680 tgggactcca atgaggagac acactatgta ggtgcaattt ctgatttctt agtttttgac 1740 caaaatagca gtaatttcaa acagttgaat gtcgtgatcg atactatgtc agttggtgat 1800 gaatgctgtg aatggtattg aatgtcctgg accaagagga acagcaacat gtccttagtc 1860 ctcagcctaa gaagtccatc gagtccttct ctcaaattgt acgtctgttg ttttcaaaag 1920 ccattgtgac aggtcaaaac cctggagtat ttggtttgtg tttaaatgta cttgacactc 1980 tggaaacact caacctaagc cctggatgca ggaggcaggg atgctgagga tgtgaattag 2040 agtgctggga tgtgctaatg cctagggagg catcaggcac tgtgctggct tgggggatcc 2100 tgtgatgact ggaacctggg ccttcattac gggctccggt tttggagtgc agagggattg 2160 gcatttgtaa agactgcttg cttacccttt gtctggcatg cacattcagg atgtgacttc 2220 agcttcattc atcctggcca aacaaaaaaa gttcaaaaaa ttgttttcaa ttaaatttct 2280 gaagatcttt gtagggaagc acccttctga gatgaaacca atttcttgtc cacacagcca 2340 ccatatcctt atatagatgg ggaaaaatcc agaaaagggg gattttcagc agctggcttg 2400 aagcccctga atggtccctt ggcagaggca aagaatgagc ccagagcctg agattcaaga 2460 tgctggtctc ttctgaacac accgtggagc aatgtggtgc acctgcagat gccgcactca 2520 gcagcctgga atgccagctc tcatgccctc acctagaaac gccttctcgg ctgaatggct 2580 gttggctctc agcagcacct gtcagcatag ctcggccgct tctgccccgt gccaaggcgt 2640 gactaggacc agaagaatca gaaagcatgg tggagtccga aagcattggc aaagccagca 2700 catctgtgag catgttacac atgggcttgc ctaagtattt ccttctctgt gaacatcact 2760 taggagctac gtcagttaag gcatcgtgag acacaggtgt ggtggaggca ttatgagggg 2820 actactccac aggaccttgg agagttgcat tttggggggc tctcctagaa gctctggggg 2880 aaggaagcag tggcctcctg gtcagctaca gacacaggcg ggttagggcc cgtcttgctt 2940 tcatgttctt ttaaacacaa atggcagctc acaaatattc ctctaaatat tcctccatac 3000 agcctagggc ccctcaagag acgtgcaaac caaagtattt gtttttctca ctttatcttt 3060 aacctagtat gtggcaagtc tggaccactg ctttagagaa agctggatta aatctcttga 3120 gcagaagtag agaccctaga gaatcttcac tggatacctt gcttcacact ttggtcaata 3180 tttatgaata agttctaaag cctatgcgaa gcccattctg ttttgcttgg ggaccagcca 3240 gaccactcct ccactccagt ggggcctttt ttgtgtcttt cacatcactg ttacaagttg 3300 tggctggaca attaatgaca tttaaatcac tgtcccacat atggatatat tagaaaaacc 3360 ctaatgtttt aaaatttttt taatcatcag ctgcttttac aaagctttgc atgcatttgt 3420 ttagaggata ttgcagtcga gatattccag tactactgtg tgatcatatg aaaaaagttg 3480 gttttctctc tgtcaaagtc aatagggtgg tagactaact cacagagtgc cttacttctt 3540 cctcccgatt aatcgtgttc actatatggt ggcagaatca gtccagtccc ccagacctca 3600 agctgcatct tccaaatggt tggtgtcttt ttaagagtcc ccgtgggctg gctttcctgg 3660 aagaagtcca ttaaattccc tgcttctata agctgcagga gtcgcctagg atatggcccg 3720 tcacgtctgg ggatgaccct gcactgctct ccagatttca ctcaaggttc gtatttttct 3780 ctgccacctt gaactacaga acaggctctc agtagcgtga taagctttaa gctagaatga 3840 gatggaaagg tgggaaagac agacaggaag tgtagctctt agtctatggg gctctcctta 3900 ggggacaaaa agatggctta ggctccgtgg gttttcaact cgtagaaaaa ataacctg 3958 51 826 DNA Homo sapiens misc_feature Incyte ID No 3839350CB1 51 gattctttcc actgaggagg caaggatgga gttgctgctg acccgtgcag atttgctgct 60 ggtaacatac tcatgggcaa agtctgaaaa acctcttcct gccctgggca aggcagatgg 120 ggcagcccag caggctggct ttgcccaccg tctccgatat catccaacac agtcagccag 180 gttgtgtggc cctctcatct acattctcat ttgccaacaa gatggtgtgg gctatgctgt 240 ctttgcacag cgatctgatc ccagggacat ttgtgtgggt gtgtgcccgg gagctgcatg 300 tctgcaggtt cagattgggg tcagctttgc tggtgagtgt ggcttcctgc catggcacca 360 aagaagaggg ctggcggatt agtcctgttg tctctcatag ctttgtaggg acacagcggg 420 ccatgtggac tgacagctgg agacttcata aagatggcct agaaaattag gacactgtcc 480 tgttgacaaa gcccctaggc ctgcccccat caggcctcat gggtcctttt caggcctaag 540 ccagggttct gaaatcatct gtaatgtgaa tttatatttc taggccacat tcgctgcatc 600 ctttccagca agatgtcatt ctgagatttt tgtcattcct gggcgttatg aggactgcca 660 agggacacaa ttccatggga ggaaagtttt cttctaagct gcaagccagc tctggcttct 720 ggagtttctc cttaggattg caagacagta gttccctgtc ctttaggtct tctccagaaa 780 taccttaaaa tagcaaataa aataagatat aagcaaaaaa aaaaaa 826 52 729 DNA Homo sapiens misc_feature Incyte ID No 6393813CB1 52 aagaattcgg aacgaggccg gcggggggtc aggatcctcc acaggtaggc gcagtcagct 60 ggagcgtcgc ggcggtccgc cggtcgtgga gggcgtgtcc tgcggcgcga tggccgtagt 120 gttgccggcg gttgtggagg agctcctgag cgagatggcg gcggcggtgc aggagagcgc 180 gcgaattcct gatgaatatc tgttatcgct gaagtttctc tttggctcat cagccaccca 240 ggccttggac ctagttgatc gacagtccat caccttaatc tcatcaccca gtggaaggcg 300 tgtttaccag gtccttggaa gttccagtaa aacatacaca tgtttggctt cttgtcatta 360 ctgttcatgt cctgcatttg cattctcagt gctacggaag agtgacagca tcctgtgcaa 420 gcatctcttg gcagtttacc tgagtcaggt tatgaggacc tgtcagcagc taagtgtctc 480 tgacaagcag ttgactgaca tattattgat ggagaagaaa caagaagcat aaaaggactg 540 caggaggtgc tgtgggttgg agccgtgggc tgtggagggt ttgtgtatga tgagaagccc 600 tgtacagtct tgtcaagaaa taccctgagc cagtctctga gacgcttcgg taaaaaatgt 660 ccctggatgg aatcaagatt ttaaattcaa ataaagccta atatcatgtt gtgtccacaa 720 aaaaaaaaa 729 53 1610 DNA Homo sapiens misc_feature Incyte ID No 5685755CB1 53 tgccaacaga aagggggtcc cttccctgtg ccaggatcct atataaggaa gagggatgtg 60 agcagagtgg tctggcttca ccgtccctcc agtggacttg ggggctgagc ataaagatgc 120 ctaggagagg ctactccaag cctgggtcct ggggcagctt ctgggccatg ctgaccttgg 180 tgggcctggt cacccatgca gcacagagag ccgatgttgg cggggaggca gctggcacct 240 ccatcaacca ctcccaggcg gtgctccagc gcttgcagga gctgctgcgg cagggcaacg 300 ccagcgatgt ggttctgcgg gtgcaggctg cgggcaccga tgaggtccgg gtattccacg 360 cccaccgcct gctgctggga ctgcacagtg agctgttcct ggagctgcta agtaaccaga 420 gcgaggcggt gctgcaggag ccacaggact gcgccgctgt cttcgacaag ttcatcaggt 480 acctgtactg cggggagctg accgtgctgc tgacccaggc catccccctg cacagactgg 540 ccaccaagta cggcgtgtcc tccctgcagc gcggcgtggc cgactacatg cgcgcgcacc 600 tggcgggagg cgcgggcccg gcggtgggct ggtaccacta cgcggtgggc accggggacg 660 aggccctgcg cgagagctgc ctgcagttcc tggcctggaa cctgtcggcc gtggcggcca 720 gcaccgagtg gggcgccgtg agccccgagc tgctctggca gctcctgcaa cgctcggacc 780 tggtgctgca ggatgaactg gagctgttcc acgcgctgga ggcctggctg ggtcgcgcgc 840 ggccgccccc tgccgtggcc gagcgggcgc tgcgcgccat acgctacccc atgatcccac 900 cggcacagct gttccagctg caggcgcgct cggcagccct ggcgcgccac ggccccgcgg 960 tggccgacct cctgctgcag gcctaccagt tccacgccgc gtcgccgctg cactacgcca 1020 agttcttcga cgtcaacggc agcgccttcc tgccccgcaa ctacctcgcg cccgcctggg 1080 gcgccccgtg ggtcatcaac aacccggccc gcgacgaccg cagcaccagc ttccagacgc 1140 agctgggccc gagtggccac gacgcgggcc gccgggtcac ctggaacgtg ctcttctcgc 1200 cgcgctggct gcccgtcagc ctgcggcccg tttacgcgga cgccgcgggc actgctctgc 1260 ccgccgcgcg cccggaggac ggccgaccgc ggctggtggt gacgccggcc agcagcggcg 1320 gcgacgcggc gggcgtgagc ttccagaaga cggtgctggt gggggcgcgc cagcagggcc 1380 gcctgctggt ccgccacgcc tacagcttcc accagagcag cgaggaggcc ggcgacttcc 1440 tggcgcacgc cgacctgcag cggcgcaact ccgagtacct ggttgagaac gccctgcacc 1500 tgcacctcat cgtcaagccc gtataccaca cccttatccg gacccccaag tagcctcggg 1560 gtctgggaat aaaggcctgg cctaggtggt ccctgtgggt ctgggaaggg 1610 54 869 DNA Homo sapiens misc_feature Incyte ID No 71728459CB1 54 ctctaggaca tccctgcaga aaggagagaa gcaaggagaa ggagtgacag gtgttttgtc 60 aggcctgtat cttcagccag atacaaagcc cccacatgta cacctgctct cattatgtct 120 cattcgtgag cagttaatca agttaattat gagcagttga gccctgggag cttttactga 180 cagtgcaacc tataatttct ctgaaagtta cagagccaga gatgaaggtt actgctcttt 240 taggagccct gtctccagtt tttgcttttg tttctgtttt tatttcatgg ttagcatcct 300 ttggagacca gaagagcatt gacagccccc cagatgagca gcagagcaat tcttatacta 360 gtggtcaagc agcttcctac agccaaaagg ctataggaag aaagggtaac tggctgccct 420 acagtttaca cgatgaagct gccttgggct ctgggtcttg gtgatttagc cagaagattg 480 tttctcagag ctcagcccta cacattctcc taaaggcctt cttcctggca taggtcaaag 540 acagaacctg agagagggaa atgagccaga acaaatatgt catctgatga cctcaccccc 600 agcaaatggg cagggaagag agctagaatg agaaggccag aacatggagc accatgaaaa 660 gaaactgctc aagcaagaga agtggcatgt gggctttaaa gaccagggtt agaaaacagc 720 agccctgacc tttgtgttga agtagcgggg cgaggatctc tcatagaagt gttaattctg 780 tactccttcc ccgattctga gtaggtgcct tttacataga gatgatcaat gtgtacttgt 840 ctaattaatt acaaactgcc cccagtgta 869 55 2209 DNA Homo sapiens misc_feature Incyte ID No 1904303CB1 55 gcctgtgcgc tgtgcctccg cttgtctgct ctcccccgcc ttggccttct ctcgccgccc 60 cctttcgcgt cctctgtcct tgtgtcctct ctctcccgtc tcgctctcgt gtccttggac 120 tgctccttct gtctcgcgcg ctccttggtc gctccctccg tgttgctctg ttgtgtggtt 180 agctgtcttc cttttctctt gttccgtcgc tctttgcttc ttttcctttg gttcgttgtg 240 tctgtgcctg tctctggctt tcttggtttt tgtgcccagg cccccacgtt ggccgctgct 300 gccgggctca ccccagcccc gcccggaggc gccccgcggc cccggctagc cagggcgggc 360 ggccacactc tgccctactc cttccctccg cgttccgggc ctcggagccg ccttgaggag 420 gatgagtccc tggagctggt tcctgctgca gaccctctgc ctcctgccca cgggcgcagc 480 ttcgcggcgc ggggcgcccg gcaccgccaa ctgcgagctc aagccccaac aaagcgagct 540 gaattccttc ttgtggacca ttaagcgaga cccaccatct tacttctttg gcacaatcca 600 tgtcccgtac acccgagttt gggacttcat ccccgacaac tctaaggagg ctttcctgca 660 gagcagcatt gtgtactttg agttggatct cacagacccc tataccatct cagctctcac 720 cagctgtcag atgctgccac agggcgagaa cctccaagat gtgctcccca gggacatcta 780 ctgccgcctc aagcgccacc tggagtatgt caagctcatg atgcccttgt ggatgacccc 840 agaccagcgc ggcaaggggc tctacgcaga ctacctcttc aatgctattg ccggaaactg 900 ggagcgcaag aggcctgtct gggtgatgct catggtcaac tccctgactg aagtggacat 960 taagtcccgt ggagtgcctg tcttagacct gttccttgcc caggaggctg agcggctgag 1020 gaaacagact ggggcagtgg aaaaggtgga agagcagtgc catccattga atgggttgaa 1080 cttttcacag gtcatctttg ctttgaacca gaccctcctg cagcaggaaa gcctgcgagc 1140 aggcagtctt cagatcccct acacgacgga ggatctcatc aaacactata actgcgggga 1200 cctcagctcc gtcatcctca gccatgacag ctcccaggtt cccaatttta ttaatgccac 1260 gctaccacct caggagcgca tcactgctca ggagattgac agctacttac gccgggagct 1320 gatctacaag cggaatgaga gaatagggaa gcgggtgaag gcccttttgg aggagttccc 1380 tgacaaaggc ttcttctttg cctttggagc tggtcatttc atgggcaaca acacagtgct 1440 ggatgttttg cggcgtgaag gctatgaggt agaacacgcc cctgctggac gacccatcca 1500 caaagggaag agtaaaaaga cctccacacg gcccactctg tccaccatct ttgctccaaa 1560 agtccctacc ctggaagtac cggcaccaga agccgtatcc tcagggcact caacgctgcc 1620 tccccttgtg tcccggcctg gaagtgccga cacgcccagt gaggccgaac agaggttccg 1680 gaagaagcgg aggcggtcac agcggaggcc gcgactccgg caattcagcg atctgtgggt 1740 ccgcctggag gagagtgaca tagtcccgca actccaggtc cctgtcctgg acaggcacat 1800 ctccactgaa ctgcggctcc ctcgccgtgg gcattcccac cacagccaga tggtggccag 1860 cagtgcctgc ctgtctctct ggactcctgt gttctgggtg ctggtgctgg ctttccaaac 1920 agagacaccc ctcctgtaac gactggaagc accaggctaa gaacctgacc cctcggactt 1980 gaagaatggc cattcctgta ctccacattc tggtctagcc ttgttgggcc caatccagaa 2040 gagactgctc ttgaaaaagc ggcccagtgt tgattcttct ctttccaagg aatgtgactt 2100 tgggttatcc aactttgggg gcaggtgtac agttttgtaa catagtgagt tgtgtgaaaa 2160 taaattataa atgagttgta tgaaaataaa aaaaaaaaaa aaaaaaaaa 2209 56 1520 DNA Homo sapiens misc_feature Incyte ID No 2911343CB1 56 ggccaacgga gcccgccttt acctccccac tcggcgtcca gtctcttagc aacgactccg 60 gcttcctagg aactgctcct ttctcaacca ttcctgccca caacacccca gcttgctgcc 120 agcaaagccc ctccacaccc ctcaaactcc agacccttca catcaattta ctgttttctt 180 cgacctcacc ccagcaattt tctctgaatc aacccccttt cctcctctcc taagtctctg 240 agtttctctc tcctcctgcc atcctgagtt ctgccatcct taggggccgc caagacctct 300 cttttcgttc ctctcccgcc tcagaccagc agccttttat tttagatcat gtctggaggg 360 aagtcagccc agggtccaga ggaagggggc gtctgcatca ctgaagccct tatcactaag 420 cggaacttga ctttccctga agatggggaa ctgtcagaga agatgtttca cactcttgat 480 gaactgcaga ctgtccgcct ggaccgggag gggattacta ctatcaggaa cttagaaggc 540 ctccagaatc ttcacagtct ctatctgcaa gggaataaga tccagcaaat tgagaacctg 600 gcttgcatcc cctccttgcg cttcctgtct ctggcaggaa accaaatcag gcaggtggaa 660 aacctcctcg acctcccatg cctccagttt ctggaccttt ctgagaacct gatagaaaca 720 ttgaagctgg atgagttccc ccagagcctt ctcatcctca acctgtctgg aaacagctgc 780 accaaccagg atggctaccg cgagctggtg acagaagccc tgccacttct cctggacctg 840 gacgggcagc ctgtggtgga gcgctggatt tcggatgagg aggatgaagc ctcaagcgat 900 gaggagttcc cagagctgag tggcccattc tgctcagaac gaggcttcct caaggagctg 960 gagcaggagc tgagcaggca cagggagcac cggcaacaga cggccctgac agagcacctg 1020 ctgaggatgg agatgcagcc caccctcacc gacctgcccc tgctacctgg ggtgcccatg 1080 gctggggaca gcagcccttc tgccactcct gcgcaagggg aggagacagt ccctgaggcc 1140 gtctcctcac cccaggcctc ctctcccacc aagaaaccat gcagtctgat tcccaggggc 1200 caccaaagct ctttctgggg aaggaagggg gcacgagcag ccacagcccc caaggcctct 1260 gtggctgagg cccccagcac aaccaaaact acggccaaga gaagcaagaa atgattctct 1320 gtcaaccttt ctctactagt ggagaggagt ggggcctgcc cctcttctca gacctctgac 1380 ctgtgacaga agcccatccc cagtaaagtg tctctaggcc ctgagtatgc ttttcatgtc 1440 acttggggta tctcagggga agaaaccagt gaaagctcca ggaaacaaaa tacagagctc 1500 agtgagccac ctgaaaaaaa 1520 57 1282 DNA Homo sapiens misc_feature Incyte ID No 7500308CB1 57 agcccctgca gcagggtggg agcattagga catgtccaca cgtcttcaag ggaaaatggc 60 taagggctgt cagagaggcc cagggaagag gcctgggtag gggcgagcag ggagcagaca 120 atcacttgtt gaaggaagat ccaagtccag gaaggaacgt agggcagttt ggtgtcatgg 180 aaggaactgg gggcccagcc gaggggctca agagcccttc agactctgcc tgagcgaggg 240 tggtgctctg tcacccaggc tggagtgtag tggtgtgatc tcagctcact gcagccttga 300 actcctaggc tcaagtgatc ctcctacctc aacctccaga gtaactggga ctacaggaaa 360 gctcagtggc ccccaagcca ggatgtccca agcttgggtc cccggcctcg cgcccacctt 420 gctgttcagc ctgctggctg gcccccaaaa ggtgattctg aagcccagcc tgggcccaac 480 tcccacagag ccaccccctc cctacagctt caggcctgaa gaatataccg gggatcagag 540 gggcattgac aacccggcct tctgagtcac ctcctgcctg gaatcttgcc atcagcaacc 600 tcctccccag tgcctcctgg atcaagctag agactgctgg caccccagga atgtccctgc 660 ccatcctgcc gtgtctctgt tcattcttgg atttaactta ttactttttc tgcttctgtt 720 tccaccccag ctgcctctct tgtcctgagg gttaggctgg agtgacagtt tccgcccacc 780 ccccagccca agaaagaggc tgccggaaag aaaatgctga ccattggagg tgcccaacag 840 tagaatgggc tactgtgagg ggtagtaaga gccccatttc tggaggtatg cgaatcttga 900 ctggacagcc agctctgaga ttttatcagg gcacttctat acctgtggga cattggactg 960 gatgagccct gagccagctt ccactcctac ctgaatagag aactcactgc acccacccac 1020 aacacatgat aaacacatgt cctcactgaa tgttactgat tgcggctgag ggcctgcctc 1080 tggctgtgtg gggaggtggg tggagaggtg agcccaggca ctgctgaggg gtgcggtgat 1140 ggggtcgctg cgccgcaatc ccaccactga tgagccacct gggaggtctg ggaggccagt 1200 ccatccatgg gccgccctcg gagagaggct tgttctagat gtattggctg tctgtttttt 1260 gatgtctctg tgtgccaaac ag 1282 58 1228 DNA Homo sapiens misc_feature Incyte ID No 7501098CB1 58 gcgaacccca ggcccttccc aggtttgcgc gcgggggcca tccagaccct gcggagagcg 60 aggcccggag cgtcgccgag gtttgagggc gccggagacc gagggcctgg cggccgaagg 120 aaccgcccca agaagagcct ctggcccggg ggctgctgga acatgtgcgg ggggacacag 180 tttgtttgac agttgccaga ctatgtttac gcttctggtt ctactcagcc aactgcccac 240 agttaccctg gggtttcctc attgcgcaag aggtccaaag gcttctaagc atgcgggaga 300 agaagatttg atctggagct cttcactccc ggcaacctag aaagagagtg caatgaagaa 360 ctttgcaatt atgaggaagc cagagagatt tttgtggatg aagataaaac gattgcattt 420 tggcaggaat attcagctaa aggaccaacc acaaaatcag ctcttcagcc gtctatgaaa 480 gggggaggca cactccctcc atcattttca gaagacctga ggaggctgcc ttgtctccat 540 tgccgccttc tgtggaggat gcaggattac cttcttatga acaggcagtg gcgctgacca 600 gaaaacacag tgtttcacca ccaccaccat atcctgggca cacaaaagga tttagggtat 660 ttaaaaaatc tatgtctctc ccatctcact gactaccttg tcattttggt ataagaaatt 720 tgtgttattt gataggccgg gcatggtggc tcatgcctgt aatcccagca ctttgggagg 780 ccaggagttc gagaccagcc tggccaacat ggtgaaaccc ggtctctact aaaaattcaa 840 aaattaccta ggcgtcatgg ggcatgcctg tagtcccacc tacttgggag gctgaagcag 900 gagaattgct cgaacctggg aggcagaggt tgcagtaagc tgagatcacg ccactgcatt 960 ccagcctggg cgacagagca agactccatc tcaaaaataa aataaaaaaa gaaaaaaaga 1020 aaagaagaag aaaagagaag aaggagaagg agatgaagga ggaggaggag gagaaggaga 1080 agaagaagaa gaagaagacc acaaaagaca tggactatcc aacttttatg acaactgcag 1140 gaataaggag aatagtcatg tactgtacac gaagtctgtc tgcatctgga ctgaactgat 1200 catcatcagt gatagagact ttgatcta 1228 59 3582 DNA Homo sapiens misc_feature Incyte ID No 7503839CB1 59 gcctctccct gccccgccgc gccccagtcc cttgacgacc ctcctctctg ggccccgccc 60 ctcccgcttc ggggtcaagc cccagagagc gccgcgaaaa ccacatttcc cagagtgcac 120 cgcgacggca ggggtcctca gaccggcgct cgctcgccgg cgccatccct atagagaaga 180 acggaggtac ggcctgtggt catggcgctg ttcccagcct ttgcggggct tagtgaggct 240 cccgatggcg ggagctccag gaaagtcaag gaaataatgc tgcagctgat actggacatc 300 gctttgtttg gcttgaggac attcaggctg tgacgggaga aaccttcaga acagataaga 360 aaccagatcc tgcgaactgg gagtacaagt ctctctaccg aggggatata gcaagataca 420 agaggaaagg agactcctgc cttggcatta accctaagaa gcagtgcata tcttgggaag 480 ggacttccac agagaagaag cattcacgca agcaggttga acgctatttt actaagaaga 540 gtgtgggatt aatgaacatc gatggagttg ccattagcag taaaactgaa cctccctcat 600 ctgagcccat ctcctttata ccagtgaagg acttggaaga tgcggctcct gttacaacct 660 ggttgaatcc tctggggatt tatgatcagt caaccacaca ttggctacaa ggacagggtc 720 ctccagagca ggaatcaaag cagccagacg cacagccaga cagcgagagt gcggctctca 780 aggccaaggt ggaggagttt aacaggaggg tgcgggagaa tcctcgggat acgcagctgt 840 ggatggcatt tgttgctttt caggacgagg tcatgaaaag tcctggcctg tatgccatcg 900 aggaaggaga gcaggaaaag cgaaagaggt ccctgaagct cattctggag aagaagctgg 960 ccattctgga gcgggccatt gagagcaacc agagcagtgt ggatctgaaa ctggccaagc 1020 tgaagctctg cacagagttc tgggagccct ccactctggt caaagagtgg cagaaactga 1080 tatttttgca tcccaataat acagcccttt ggcagaaata ccttttattt tgccagagcc 1140 agtttagtac cttttcgata tcaaaaattc acagtcttta tggaaaatgc ttgagcactt 1200 tgtctgctgt taaggacggc agcatcttat ctcaccctgc gttgcctggc acggaagagg 1260 ccatgtttgc actctttctt cagcagtgcc actttctgcg gcaggctggc cactctgaga 1320 aggccatctc attgttccag gccatggtgg acttcacctt cttcaaaccc gacagcgtaa 1380 aagatctgcc taccaaagga caggtggaat tctttgaacc cttttgggac agtggagagc 1440 cccgggctgg ggagaaggga gcccgaggct ggaaggcgtg gatgcaccag caggaacgag 1500 gtggctgggt ggtcatcaac ccagatgagg atgacgatga accagaagag gatgaccagg 1560 aaataaaaga taagactctg cccaggtggc agatctggct tgctgctgag cgttcccgtg 1620 accagaggca ctggcggccc tggcgccctg ataagaccaa gaagcaaacc gaggaagact 1680 gtgaggatcc cgagagacag gtgttgtttg atgatattgg gcaatctttg atcagacttt 1740 ccagccatga tcttcagttc cagctggtgg aggccttcct gcagttcttg ggtgtgcctt 1800 ctggctttac tcctccagcc tcctgtcttt atctggccat ggatgagaac agcatctttg 1860 ataatggact ttatgatgaa aagcccttga cttttttcaa ccctttgttt tctggggcta 1920 gctgtgttgg ccgcatggat aggttgggct atcctcgctg gaccaggggt cagaaccgag 1980 agggcgagga gttcatccgc aatgtcttcc accttgtcat gcctttattt tcaggcaaag 2040 agaagtccca gctctgcttc tcctggttac agtatgagat tgcaaaggtc atttggtgcc 2100 tgcacactaa aaacaagaag agattaaagt ctcaagggaa gaactgcaaa aaactagcca 2160 agaatctcct taaggagcca gaaaactgca acaacttttg cctgtggaag cagtatgcac 2220 atctggagtg gttgcttggc aacacggagg atgccagaaa agtttttgac acagcacttg 2280 gcatggcagg aagcagagaa ctgaaagact ctgacctctg tgagctcagt ctgctctatg 2340 ctgagctgga ggtggagctg tcgccagaag tgagaagggc tgccacagct cgagctgttc 2400 acatattaac caagctgact gagagcagcc cctatgggcc ctacactgga caggtgttgg 2460 ctgttcacat tttgaaagcg cgaaaggctt atgagcacgc actgcaggac tgtttgggtg 2520 acagctgtgt ctccaatcca gctcccaccg attcctgtag ccgcctaatt agcctggcta 2580 aatgcttcat gctcttccag tatttgacca tagggattga tgctgctgtg cagatatacg 2640 aacaggtgtt tgcaaaactg aacagttctg ttttcccaga aggctctggc gagggggaca 2700 gtgccagctc ccagagttgg accagtgttc tcgaagccat cacaccgatg cacacgagcc 2760 tgctgagatt ccacatgaaa gtgagtgttt acccgctggc ccctctgcga gaggcactct 2820 cacaggcttt aaagttgtat ccaggcaacc aggttctttg gaggtcctat gtacagattc 2880 agaataagtc ccacagtgcc agcaaaacca ggagattttt tgacacaatc accaggtctg 2940 ccaaaccctt ggagccttgg ttgtttgcaa ttgaagctga gaaactgagg aagagactgg 3000 tggaaactgt ccagaggtta gacggtagag agatccacgc cacaattcct gagaccggct 3060 taatgcatcg gatccaagcc ctgtttgaaa atgccatgcg cagcgacagt ggcagccagt 3120 gccccttgct gtggaggatg tatttgaact ttctggtttc cttaggaaat aaagaaagaa 3180 gcaaaggtgt attctacaaa gcacttcaga gttgcccttg ggcaaaggtg ttgtacctgg 3240 acgccgtgga gtatttcccc gatgagatgc aggagatcct ggacctgatg actgagaagg 3300 agctccgggt gcgcctgccg ctggaggagc tggagctgct gctggaggat tagagagcag 3360 tgggaaaacg ggctgtgcct gcgaggccaa gttgcccacc ctgcggagct aggaggcgcg 3420 agcagagaac gtgtgtgtta ggagaactcg gcttttgaaa tgttctttct cgatagtaat 3480 aatgtgggct gccagcctct cacatcttgc acactttttg ggtgtgtaaa tgacacaaaa 3540 gttatttaca tattatatat gataatacgc gtgtatatga ca 3582 60 2063 DNA Homo sapiens misc_feature Incyte ID No 7503698CB1 60 gcctgtgcgc tgtgcctccg cttgtctgct ctcccccgcc ttggccttct ctcgccgccc 60 cctttcgcgt cctctgtcct tgtgtcctct ctctcccgtc tcgctctcgt gtccttggac 120 tgctccttct gtctcgcgcg ctccttggtc gctccctccg tgttgctctg ttgtgtggtt 180 agctgtcttc cttttctctt gttccgtcgc tctttgcttc ttttcctttg gttcgttgtg 240 tctgtgcctg tctctggctt tcttggtttt tgtgcccagg cccccacgtt ggccgctgct 300 gccgggctca ccccagcccc gcccggaggc gccccgcggc cccggctagc cagggcgggc 360 ggccacactc tgccctactc cttccctccg cgttccgggc ctcggagccg ccttgaggag 420 gatgagtccc tggagctggt tcctgctgca gaccctctgc ctcctgccca cgggcgcagc 480 ttcgcggcgc ggggcgcccg gcaccgccaa ctgcgagctc aagccccaac aaagcgagct 540 gaattccttc ttgtggacca ttaagcgaga cccaccatct tacttctttg gcacaatcca 600 tgtcccgtac acccgagttt gggacttcat ccccgacaac tctaaggagg ctttcctgca 660 gagcagcatt gtgtactttg agttggatct cacagacccc tataccatct cagctctcac 720 cagctgtcag atgctgccac agggcgagaa cctccaagat gtgctcccca gggacatcta 780 ctgccgcctc aagcgccacc tggagtatgt caagctcatg atgcccttgt ggatgacccc 840 agaccagcgc ggcaaggggc tctacgcaga ctacctcttc aatgctattg ccggaaactg 900 ggagcgcaag aggcctgtct gggtgatgct catggtcaac tccctgactg aagtggacat 960 taagtcccgt ggagtgcctg tcttagacct gttccttgcc caggaggctg agcggctgag 1020 gaaacagact ggggcagtgg aaaaggtgga agagcagtgc catccattga atgggttgaa 1080 cttttcacag gttcccaatt ttattaatgc cacgctacca cctcaggagc gcatcactgc 1140 tcaggagatt gacagctact tacgccggga gctgatctac aagcggaatg agagaatagg 1200 gaagcgggtg aaggcccttt tggaggagtt ccctgacaaa ggcttcttct ttgcctttgg 1260 agctggtcat ttcatgggca acaacacagt gctggatgtt ttgcggcgtg aaggctatga 1320 ggtagaacac gcccctgctg gacgacccat ccacaaaggg aagagtaaaa agacctccac 1380 acggcccact ctgtccacca tctttgctcc aaaagtccct accctggaag taccggcacc 1440 agaagccgta tcctcagggc actcaacgct gcctcccctt gtgtcccggc ctggaagtgc 1500 cgacacgccc agtgaggccg aacagaggtt ccggaagaag cggaggcggt cacagcggag 1560 gccgcgactc cggcaattca gcgatctgtg ggtccgcctg gaggagagtg acatagtccc 1620 gcaactccag gtccctgtcc tggacaggca catctccact gaactgcggc tccctcgccg 1680 tgggcattcc caccacagcc agatggtggc cagcagtgcc tgcctgtctc tctggactcc 1740 tgtgttctgg gtgctggtgc tggctttcca aacagagaca cccctcctgt aacgactgga 1800 agcaccaggc taagaacctg acccctcgga cttgaagaat ggccattcct gtactccaca 1860 ttctggtcta gccttgttgg gcccaatcca gaagagactg ctcttgaaaa agcggcccag 1920 tgttgattct tctctttcca aggaatgtga ctttgggtta tccaactttg ggggcaggtg 1980 tacagttttg taacatagtg agttgtgtga aaataaatta taaatgagtt gtatgaaaat 2040 aaataccttt ttttgtataa aaa 2063 

1. An isolated polypeptide selected from the group consisting of: a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4-5, SEQ ID NO:7-12, SEQ ID NO:14-22, and SEQ ID NO:24-30, c) a polypeptide comprising a naturally occurring amino acid sequence at least 94% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:3, d) a polypeptide comprising a naturally occurring amino acid sequence at least 98% identical to an amino acid sequence of SEQ ID NO:6, e) a polypeptide comprising a naturally occurring amino acid sequence at least 92% identical to an amino acid sequence of SEQ ID NO:13, g) a polypeptide comprising a naturally occurring amino acid sequence at least 93% identical to an amino acid sequence of SEQ ID NO:23, h) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30, and i) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-30.
 2. An isolated polypeptide of claim 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-30.
 3. An isolated polynucleotide encoding a polypeptide of claim
 1. 4. An isolated polynucleotide encoding a polypeptide of claim
 2. 5. An isolated polynucleotide of claim 4 comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:31-60.
 6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim
 3. 7. A cell transformed with a recombinant polynucleotide of claim
 6. 8. A transgenic organism comprising a recombinant polynucleotide of claim
 6. 9. A method of producing a polypeptide of claim 1, the method comprising: a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and b) recovering the polypeptide so expressed.
 10. (canceled)
 11. An isolated antibody which specifically binds to a polypeptide of claim
 1. 12. An isolated polynucleotide selected from the group consisting of: a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:31-60, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:32, SEQ ID NO:34-35, and SEQ ID NO:37-60, c) a polynucleotide comprising naturally occurring a polynucleotide sequence at least 94% identical to the polynucleotide sequence selected from the group consisting of SEQ ID NO:31 and SEQ ID NO:33, d) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 98% identical to the polynucleotide sequence of SEQ ID NO:36, e) a polynucleotide complementary to a polynucleotide of a), f) a polynucleotide complementary to a polynucleotide of b), g) a polynucleotide complementary to a polynucleotide of c), h) a polynucleotide complementary to a polynucleotide of d), and i) an RNA equivalent of a)-h).
 13. (canceled)
 14. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising: a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
 15. (canceled)
 16. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising: a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
 17. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.
 18. A composition of claim 17, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-30.
 19. (canceled)
 20. A method of screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising: a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting agonist activity in the sample. 21-22. (canceled)
 23. A method of screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising: a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting antagonist activity in the sample. 24-25. (canceled)
 26. A method of screening for a compound that specifically binds to the polypeptide of claim 1, the method comprising: a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim
 1. 27. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, the method comprising: a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1, b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim
 1. 28. (canceled)
 29. A method of assessing toxicity of a test compound, the method comprising: a) treating a biological sample containing nucleic acids with the test compound, b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 12 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 12 or fragment thereof, c) quantifying the amount of hybridization complex, and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound. 30-115. (canceled) 